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The term protein aggregation is used in pharmaceutical biotechnology literature to 
describe a collection of different mechanisms that produce non-native, net irreversibly associated 
protein molecules.  The presence of protein aggregates in therapeutic protein drugs is 
problematic because certain protein aggregates may induce an anti-drug immune response in 
patients.  The work described in this Ph.D. thesis is focused on developing quantitative tools and 
theoretical models to better characterize and understand protein aggregation as a function of 
formulation conditions (solution pH, ionic strength, excipients, etc.) and external stresses (e.g., 
temperature, agitation, light, etc.).  The methods developed here are then applied to develop a 
comprehensive understanding of the aggregation pathways of an IgG1 monoclonal antibody 
(mAb) under various conditions. 
Depending upon the protein itself, the formulation composition and the processing stress, 
protein aggregation may produce heterogeneous distribution of aggregates with different sizes 
and morphological properties.  This work presents a novel data visualization method to monitor 
aggregate size, morphology, and concentration as a function of formulation variables such as 
solution composition, type of external stress, and stress duration.  Such data visualization 
methods can be useful for isolating the effect of single variables.  Another complementary 
method to determine the mass of subvisible particles (large aggregates with an equivalent 
spherical diameter of ~1-100 μm) was also developed in this work to better relate protein 
subvisible particle numbers to sample stability.  Such calculation methods are often necessary 
because particle mass is often too low to be measured experimentally.  When combined, these 
two methodologies serve as a set of powerful tools to better analyze protein aggregation because 
stressed samples with high particle numbers and small masses suggest that aggregate nucleation 
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(monomers forming aggregate seeds) mechanisms are dominant.  On the other hand, stressed 
protein samples with low particle numbers and large masses may point to aggregate growth 
mechanisms being dominant.   
Application of the data visualization and mass calculation methods to better characterize 
mAb aggregation led to a striking experimental observation that certain formulations could 
stabilize the IgG1 mAb against elevated temperatures but destabilize it against mechanical 
agitation.  This, among other observations, led to the hypothesis that elevated temperatures 
promoted aggregation of this mAb in the bulk solution while mechanical agitation induced mAb 
particle formation at the air-solution interface.   
To better understand how formulation affected temperature induced aggregation of this 
mAb, kinetic models describing nucleation and growth processes were fit to mAb aggregation 
data collected at several incubation temperatures (25, 40 and 57 °C).  The results of this study 
suggested that partially unfolded intermediates are an important driver of both aggregate 
nucleation and growth.  Protein-protein interactions, on the other hand, only appeared to affect 
aggregate growth for this mAb.   
To further elucidate how mechanical agitation of mAb solutions could induce protein 
particle formation, controlled compression-expansion cycles were applied to the air water 
interface of mAb solutions.  In this study, in collaboration with the Dhar laboratory, slow 
compression-expansion rates were found to induce aggregate formation at the air-solution 
interface.  Faster compression-expansion rates appeared to disrupt the air-solution interface 
releasing protein particles into the bulk mAb solution. In addition, formulation composition was 
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The presence of protein aggregates in biopharmaceutical drug products raises clinical and 
regulatory concerns about potentially increasing risk of unwanted anti-drug immunogenicity 
responses in patients upon administration (1, 2).  The work outlined in this thesis is focused on 
developing quantitative tools and theoretical models to better characterize and understand the 
protein aggregation process.  The models and methods developed are applied to elucidate the 
effect of pharmaceutically relevant variables (e.g., formulation composition, varying external 
stress conditions) on the aggregation of an Immunoglobulin-1 (IgG1) monoclonal antibody 
(mAb).  
This review will focus on discussing the role of colloidal interactions, protein structural 
integrity, and interfacial surfaces on the protein aggregation pathway, with a focus on the 
formation of larger aggregates called subvisible particles (defined here as 1-100 microns in 
equivalent circular diameter).  In the first section, colloidal stability will be defined in terms of 
intermolecular interactions and the pharmaceutical relevance of such interactions will be 
discussed.  The second section will cover the role of protein structure, conformational stability, 
and/or adsorption to the air-solution interface on aggregation rates and mechanisms, especially in 
the case of monoclonal antibodies (mAbs).  In the final section of the introduction, we focus our 
attention on the formation of a particular subset of protein aggregates, subvisible particles, and 
review the current understanding published in the biopharmaceutical literature and discuss 
outstanding challenges (and opportunities) that remain to be addressed. 
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1.1. Colloidal Interactions 
In general, intermolecular interactions govern the kinetics and thermodynamics of non-
specific association (aggregation/coalescence) between colloidal particles (3).  Any object with 
linear dimensions between 1 nm and 1 μm can be classified as a colloidal particle (CP).  
Aggregation refers to a process in which two or more CPs come together while largely retaining 
their individual physical identity.  For example, the total solvent exposed surface area of 
aggregated CPs is not substantially reduced compared to the same number of non-aggregated 
CPs (although specific interfaces can become sequestered from the solvent).  This more general 
definition of colloidal aggregation will become important for better understanding and modeling 
mechanisms of protein aggregation as described below. 
1.1.1. Intermolecular Interactions and Colloidal Stability   
Colloidal stability, the ability of CPs to resist aggregation/coalescence, is related to the 
long and short range forces between CPs (4).  In a dilute solution, the colloidal stability of CPs 
can be described by the pairwise potential of mean force.  The potential of mean force (𝑊22) 
describes the net pairwise interaction between two colloidal particles as a function of center-to-
center distance(𝑟).  Mathematically, 𝑊22 can be expressed as 
𝑊22(𝑟) = 𝑊𝐻𝐻(𝑟) + 𝑊𝑍(𝑟) + 𝑊𝑑𝑑𝑑𝑑(𝑟) + 𝑊𝑜𝑑𝑜𝑜𝑜𝑑𝑜(𝑟) + 𝑊𝑑𝑑𝑑𝑜𝑑𝑑(𝑟)  + 𝑊𝑎𝑑𝑑𝑜𝑜(𝑟),   (1.01) 
where 𝑊𝐻𝐻, 𝑊𝑍, 𝑊𝑑𝑑𝑑𝑑, 𝑊𝑜𝑑𝑜𝑜𝑜𝑑𝑜, 𝑊𝑑𝑑𝑑𝑜𝑑𝑑, 𝑊𝑎𝑑𝑑𝑜𝑜 represent pairwise interaction potentials 
arising from hard sphere, electrostatic, dispersion, osmotic, dipole and specific interactions, 
respectively (5, 6). 
For a sufficiently dilute solution of uniform colloidal spheres, the interaction potential 









  for 𝑟 > 𝑑,          (1.02) 
where 𝑧, e, к, 𝜀𝑜, and 𝜀𝑟 represent the net charge, elemental charge, inverse Debye length, 
dielectric permittivity of a vacuum and dielectric constant of water, respectively (7).  For this 
relationship to hold, the center-to-center distance (𝑟) between CPs must remain larger than their 
diameter (𝑑).  From Equation 1.02, it is apparent that increasing the net charge (𝑧) will increase 
the repulsive electrostatic potential energy between two colloidal particles.  The value of Wz can 
also be increased by reducing the value of the inverse Debye length (к).  For dilute salt solutions 




 ,             (1.03) 
where 𝑁𝐴 is Avogadro’s number, 𝐼 is ionic strength, 𝑘𝑏 is Boltzmann’s constant, and 𝑇 is the 
absolute temperature (8).  This calculation can be simplified to к = 3.27 ∗ 107√𝐼  at 20 °C (9).  
Equation 1.02 demonstrates that increased ionic strength should decrease both the range and 
strength of repulsive interactions between CPs. 
The rate of collisions between colloidal particles (CPs) is directly proportional to the 
colloidal stability of a system.  For uniformly charged spheres that stick upon contact, the rate of 
colloidal aggregation (𝑘) can be described by the theory of slow coagulation (3).  The expression 







 ,                                   (1.04) 
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where 𝐷 is the diffusion coefficient, 𝑅𝑑 is the radius of the CP, and the other terms have been 
defined in the previous section (3).  If there are no interactions between CP in solution (𝑊22 =
0), but the CP associate (aggregate) upon contact, then Equation 1.04 reduces to its diffusion 
limited form 
𝑘 ≈ 8𝜋(𝐷)𝑅𝑑 =
4𝑘𝑏𝑇
3𝜂
,           (1.05) 
where 𝜂 is the solution viscosity.  The theory of slow coagulation theoretically demonstrates that 
increasing repulsive intermolecular interactions (quantified by 𝑊22) can be an effective way to 
stabilize thermodynamically unfavorable colloidal dispersions against aggregation. 
1.1.2. Pharmaceutical Relevance of Colloidal Stability for Protein Drugs   
Protein aggregation, reversible self-association (RSA), and phase separation (PS) are 
undesirable outcomes that result from unwanted protein associations (10).  These physical 
processes can prohibit the successful pharmaceutical development of therapeutic protein 
candidates (11).  Aggregation, for example, can reduce drug efficacy and/or increase 
immunogenicity reactions of therapeutic proteins in patients (1, 2, 12-14).  RSA, on the other 
hand, can produce networks of associated species which can affect viscoelastic properties of the 
solution (5, 15).  This increase in the elasticity can manifest as an apparent increase in solution 
viscosity leading to pharmaceutical challenges in terms of manufacturing (e.g., filterability) and 
patient delivery (e.g., syringeability) (16-20).  Extensive RSA can cause phase separation which 
can negatively affect homogeneity of formulations containing therapeutic proteins and excipients 
(21-23) leading to protein instability and solution turbidity.      
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Increasing the colloidal stability between protein molecules has been shown to be an 
effective method of disrupting protein aggregation and/or RSA within experimentally measured 
timescales (4, 5).  In other words, an unstable solution phase can become a metastable solution 
phase provided that the interaction potential between molecules is sufficiently large.  In such 
situations, the implications on the storage stability of biopharmaceutical protein drugs are 
critical:  i.e., the thermodynamics of protein association may not always affect product shelf-life 
(i.e., the extent of aggregate formation) because the protein solution might not reach equilibrium 
within that timescale (i.e., the expiry date and storage temperature).    
One common approach to design stable formulations of protein drugs is to maximize 
colloidal stability by increasing/decreasing the solution pH relative to the isoelectric point of a 
specific protein.  Such changes in the solution pH can increase electrostatic repulsions (given 
by 𝑊𝑍) between protein molecules by increasing their overall net charge.  This behavior is 
roughly captured by Equation 1.02.  It is important to note, however, that Equation 1.02 poorly 
describes 𝑊𝑍 for most proteins (with the possible exception of extreme pH values for proteins 
that can maintain their higher-order structure under such conditions) because it assumes spherical 
geometry with uniformly distributed charge.   
In general, proteins tend to have anisotropic charge distributions and can have oppositely 
charged “patches” that introduce specific interaction contributions (𝑊𝑎𝑑𝑑𝑜𝑜) to the potential of 
mean force (24).  Theoretically such attractive interactions reduce the potential of mean force 
(𝑊22) at particular molecular orientations (25).  Such clustered “patches” of charged or 
hydrophobic amino acid residues can be responsible for low apparent solubility and/or reversible 
self-association of certain proteins (20, 26, 27).  
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1.1.3. Experimental Parameters as Indicators of Colloidal Stability 
The second osmotic virial coefficient (𝐵2) and diffusion interaction parameter (к𝐷) are 
two commonly used, experimentally obtained values to quantify the interactions between protein 
molecules under different solution conditions.  In the following sections, the measurement of 
these parameters and their relationship to colloidal stability will be reviewed. 
1.1.3.1. The Second Osmotic Virial Coefficient 
The osmotic pressure (𝜋), i.e., the pressure required to prevent the diffusion of solute 
molecules in an ideal solution, can be expressed as 
𝜋 = 𝑅𝑇𝑜
𝑀
 ,                        (1.06) 
where 𝑅 is the ideal gas constant, 𝑇 is the absolute temperature, 𝑐 is the concentration of solute 
molecules (mass/volume), and 𝑀 is the number averaged molecular weight.  Intermolecular 
interactions between colloidal particles cause values of 𝜋 to systematically deviate from the 
values predicted by Equation 1.06.     
The osmotic pressures of non-ideal solutions are fit using a truncated virial expansion of 
Equation 1.06:   
𝜋 = 𝑅𝑇𝑐 �1
𝑀
+ 𝐵2𝑐�                  (1.07)  
where 𝐵2 is the second osmotic virial coefficient.  Equation 1.07 is only valid for dilute solution 
conditions where pairwise molecular interactions dominate (28).  In concentrated or crowded 
solutions, short intermolecular distances can give rise to each solute molecule “feeling” forces 
from multiple solute molecules (29).       
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The second osmotic virial coefficient can be related to the pairwise potential of mean 
force (𝑊22) using statistical mechanics.  This virial coefficient can be expressed as   
𝐵2 = −
𝑁𝐴
2𝑀2 ∫{𝑒𝑒𝑒[−𝑊22(𝑟)/𝑘𝐵𝑇] − 1} 4𝜋𝑟
2𝑑𝑟,        (1.08) 
where 𝑁𝐴 is Avogadro’s number, 𝑀 is the molecular weight of the solute, and 𝑊22(𝑟) is the 
orientation averaged potential of mean force (6, 28, 30).  From this statistical mechanical 
definition of 𝐵2, it is clear that 𝐵2 is an indirect measure of 𝑊22 (and therefore of colloidal 
stability).  Furthermore, when there are no intermolecular interactions (e.g., 𝑊22 = 0), the value 
of  𝐵2 reduces to 0.  When the net intermolecular interactions are either repulsive or attractive, 
the 𝐵2 values are then or negative, respectively.        
1.1.3.2. Static Light Scattering and 𝑩𝟐 
The Zimm equation can be used to determine an apparent second virial coefficient from 
static light scattering (SLS) data measured at multiple protein concentrations (31).  This 





+ 2𝐴2𝑐2 ,           (1.09) 
where 𝑲∗ is an optical constant, 𝑹(𝜽) is the experimentally determined excess Rayleigh ratio, 𝑐2 
is the protein concentration (mass/volume), 𝑀𝑤 is the weight averaged molecular weight, and 
𝐴2 is the apparent second virial coefficient.  Although 𝐴2 and 𝐵2 differ in terms of their 
statistical mechanical definitions (30, 32, 33), SLS remains one of the most common 
experimental measures of colloidal stability.  This is because 𝐴2 ≈ 𝐵2 at sufficiently dilute 
protein concentrations (33-35).  When measured at higher protein concentrations, 𝐴2 
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measurements can still be used qualitatively to rank order solutions in terms of colloidal stability 
because it systematically overestimates repulsive interactions (and systematically underestimates 
attractive interactions) (33).      
Virial coefficients (both 𝐴2 and 𝐵2) can also be reported as normalized values. 
Normalization is performed to account for the excluded volume of hard spheres to better capture 
other weak intermolecular interactions such as electrostatic interactions (36, 37).  Using 
statistical mechanics, the excluded volume contribution to 𝐵2 can be expressed as 
𝐵2 =  
𝑁𝐴𝑢
2𝑀2
 ,             (1.10) 
where 𝑢 is the excluded volume, 𝑁𝐴 is Avogadro’s number and 𝑀 is the molecular weight (3, 9).  
One possible normalization approach is described by  
𝑎2 =  
𝐴2−𝐵2𝑒𝑒𝑒
𝐵2𝑒𝑒𝑒
 ,            (1.11) 
where 𝑎2 the normalized second virial coefficient and 𝐵2𝑑𝑒𝑜 is the calculated contribution of 
excluded volume on the second virial coefficient.  Normalizing virial coefficients  is a practical 
approach because contributions from excluded volume can dominate the value of 𝐵2 when other 
intermolecular interactions are weak making it difficult to determine whether intermolecular 
interactions are attractive or repulsive (38).   
1.1.3.3. The Diffusion Interaction Parameter 
In a dilute ideal solution, the diffusion coefficient of non-interacting spherical particles is 




 ,              (1.12) 
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where 𝐷𝑑 is the ‘self-diffusion coefficient’, 𝑘𝐵 is the Boltzmann constant, 𝑇 is the absolute 
temperature,  𝜂 is the solution viscosity, and  𝑅𝑑 is the radius of the spherical particles (3, 8).  In 
more concentrated environments, particles begin to prevent each other from randomly diffusing 
(i.e., the frictional coefficient increases).  In such a case, the frictional coefficient, denoted by 𝑓, 
can be described by 
𝑓 = 𝑓0(1 + 𝑓1𝑐 + ⋯ ),             (1.13) 
where 𝑓0 is the frictional coefficient of particles in an infinitely dilute solution and the other 
coefficients correct for concentration dependent effects (39). 
In protein solutions, intermolecular interactions may also affect diffusion in a 
concentration dependent manner.  The relationship can be described by 
𝐷𝑜 = 𝐷𝑑(1 + к𝑫𝑐 + ⋯ ) ,           (1.14) 
where 𝐷𝑜 is typically referred to as the ‘collective’ or ‘mutual’ diffusion coefficient, 𝑐 is the 
solute concentration (mass/volume), and к𝑫 is the diffusion interaction parameter (34, 40). 
 The diffusion interaction parameter is often used as an experimental value in 
biopharmaceutical formulation research to quantify protein-protein interactions under different 
conditions (15, 41-43).  Theoretically, the diffusion interaction parameter can be related to the 
second osmotic virial coefficient (𝐵2) by the expression 
к𝑫 = 2𝐵2𝑀 − 𝑓1 − 2𝜈,            (1.15) 
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where 𝑀 is the molecular weight of the protein, 𝜈 is the partial specific volume, and 𝑓1 is given 
in Equation 1.13 (39, 43).  Using Equation 1.08 to substitute for 𝐵2, к𝑫 can be defined in terms 
of the potential of mean force (𝑊22) as 
к𝑫 = −
𝑁𝐴
𝑀 ∫{𝑒𝑒𝑒[−𝑊22(𝑟)/𝑘𝐵𝑇] − 1} 4𝜋𝑟
2𝑑𝑟 − 𝑓1 − 2𝜈.     (1.16) 
From Equation 1.16, it is apparent that the diffusion interaction parameter is related to colloidal 
stability (through 𝑊22) provided that 𝑓1 and 𝜈 remain constant between different formulation 
conditions.  
1.1.3.4. Dynamic Light Scattering and к𝑫 
The most common experimental approach to determine к𝑫 values for various protein 
solutions is by dynamic light scattering (DLS).  The calculated correlation function 𝑔1(𝑠, 𝑡𝑑) for 
light scattering intensity fluctuations over time can be related to the diffusion coefficient (𝐷𝑜) of 
monodisperse spherical particles through the relationship 
𝑔1(𝑠, 𝑡𝑑) = exp (−𝑠2𝐷𝑜𝑡𝑑),           (1.17) 
where 𝑠 is the magnitude of the scattering vector and 𝑡𝑑 is the time delay used in the calculation 
of the correlation function (3).  Using Equation 1.14, it is possible to determine к𝑫 by plotting 
‘mutual’ diffusion coefficient ( 𝐷𝑜 ) vs. protein concentration ( 𝑐 ).  The y-intercept 
(extrapolation to zero protein concentration) provides 𝐷𝑑 and the slope divided by 𝐷𝑑 provides 
the value of к𝑫.  This approach only holds true for dilute protein concentrations where the plot of 
𝐷𝑜 vs. 𝑐 is linear.     
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1.2. Protein Aggregation 
The term “protein aggregation” is generally used by pharmaceutical scientists to describe 
unwanted, non-native, irreversible processes where conformationally altered protein molecules 
agglomerate through multiple conformational rearrangement and colloidal association steps (10, 
44, 45).  Protein aggregation is important to minimize in biotherapeutic products because such 
aggregates can decrease potency and are theoretically posited to increase patient immunogenicity 
(1, 2).  Experimental evidence supporting such arguments that formation of anti-drug antibodies 
in patients is related to the presence of protein drug aggregates has been suggested using both in-
vitro and animal models (12-14, 46, 47).  It is important to note, however, that not all aggregates 
are necessarily equal in regard to their immunogenic potential in patients and that the 
determination of such physicochemical and immunological properties remains an active area of 
research (14).      
1.2.1. Protein Aggregation Mechanisms 
 The thermodynamics and kinetics of protein aggregation have been classically interpreted 
using the Lumry-Eyring model (4, 48-50).  In this model, proteins undergo a reversible 
conformational change prior forming “irreversible” aggregates.  The reversible conformational 
change is generally expressed as 
𝑀
𝐾𝑢𝑢𝑢
�⎯�𝑈              (1.18) 
where 𝑀 represents native monomer, 𝑈 represents a conformationally altered monomer, and 
𝐾𝑢𝑢𝑢 represents the equilibrium constant for this reaction.  Two conformationally altered 





�⎯�𝐴2             (1.19) 
where 𝑘𝑎𝑎𝑎 is the rate aggregate formation, and 𝐴2 is a dimeric aggregate.  Protein aggregation 
that follows the Lumry-Eyring model can be conceptualized in a simple reaction coordinate 
energy diagram (Figure 1.1).   
 
Figure 1.1.  Theoretical reaction coordinate energy diagram for the Lumry-Eyring model of 
protein aggregation (Ref (51): Reproduced with permission from Elsevier). 
Thermodynamic stabilization of protein monomers (against aggregation) can theoretically be 
achieved by increasing the free energy of partially unfolded intermediate and/or small aggregate 
states (Figure 1.1).  Based on these considerations, one common formulation approach to 
stabilize proteins against aggregation is by adding inert excipients which are preferentially 
excluded from the surface of the protein and thus destabilize the unfolded intermediate (𝑈)  (11, 
51, 52).  The difference in excipient concentration at the surface of the protein and in the bulk 
solution can induce an osmotic stress if the local chemical potentials are unbalanced.  In such an 
event it becomes less favorable for water to hydrate the protein thereby destabilizing structurally 
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expanded unfolded states which have more surface area than the folded, more compact native 
state (53). 
Proteins which aggregate according to the Lumry-Eyring model can also be kinetically 
stabilized by increasing the activation energy of the unfolding and/or associations steps.  In 
Figure 1.2, the initial activation energy of the association step is similar to the activation energy 
of the unfolding step (solid trace).  When the activation energy of the association step is 
increased (dotted trace), it becomes the rate limiting step of the protein aggregation process.  
 
Figure 1.2.  Theoretical reaction coordinate energy diagram for the Lumry-Eyring model of 
protein aggregation.  Dotted trace reflects increased activation energy for the associated 
transition state. (Ref (51): Reproduced with permission from Elsevier). 
According to the theory of slow coagulation presented in section 1.1.1., the rate of association 
should decrease (increased activation energy) when the potential of mean force between 
molecules is increased (increased colloidal stability).  The arguments outlined above establish a 
theoretical basis for why solution conditions resulting in increased colloidal stability appears to 
influence protein aggregation in some situations (4, 54, 55), but not in others (56, 57).    
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 Although the Lumry-Eyring model is useful for a basic conceptual understanding of 
protein aggregation, actual mechanisms are rarely as straightforward.  Protein aggregation 
generally involves simultaneous competing aggregation pathways which can be initiated by 
conformational changes (44, 58), chemical changes (44), native associations (44, 59, 60), and/or 
adsorption to interfaces (air-solution, container-solution, etc.) (44, 61-65).  Furthermore, protein 
aggregates may range in size from small, soluble non-native dimers to large, insoluble visible 
particulates (66).  The size of aggregates and extent of aggregation are predominantly a function 
of protein sequence (67, 68), the solution environment (51, 54, 69), and exposure to different 
environmental variables (e.g., temperature, light, agitation) (54, 66, 70, 71). 
1.2.2. Aggregation of Monoclonal Antibodies 
Monoclonal antibodies are becoming increasingly important class of protein drugs used 
in the ongoing effort to improve human health.  As of 2013, there were 35 approved mAb 
products on the market that have been approved to treat a wide variety of indications (72).  
Protein aggregation is a formulation development challenge that must be overcome to 
successfully bring a product candidate mAb to market.  Additionally, mAbs are also being 
developed as antibody-drug-conjugate (ADC) therapies, where cytotoxic small molecules drugs 
are covalently conjugated to the antibodies using a chemical linker (73, 74).  These ADC can be 
more prone to aggregation because they often have reduced conformational stability and 
solubility compared to unconjugated antibodies (75, 76). 
1.2.2.1. IgG1 mAb Structure and Conformational Stability 
IgG1 mAb molecules are “Y shaped” proteins that are composed of two identical 
“heavy” polypeptide chains and two identical “light” polypeptide chains.  The protein is thus a 
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homodimer, has a molecular weight of approximately 150 kDa, and is held together by 4 inter 
chain and 12 intra chain disulfide bonds. 
 
Figure 1.3.  Structure of a human IgG1 mAb (Ref (77): Reproduced with permission from Dove 
Press). 
As shown in Figure 1.3, the molecule is folded such that the heavy chain has one variable 
domain (VH) and three constant domains (CH1, CH2, CH3) which are conserved across 
different IgG1 mAbs.  The light chain has one variable domain (VL) and one constant domain.  
The VH, VL, CH1, and CL domains of a heavy chain-light chain pair compose the fragment 
antigen binding (Fab) region and the CH2 and CH3 domains of the heavy chains compose the 
fragment crystallizable (Fc) region. The CH2 domain also contains two N-linked glycosylation 
sites (i.e., one per each heavy chain). 
 The Lumry-Eyring model of protein aggregation requires individual protein monomers to 
partially unfold, and multiple structurally altered monomers associate to form small aggregates.  
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Therefore, conformational stability of mAb molecules is expected to be an important parameter 
for aggregation pathways which follow a similar process.  Thermodynamically, conformational 
stability reflects the difference in free energy between native and partially unfolded monomer 





 ,            (1.20) 
where  𝑚𝑜𝑜𝑜 reflects the total monomer concentration, 𝑅 is the ideal gas constant, 𝑇 is the 
absolute temperature, and ∆𝐺 reflects the free energy difference between native and partially 
unfolded states. 
 The conformational stability of IgG1 mAbs is commonly evaluated using a variety of 
biophysical techniques monitoring mAb structural integrity as a function of temperature 
including differential scanning calorimetry (DSC) (78, 79).  In general, the irreversible nature of 
mAb unfolding vs. temperature precludes reversible 2-state thermodynamic analysis of DSC 
data.  If irreversibility is caused by Lumry-Eyring protein aggregation and the unfolding process 
is much faster than aggregation, such analysis may still provide reasonable results (48, 49).  On 
the other hand, if aggregation is much faster than unfolding, DSC thermograms may reflect 
unfolding kinetics.  Despite the challenges outlined above, DSC remains as an effective tool to 
evaluate relative differences in the conformational stability of different mAb domains/regions as 
well as to compare different mAbs, and effect of different solutions conditions (80). 
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1.2.2.2. Aggregation Mechanisms for mAbs in Bulk Solution 
 Aggregation of mAb molecules in bulk solution is a multistep process that can involve 
several competing aggregation pathways (57, 81, 82).  As shown in Figure 1.4, mAb aggregation 
can be initiated by formation of native clusters and/or partial unfolding of specific 
domain/regions of the mAb. 
 
Figure 1.4.  Schematic representation of mAb aggregation in bulk solution  (Ref (83): 
Reproduced with permission from Elsevier). 
Unlike the Lumry-Eyring model, more advanced models of protein aggregation also consider 
aggregate growth by monomer addition and/or aggregate-aggregate addition (84-87).  Similar to 
actual experimental results, it tends to be less clear how experimental surrogate parameters for 
conformational and/or colloidal stability will affect aggregation kinetics for these models (71).  
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Additionally, excipients may directly interact with the protein which can complicate predictions 
based on colloidal models or simulations (35, 88-90).  Thus, accurately predicting the effect of 
formulation on the long term aggregation behavior of mAbs remains an outstanding challenge. 
1.2.2.3. Adsorption of mAbs to the Air-Solution Interface and Aggregation 
In addition to bulk solution pathways, mAb aggregation may also occur at the air-solution 
interface (62, 91, 92).  Since mAbs are amphipathic molecules, they can preferentially 
accumulate at interfaces which can result in very high local concentrations.  In the absence of 
added detergents, preferential accumulation of mAb molecules may cause the air-solution 
interface to display high surface pressures values (62, 92).  Surface pressure, or the decrease in 
surface tension of the solution due to monolayer formation, represents a decrease in the free 
energy of the air-water surface (8).  Therefore, surface pressure will increase when amphipathic 
molecules adsorb to the interface and when they have favorable interactions at the surface.  As 
the air is much more hydrophobic than water, this can result in protein molecules partially 
unfolding forming structurally altered species leading to subsequent protein aggregation at the 
air-solution interface (92).   
1.3. Subvisible and Submicron Protein Particles 
 Very large protein aggregates are often called protein particles in the pharmaceutical 
literature (93, 94).  This term is completely unrelated and should not be confused with colloidal 
particles as reviewed above.  Protein particles can be large enough to be seen by eye (~having 
linear dimensions greater than 100 microns), and are called visible particles, or they can be 
smaller in size and are not visually detectable and are further classified as submicron or 
subvisible particles   (54, 93, 94).  The exact size range of particles described by the terms 
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“submicron” and “subvisible” tends to vary depending upon the research group as well as the 
type of instrumentation used.  In this review, we define submicron particles as having an 
equivalent spherical diameter (diameter of a sphere that has equivalent volume to the protein 
particle) ranging from 0.1-1 µm and subvisible particles as having a 2-dimensional cross 
sectional area which ranges from 1-100 µm in equivalent circular diameter (diameter of a circle 
that has equivalent area to a 2-dimensional image of the protein particle).  These definitions of 
particle size accommodate the analytical instruments currently used to detect and quantify the 
particle size distributions of protein aggregates (95).   
 Particles with dimensions in the range of 0.1-10 µm are especially important to monitor 
because of their potential to stimulate immunogenic responses in patients (1, 13, 14).  This is 
because such particles are the optimal size to be internalized by antigen presenting cells and they 
may also display repeating arrays antigenic motifs (96).  Determining the particular 
physicochemical properties which make protein particles more or less immunogenic remains an 
outstanding challenge of the field (97). 
 The purpose of this review is to propose a methodology of how to efficiently interpret 
and communicate certain types of protein particle data. This review is geared towards protein 
pharmaceutical researchers that are already proficient with protein particle analysis.  The focus 
will be directed towards communicating and interpreting measurements of protein particle “size” 
and “density” across different instruments.  
1.3.1. Protein Particle Density 
 The density of an IgG1 mAb has been approximated at 1.41 g/ml, and the density of 
proteins can be empirically described as a function of molecular weight (98).  Folzer et al. 
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recently measured the density of protein particles with “sizes” ranging from approximately 0.2 to 
5 μm in diameter using resonant mass measurement and found that the density of the protein 
particles ranged from 1.28 and 1.33 g/ml  (99).  The results published by Folzer et al., highlight 
the critical importance of how protein particle boundaries are defined to determine particle 
density.   
 
 
Figure 1.5.  Various ways to define protein particle boundaries for density determination 
In Figure 1.5, all three schematics of protein particles are identical, but the density determined 
for each of the particles will be dramatically different due to differences in the defined 
boundaries.  The boundary of a protein particle is defined by the “measuring stick” or probe used 
to determine such a boundary.  For example, a probe the size of a solvent molecule would likely 
determine a particle boundary resembling Figure 1.5A.  The density values reported by Folzer et 
al., reflects such a boundary.  On the other hand, instruments using a larger probe such as visible 
light may detect boundaries which more closely resemble Figure 1.5B or C.   
Let’s hypothetically consider a situation in which the solvent has a density of 1.00 g/ml 
and the protein has a density of 1.35 g/ml.  Further, let’s assume that the boundary of Figure 
1.5A is so precise that the particle is defined as 100 % protein.  Next let’s assume that the 
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boundary defining Figure 1.5B contains 30% solvent and 70 % protein and that the boundary 
defining Figure 1.5C contains 70% solvent and 30% protein.  The density values for the protein 
particle will be either 1.35, 1.24, and 1.11 g/ml, depending on the assumption used.  Technically, 
none of these density values are wrong depending upon how particle boundary size is defined.  
On the other hand, use of different density values for protein particles will dramatically affect 
results when provided as an input for other calculations such as particle weight.   Therefore, we 
emphasize caution in interpreting published density values for protein particles and suggest that 
extra consideration be given to the size of the probe used to establish particle boundary 
conditions. 
1.3.2. Protein Particle Size 
The accurate detection and sizing of protein particles is limited by current analytical 
instrumentation (100, 101).  Some of the properties which make protein particles challenging to 
size/count is their heterogeneous morphology, low contrast (particle refractive index similar to 
solution refractive index), wide size distribution, unclear density value (see previous section), 
and high number (54, 102-104).  These properties necessitate that multiple analytical instruments 
be used to characterize the full size range protein particles.  The basic operation and principles of 
current particle counting instruments have been extensively reviewed elsewhere (95, 105-111).  
Each instrument uses a different measurement principle to detect and quantify the size of protein 
particles based on certain properties of protein particles.  In this section, we demonstrate how 
particle properties such as shape and density can affect the quantification of protein particle size 
for commonly used instruments.   
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1.3.2.1 Nanoparticle Tracking Analysis (NTA) 
In nanoparticle tracking analysis, particles suspended in solution are illuminated by a 
laser and light scattered from particles within the field of view is focused and tracked.  The 
motion of the scattering centers is captured using a CCD camera and related to a hydrodynamic 
radius through a 2-dimensional Stokes-Einstein equation  
(𝑒,𝑦)2 =  2𝑘𝐵𝑇
3𝑟ℎ𝜋𝜂
 ,            (1.21) 
where (𝑒,𝑦)2 is the mean-squared speed of the particle, T is the temperature, 𝑘𝐵 is the 
Boltzmann constant, 𝑟ℎis the hydrodynamic radius, and 𝜂 is the solution viscosity (105).   
Stokes law, given by 𝑓 = 3𝑟ℎ𝜋𝜂 in this example, describes the frictional coefficient (𝑓) of 
spherical particles.  As protein particles are non-spherical, particle size is reported as a 
‘fictitious’ sphere with the same diffusion coefficient as the actual particle.  This approach 
provides valid values but can make comparisons of size between different instruments 
challenging.  For example, an ellipsoidal particle will have a different frictional coefficient than a 
spherical particle.  The effect of asymmetry on the frictional coefficient ( 𝑢
𝑢∗
) of a prolate ellipsoid 
of revolution �𝑏
𝑎













 ,           (1.22) 
where 𝑏 is the minor axis and 𝑎 is the major axis of the prolate ellipsoid of revolution (3).  
Therefore, a prolate ellipsoid of revolution with an aspect ratio of 0.1, 0.2, or 0.3 will have a 
calculated friction ratio 1.54, 1.25, or 1.14 times larger than that of an equivalent volume sphere, 
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respectively.  Therefore, a fiber-like protein aggregate with an equivalent spherical diameter of 
200 nm and an aspect ratio of 0.1, 0.2, or 0.3 could be measured by NTA as having a 
hydrodynamic diameter of ~309, 250, or 227 nm, respectively.  
1.3.2.2. Resonant Mass Measurement (RMM) 
Resonant mass measurement is performed by passing a solution through a microfluidic 
channel in a cantilever resonator (106, 112).  When a particle in solution travels through the 
resonator, there is a drop in the frequency which can result in the detection of a particle 
depending upon the assigned limit of detection.  The buoyant mass of a particle travelling 
through the resonator is calculated using 
𝑀𝐵 = ∆𝑓 ∗ 𝑆             (1.23) 
where ∆𝑓 describes the frequency drop and S is a parameter accounting for the sensitivity of the 
resonator.  The mass of the particle is then calculated using entered values of particle density (𝑒𝑑) 
and solution density (𝑒𝑑) by the equation 
𝑀 = 𝑀𝐵
1−𝑝𝑠𝑝𝑝
.           (1.24) 




3 .           (1.25) 
Equations 1.23, 1.24, and 1.25 were obtained from the Archimedes user manual.  It is important 
to note that the buoyant mass is an experimentally measured parameter determined by RMM and 
that reported size values are calculated using a user entered value for protein particle density.  
For example, using the protein density values calculated from Figure 1.5, user inputted density 
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values of 1.35, 1.24, or 1.11 g/ml, describing the same protein particle, could result in a particle 
size detection of 379, 438, or 558 nm equivalent spherical diameter for a buoyant mass of 10−11 
g, respectively. 
1.3.2.3. Flow Microscopy 
In flow microscopy experiments, sample is passed through a flow cell using a 
peristaltic/syringe pump and illuminated using an LED.  Snapshots of the flow cell are captured 
using a high definition digital camera and particles are identified using image analysis.  Particle 
size is determined using proprietary image analysis algorithms based upon the 2-dimensional 
particle image.  Particle morphology will clearly affect the sizing results because a sphere will be 
homogenously sized regardless of particle rotation whereas an ellipse or fiber-like particle will 
be randomly oriented and display a much wider distribution of particle sizes.   
 The assumption that an equivalent circular diameter of protein particles can be equated to 
an equivalent spherical diameter has been demonstrated to be very inaccurate (104).  The volume 
of protein particles with spherical or prolate ellipsoid of revolution morphology can be calculated 
using equivalent circular diameter or area based diameter and circularity by 
𝑉 = 𝜋
6
∗ 𝑑3 ∗ �1.70763 − 1.70864 ∗ (1 − 𝐶)0.45 − 0.70638 ∗ 𝐶   , 
where 𝑉 is the volume, 𝑑 is the diameter, and 𝐶 is the circularity (104). 
1.3.3. Size and Density Conclusions 
In this section, we have theoretically demonstrated how both measurement principles and 
user based assumptions about particle properties can affect the determination of protein particle 
size and/or density.  A spherical protein particle with a 2.6 μm diameter that is 30% 
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protein/volume when measured by flow microscopy could be measured at 1.76 μm diameter by 
resonant mass measurement if the density is assumed to be 100% protein/volume.  If the particle 
morphology is similar to a prolate ellipsoid of revolution, the resonant mass measurement would 
not be affected, but equivalent circular diameter could increase to 4.95 μm if the largest cross 
section possessing an arbitrary circularity of 0.2 was imaged. 
Therefore, it is quite plausible that the same protein particle could be measured at 1.76 
μm equivalent spherical diameter by resonant mass measurement and 4.95 μm equivalent 
circular diameter by flow microscopy.  This theoretical example demonstrates why perfect 
correlation between different analytical instruments, such as resonant mass measurement and 
flow microscopy, should not be expected in most cases.  Certain examples do exist in the 
literature where resonant mass measurement and flow microscopy measurements show good 
correlations between particle size values from the two instruments, but this should not be the 
case when protein particle morphologies become heterogeneous and thus notably deviate from a 
spherical shape (109).  
 Resonant mass measurement and nanoparticle tracking analysis data are also theoretically 
expected to show poor correlation in protein particle size depending on the assumptions used.  
As illustrated in the previous sections, particle morphology has a large effect on the particle size 
output of nanoparticle tracking analysis, but will not affect the size output from resonant mass 
measurements.  In contrast, during resonant mass measurements, solvent molecules are the probe 
of particle boundaries whereas in nanoparticle tracking analysis, the boundaries are defined in 
terms of the external dimensions of the particle.  Therefore, the different sizes presented by the 
two techniques inherently assume different particle densities.  
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Chapter 2: Radar Chart Array Analysis to Visualize Effects of Formulation 

























Improving our basic understanding of protein aggregate and particle formation pathways 
during the manufacturing and storage of therapeutic protein candidates is of increasing interest to 
protein formulation scientists and regulators alike.  This interest primarily arises from the 
potential ability of these particles to induce an unwanted, humoral immune response resulting in 
the production of anti-drug antibodies that reduce the efficacy of the administered therapy (1).  
Previous investigators have shown that particles generated by different stresses vary in average 
size, shape, concentration, transparency, and chemical modifications, however, the 
physicochemical properties of a protein particle that potentially elicit an immune response 
remain elusive (66, 113, 114).  The immunogenic potential of particle subpopulations is difficult 
to study because separating and isolating species from a highly heterogeneous population, while 
maintaining their structural integrity, is technically challenging (114).  Additionally, sample 
handling must be minimized during particle characterization to preserve the integrity of the 
measured particle populations (101, 115). Because of these challenges, formulation development 
strategies for protein therapeutics are increasingly focused on reducing the number of submicron 
and subvisible particle degradants that form during manufacturing and storage (97).  The 
formation of proteinaceous particles can be reduced by increasing both the conformational and 
colloidal stability of the protein in solution as well as by decreasing the number of nucleating 
species (4).  Non-native aggregation is often initiated by partially unfolded or misfolded 
monomers that associate if there is a favorable change in the free energy of the system (44, 68, 
81, 87, 116, 117).  Certain anions (e.g., chloride) preferentially accumulate on the surface of 
proteins and can influence both the conformational and colloidal stability of proteins in solution 
(90, 118).   
29 
 
Multiple analytical instruments are needed to measure the full range of aggregates and 
particles in solution because no single technique is currently capable of providing an accurate, 
quantitative description of the entire aggregation profile of a protein solution (95, 100, 108, 119). 
Subvisible and submicron are terms used to classify particles that are 1-100 µm and 0.1 to <1 
µm, respectively (97).  Microflow digital imaging (MFI) has become a popular technique to 
characterize subvisible particles and has been used to study particle formation in monoclonal 
antibody formulations (120-123).  MFI captures digital images of particles from a solution 
passing through a flow cell and uses algorithms to measure a wide variety of parameters 
including, but not limited to, equivalent circular diameter, concentration, counts, circularity, 
aspect ratio, and intensity.  These parameters provide an advantage over other subvisible particle 
counting techniques because morphological filters can be used to discriminate between 
proteinaceous particles and non-proteinaceous silicone oil droplets or air bubbles (124).  A 
limitation of MFI, however, is the possible undercounting of particles that have a refractive index 
similar to that of the solvent (110). This experimental artifact can be partially corrected through 
the proper use of the optimize illumination function (107, 110, 121).  A complementary 
technology is the Archimedes Particle Metrology System, which uses the principle of resonant 
mass measurement (RMM) to measure the buoyant mass of particles from a solution passing 
through a suspended microchannel resonator (SMR).  SMR technology complements MFI 
because it detects submicron particles from 200 nm to subvisible particles <5 µm in equivalent 
spherical diameter. and has also been used to study submicron particle as low as ~104 
particles/ml in a monoclonal antibody formulation (106).  Both RMM and MFI provide high 
resolution particle size and concentration data by counting individual particles, but the large 
quantity of data produced makes it challenging to compare trends across multiple data sets.   
30 
 
 Data visualization methods have been developed to aid in the formulation development of 
protein-based therapeutic drugs and vaccines.  The empirical phase diagram (EPD) visualizes 
macromolecule structural changes as a shift in colors as a function of environmental stresses 
(e.g., temperature and solution pH).  The EPD visually summarizes biophysical stability data 
from multiple techniques that have been reduced in dimensionality through principle components 
analysis (125, 126).  There are several reports in which the EPD has been used to visualize 
changes in mAb conformational stability and dynamics (127-129).  Additional data visualization 
methods have more recently been developed to examine protein stability data including radar 
chart analysis and comparative signature diagrams (130, 131).  Radar charts have the advantage 
of displaying multidimensional data without truncating the data or using statistical methods such 
as principle components analysis.  
 In this report, we apply radar chart array analysis to compare multiple, large data sets 
from different analytical methods to determine the effect of formulation variables on the nature 
of IgG1 mAb aggregates and particles generated through different stress conditions.  First, we 
assess the effect of solution pH and NaCl on the concentration, size, and formation kinetics of 
subvisible particles, measured by MFI, created due to stirring and shaking of the solutions.  
Additionally, we use radar chart array analysis to evaluate how IgG1 mAb particle morphology, 
i.e., the particle’s aspect ratio (a measure of elongation) and intensity (a measure of particle 
transparency), are affected by formulation conditions.   Lastly, we examine the potential of radar 
chart analysis to visualize formation of the particles and aggregates across the entire size profile, 
from subvisible and submicron sized particles to small soluble aggregates as measured by MFI, 
RMM, and size exclusion high performance liquid chromatography (SE-HPLC), respectively.   
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2.2. Experimental Procedures 
2.2.1. Materials and Sample Preparation 
An IgG1 mAb (pI ~9) was supplied by Janssen Biotech Inc. (Horsham, PA) at ~40 
mg/ml.  Working mAb solutions were made by diluting the stock solution into 20 mM citrate-
phosphate buffer to a final protein concentration of 1.0 mg/ml.  Individual samples were 
prepared at pH 4.0, 6.0 and 8.0 and NaCl concentrations of 0, 0.15, and 1.0 M.  These working 
solutions (3 mL) were prepared in glass vials (37.7 x 16.75 mm) from Schott (Lebanon, PA) and 
capped with 20 mm lyophilization vial stoppers (West Pharmaceutical Services, Exton, PA). 
2.2.2. Generation of Aggregates 
Heat stressed aggregates were generated by incubating samples at 65°C for 10, 120, and 
240 min.  Stirred stressed aggregates were generated by stirring samples with teflon coated micro 
spinbars (Fisher) for 10, 120, and 240 min.  The stirring speed was adjusted to setting 5 on a 
Pierce Reacti-Therm III from Thermo Scientific (West Palm Beach, FL).  Shaking stressed 
protein aggregates were made by shaking samples side to side at 300 RPM for 10, 120, and 240 
min using a HS 260 shaker from IKA Works Inc. (Wilmington, NC). 
2.2.3. Differential Scanning Calorimetry 
DSC was performed with 1.0 mg/ml protein samples, prior to stress exposure, using a 
high throughput capillary VP-DSC (MicroCal, Piscataway, NJ).  Thermograms were obtained by 
scanning from 10° to 90°C at a rate of 60°C/hr as described previously (132).  Tm values were 
obtained by iteratively fitting the thermogram to a non-2-state model for unfolding.  To values 
were obtained by determining the point at which a specific interpolated tangent line intersects the 
horizontal axis.  
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2.2.4. Extrinsic Fluorescence Spectroscopy 
IgG1 mAb samples were diluted to 0.1 mg/ml in their corresponding buffers and a 20 
molar excess of 1-anilinonaphthalene-8-sulfonate (ANS, Sigma) was added.   The fluorescence 
emission was measured using a QM-40 spectrofluorometer from Photon Technology 
International (Birmingham, NJ) as described previously (120).  
2.2.5. Size Exclusion High Performance Liquid Chromatography 
A Tosoh Bioscience TSKgel G3000SWx1 stainless steel column (San Francisco, CA) 
along with the corresponding guard column (TSKgel SWxl guard column) operated at 30°C was 
used in all experiments.  A Shimadzu Prominence UFLC HPLC system (Kyoto, Japan) 
connected to a diode array detector was used.   Twenty five µL of each sample were injected into 
a column that was equilibrated with at least 10 column volumes of  20 mM sodium phosphate 
buffer (pH 6.8).  The flow rate was 0.7 mL/min and the measurement time was 30 minutes.  LC 
Solution software was used for data analysis and peak integration.  Total area loss, percent 
monomer loss of the solution, and percent soluble aggregates of the solution were reported as 
described previously (133).  
2.2.6. Resonant Mass Measurement 
An Archimedes Particle Metrology System (Affinity Biosensors, Santa Barbara, CA) was 
used to quantify submicron and small subvisible particles from 0.275 to 1.85 µm. A Hi-Q micro 
sensor, calibrated using 1.03 µm polystyrene beads (Affinity Biosensors), was used for all 
measurements.  Reference solutions of 1:20 D2O:H2O or pure H2O were used depending upon 
the solution density of the sample being measured.  Prior to daily measurements, the accuracy of 
the Hi-Q microsensor was tested using the 1.03 µm bead standard.  Before each measurement, 
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the sensor and the micro tubing, was rinsed with 2% PCC-54 detergent, by applying high 
pressure on the sample and reference vials to clean the bypass channels.  In addition to the high 
pressure applied to the sample and reference vials, low pressure was also applied to the sample 
waste vial to induce a flow to rinse the sensor with 2% PCC-54 detergent.  This process was 
applied until a clean frequency trace was achieved.  The sensor was then loaded with particle 
free water and two “sneeze” operations were performed.  The sample was loaded for 30 s, and a 
stop trigger of 200 particles or 30 min measurement time was used.  The limit of detection was 
empirically determined (0.035 Hz) and used throughout the study.  The density value for the 
mAb was estimated at 1.41g/ml based on protein molecular weight (98).  
2.2.7. Microflow Digital Imaging 
A DPA-4200 flow microscope (Protein Simple, Santa Clara, CA) was used to capture 
digital images of subvisible particles with ECD from 2-70 µm.  Before each measurement, the 
flow cell was primed in the following manner: particle free water was flushed through the flow 
cell at the maximum flow rate until the flow cell was observed to be particle free for at least 30 s.  
The optimize illumination function was then used to ensure the proper level of solvent 
illumination.  Samples underwent the minimal required amount of sample handling prior to 
measurement and were degassed by exposure to a vacuum chamber for 10 min.  To prevent 
clogging of the flow cell, samples containing approximately 50 or more visible particles 
(observed through visual inspection) were set aside for 30 min to allow the largest particles to 
settle.  Samples with particle concentrations over the limit of quantitation (900,000 
counts/ml)(121) were diluted and the results were corrected for the dilution factor (samples 
subjected to 240 min of stirring were diluted 1:3, and samples stressed for ≥120 min by heat 
were diluted 1:10).  Particle statistics were generated using MFI View Analysis Suite (MVAS) 
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version 1.3 (Protein Simple, Santa Clara, CA).  Each MFI measurement was separated into five 
subpopulations based upon particle equivalent circular diameter (ECD); 2≤x<5, 5≤x<10, 
10≤x<25, 25≤x<50, and 50≤x<70 µm.  
2.2.8. Radar Chart Construction 
Radar charts were generated using software developed in our laboratory (MiddaughSuite) 
as described previously (131).  This report is, however, the first time that radar chart arrays have 
been applied to protein aggregation and particle formation data sets from MFI, RMM and SEC.  
To create the MFI particle number and size range radar charts, particle concentration data, 
obtained from analysis using MVAS 1.3 software described above, were pre-processed by 
calculating the mean, standard deviation, and mean minus standard deviation (m-SD) for the five 
particle size populations listed in the previous section.  The mean and m-SD values were then 
uploaded to MiddaughSuite software.  The radar charts were set to a log scale and each axis was 
defined to have a minimum of 10 and a maximum of 1,000,000 particles.  Radar charts were 
generated for both the mean and the m-SD values and then precisely superimposed using pixel 
alignment in Adobe Photoshop CS6 (Adobe Systems, San Jose, CA).  The purpose of 
superimposing the two radar charts was to include an indication of error for n=3 replicate 
experiments because particle measurements are often highly variable.  The m-SD was chosen 
because m+SD would be hard to visualize because positive error bars appear smaller on a log 
scale. 
Particle morphology radar charts were created using the average mean intensity and 
aspect ratio values for each of the five particle size populations (obtained through the filter 
manager tool in MVAS 1.3).  These data were pre-processed and the mean and m+SD values 
were uploaded to MiddaughSuite.  The axes of this radar chart were set to an inverted linear 
35 
 
scale and each axis was defined to have a minimum value of 0.35 and a maximum of 0.85.  Axes 
with an insufficient number of particles (empirically determined to be < 25 counted) were 
highlighted with a light red background color.  The mean and the m+SD particle morphology 
radar charts were also superimposed using Adobe Photoshop to indicate variability between n=3 
measurements.  The m+SD were used to maintain the consistency of radar chart interpretation 
because the morphology radar chart arrays use an inverted linear axis. 
To create the “multiple instruments” radar chart, data from SEC, RMM, and MFI were 
preprocessed to obtain the mean and the m-SD for each condition.  The data were then uploaded 
to MiddaughSuite and each axis was highlighted with a background color according its scale.  
Axes 1 and 2, corresponding to total area loss and monomer loss were set to an inverted linear 
scale between 0 and 100%.  Axis 3, the soluble aggregate content, was set to a linear scale 
between 0 and 25%.  Axes 4-6, representing submicron and small subvisible particle 
concentrations between 0.275 and 1.85 µm were set to a log scale with a minimum value of 104  
and a maximum value of 109 particles (approximate limit of quantitation for the Archimedes).  
Lastly, axes 7-9, representing subvisible particles from 2-70 µm, were set to a log scale with a 
minimum of 100 and a maximum of 107  particles.  The mean and m-SD radar charts were 
generated and superimposed using Adobe Photoshop to indicate error between the n=3 
measurements.   
2.3. Results 
2.3.1. Conformational Stability of IgG1 mAb vs. Solution pH and NaCl 
Concentration 
Prior to examining the effect of formulation variables on particle formation, differential 
scanning calorimetry was used to study the relative conformational stability of the IgG1 mAb in 
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solutions with varying pH and NaCl concentrations.  For example, at pH 4, three thermal melting 
events were observed at 56.1, 70.7, and 72.6 °C, which are referred to as Tm1, Tm2, and Tm3, 
respectively (See Figure 2.1).  The effects of solution pH and NaCl on the observed Tm values 
for the mAb are summarized in Table 2.1.  mAb solutions at pH 4 had the lowest thermal melting 
value (and onset temperatures) while the addition of 0.15 and 1 M NaCl to the pH 4 solutions 
caused further reductions in melting and onset temperatures (Table 2.1).  At pH 6 and 8 with no 
NaCl, only Tm2 and Tm3 were reproducibly detected.  Addition of 0.15 M NaCl appeared to 
slightly lower the melting and onset temperatures, and the addition of 1 M NaCl resulted in 
detection of Tm1.  In addition, fluorescence measurements using ANS as an extrinsic probe were 
used to determine if solution pH and NaCl concentration influenced ANS interactions with 
hydrophobic surfaces within the mAb (or potentially between mAbs).  No major differences in 
ANS fluorescence intensity were observed in the various mAb solutions described above, 
suggesting no major alterations of mAb’s overall tertiary structure (or self-associations) across 
the pH range of 4-8 and NaCl concentrations of 0 to 1M (data not shown). 
2.3.2. Radar Chart Analysis of Effects of Solution pH, NaCl Concentration, 
and Stress on IgG1 mAb Particle Formation as Measured by MFI 
2.3.2.1. Particle Number and Size 
Radar Charts were initially constructed to visualize various data sets of subvisible particle 
formation as obtained by MFI with an IgG1 mAb under different formulation conditions.  First, 
we present some generic MFI data to demonstrate how to interpret a radar chart.  Figure 2.2A 
shows a commonly used graphical representation of generic MFI data from one experimental 
condition, i.e., a histogram of particle concentration (log scale) as function of particle size 
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(grouped together in different size bins).  Figure 2.2B shows the same MFI data in the form of a 
radar chart.  The numbered axes of the radar chart correspond to the same numbered size bins on 
the histogram (e.g., number one refers to particle size bin 2-5 microns in both Figures 2.2A and 
2.2B).  The axes of radar charts are linearly connected so that the data set can be visualized as a 
polygon.  In addition, particle concentration is displayed in this radar chart using concentric rings 
positioned from the center to the edge of the circle.  For example, as shown in Figure 2.2C, each 
ring shows a ten-fold increase in particle concentration.   
In Figure 2.3, radar chart analysis was used to elucidate the effect of varying solution pH, 
NaCl concentration, and stress conditions on the kinetics of subvisible particle formation 
(number and the size distribution as measured by MFI) for an IgG1 mAb.  Prior to stress, a low 
number (i.e., 100 to 3,000) subvisible particles were detected in the various protein samples with 
samples at pH 4 having fewer particles than pH 6 regardless of the NaCl concentration.  After 10 
min of shaking stress (left panel of Figure 2.3), more than 5,000 particles (2-25 µm) had formed 
at pH 4 with no added NaCl.  Samples containing 0.15 M NaCl formed particles at a similar rate, 
however, ~50 particles from 25-50 µm had also formed.  Samples in the presence of 1 M NaCl 
had the highest particle concentration in size range of 2-25 µm as well as >100 particles/ml from 
25-50 µm.  The concentration of subvisible particles, generated through shaking, increased over 
the time of shaking with increased values noted at 120 min.  Particle formation decelerated after 
120 min (no longer forming at a logarithmic rate) with the 240 min shaking sample showing 
similar particle concentrations and size distributions across the pH and NaCl conditions 
examined.  The presence of 1 M NaCl had a more pronounced effect on IgG1 mAb samples at 
pH 4 that were shaken for more than 2 h since an average of 10,000 particles from 25-50 µm and 
1,000 particles from 50-70 µm had formed.  In general, the presence of 1 M NaCl at pH 4, 6 or 8 
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caused larger subvisible particles to form when these protein samples were shaken (Figure 2.3, 
left panel and Figure 2.11).  
The IgG1 mAb samples stirred at pH 4 resulted in an entirely different subvisible particle 
distribution, compared to shaking under the same solution conditions (Figure 2.3, middle panel).  
For example, particles generated from stirring stress tended to be primarily 2-25 µm in size.  
After 10 min of stirring, samples with 0 M NaCl had the least amount of subvisible particles, 
0.15 M NaCl had ~104 particles/ml, and 1 M NaCl  had >104 particles. The concentration of 
small particles noticeably increased between 2 and 4 h of stirring.  After 4 h of stirring, for IgG1 
mAb samples with 1 M NaCl, the most subvisible particles (> 106 particles/ml from 2-5 µm) 
were formed, while samples with 0.15 M NaCl formed ~300,000 particles/ml from 2-5 µm and 
samples with no NaCl formed <50,000 particles/ml (Figure 2.3, middle panel).   
Samples stirred at pH 6 (Figure 2.3, right panel) and pH 8 (Figure 2.10, right panel) 
exhibited very different behaviors in terms of the effect of NaCl on particle formation compared 
to pH 4. Samples at pH 6 in the absence of NaCl had the highest concentration of subvisible 
particles over 4 h (particle concentrations >106 particles/ml).  In contrast, the presence 1 M NaCl 
greatly reduced the concentration of subvisible particles to ~50,000/ml.  At pH 8, the presence of 
either 0.15 or 1M NaCl greatly reduced the concentration of subvisible particles for IgG1 mAb 
samples stirred for 2 and 4 h (Figure 2.10). 
 2.3.2.2. Particle Morphology 
Representative particle images captured by MFI demonstrate formation of low, medium, 
and high aspect ratio/intensity valued protein particles in the IgG1 mAb solutions depending on 
the formulation and stress (Figure 2.4).  Model ellipses that correspond to particle aspect ratio 
values are also presented as a simplified method to visualize particle elongation (i.e., aspect 
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ratio).  We present some MFI data to demonstrate how to interpret a radar chart for particle 
morphology.  In Figure 2.5A, these data are presented in a manner similar to other reports with 
published MFI morphological data (134).  Figure 2.5A shows scatter plots (for the first 3,000 
particles counted by MFI, n=1) of particle size vs. a morphological parameter, one plot for 
particle aspect ratio and the other for particle intensity.  Morphological data from additional 
particles cannot be added to these scatter plots since resolution would be lost as additional data 
points merge into one continuous color (not shown).  In contrast, the aspect ratio and intensity 
values from the same experiment, but this time using the entire, complete data set (>200,000 
particles/ml, n =3) are presented as an radar chart (Figure 2.5B) showing particle size vs. 
morphological parameter, using a scale for the morphology parameters as shown in Figure 2.5C 
(i.e., aspect ratio or intensity/1000).  Regions shaded in light red in the radar charts in Figure 
2.5B denote insufficient particles were present in the samples (empirically defined as < 25 
particles as measured by MFI) to effectively compare the effect NaCl, pH, and stress on particle 
morphology.   One reason this was done was so that the few subvisible particles present at time 
zero did not affect the radar chart analysis of the morphological properties of particles formed 
from stress and solution conditions over time.   
As an example, radar chart analysis of MFI particle morphological parameters are shown 
for IgG1 mAb samples stressed for 4 h with varying pH, NaCl, and stress conditions (Figure 
2.6).  As shown on the left panel, the average particle aspect ratio and intensity values did not 
change with NaCl concentration when samples were stirred for 4 h at pH 4.  As another example, 
the addition of 1 M NaCl had a profound effect on particle morphology when the samples were 
subjected to 4 h of shaking at pH 4 and 8.  When the mAb samples were shaken at pH 4 (Figure 
2.6, middle panel), the presence 1 M NaCl caused the average aspect ratio of all size ranges in 
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the particle distribution to decrease (i.e., the particle elongation increases).  Particles larger than 
25 µm had an average aspect ratio of less than 0.35 (refer to the ellipse models presented in 
Figure 2.4).  Additionally, the intensity of subvisible particles in the size range from 25-50 µm 
increased (became more transparent) in the presence of 1M NaCl when compared with both 0 M 
and 0.15 M NaCl.  Samples of IgG1 mAb subjected to the same shaking stress but now at pH 8 
(Figure 2.6, right panel), in the presence of 0 M and 0.15M NaCl, contained particles with low 
intensity (i.e., were not transparent) and had a high aspect ratio (i.e., more globular).  
Interestingly, the presence of 1 M NaCl at pH 8 caused a large increase in average intensity and a 
substantial reduction in the aspect ratios for particles in the size range over 10-50 µm.    
2.3.3. Radar Charts Incorporating Protein Aggregate and Particle Formation 
Data from Multiple Analytical Techniques 
Radar chart array analysis was then applied to data sets from multiple analytical 
techniques, which measured mAb particle and aggregate formulation over different size ranges.  
The ‘multiple-instruments radar chart’ was designed to provide mechanistic information relating 
to the potential interrelationships of soluble aggregate and particle formation.  A representative 
example of the multiple-instrument radar chart is shown in Figure 2.7.  For SEC, Figure 2.7A 
shows a typical bar graph of SEC data for pH 6, 0.15 M NaCl mAb samples that were heated for 
2 h.  SEC data includes the percent of monomer loss, total area loss (insoluble aggregate), and 
soluble aggregates formed.  The same SEC data are also presented in radar chart form in Figure 
2.7D (axes 1-2 in the purple region, and axis 3 in the blue region, of the radar chart in Figure 
2.7D correspond to bars 1-3 in Figure 2.7A).  Similarly for submicron particle data, Figure 2.7B 
is a histogram of RMM data, for the same heat stressed mAb sample, providing particle size data 
in the submicron range up to particles with an equivalent spherical radius of 1.85 µm.  The 
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numbered size bins (4-6) in Figure 2.7B correspond to axes 4-6 in the yellow region of the 
corresponding radar chart (Figure 2.7D).  Finally, Figure 2.7C is a histogram of MFI particle size 
and concentration data for the heat stressed mAb sample for subvisible particles of size 2-70 µm.  
The particle size bins numbered 7-9 in the histogram (Figure 2.7C) correspond to axes 7-9 in the 
red region of the radar chart (Figure 2.7D).  A more detailed key showing the labeling of the 
multiple-instruments radar chart in terms of scale and measurements, are provided in Figure 
2.7E. 
An example of utilizing a ‘multiple-instruments radar chart’ to characterize aggregate and 
particle formation is shown for heat and stirring stresses of an IgG1 mAb solution at pH 6 with 
varying NaCl concentrations (left panel of Figure 2.8).  At time zero (at all NaCl concentrations), 
the mAb samples contained <1,000 subvisible particles, >105 submicron particles, and were > 
99% monomer with <0.2% soluble aggregates.  After 10 min of heat stress at 65˚C, mAb 
samples without NaCl showed a ~10% total peak area loss as well as a ~10% monomer loss as 
measured by SEC, and after 2 h of heating, the samples had 35% total area loss, 40% monomer 
loss, and 5% soluble aggregates.  In addition, an extremely high concentration of subvisible 
particles (>107 particles/ml) was now observed.  Interestingly, under the same conditions, the 
addition of 0.15 M NaCl increased soluble aggregate levels to 10% based on SEC with a 
concomitant decrease the total concentration of subvisible particles by ~10 fold as measured by 
MFI (and did not substantially change the amount of submicron particles).  The presence of 1 M 
NaCl in the mAb solution greatly increased the levels of soluble aggregates to ~22% while the 
measured total area loss was approximately 20%, and the monomer loss was ~50%  as measured 
by SEC.  In addition, the 1M NaCl containing mAb samples showed a greatly reduced 
concentration of subvisible particles  (<50,000 measured by MFI), as well as a reduced 
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concentration of submicron particles by more than 10x as measured by RMM.  After 4 h of 
heating, there was essentially complete aggregation and the monomer species was virtually 
undetectable by SEC (left panel of Figure 2.8).    
The effect of stirring stress on IgG1 mAb solutions is shown in the right panel of Figure 
2.8.  In contrast to heating stress, no major changes in soluble aggregate levels were observed 
(with less than 10% total area loss) by SEC in the majority of samples subjected to stirring stress.  
This result in itself suggests different aggregation mechanisms are dominant for heating and 
stirring stresses.  After 10 min of stirring, ~106 submicron sized particles formed in all of the 
samples, and the mAb sample without NaCl had formed the most subvisible particles ranging 
from 2-10 µm.  After 2 and 4 h of stirring, the particle number and size distributions in the mAb 
samples with 0 and 0.15 M NaCl appeared similar, but samples with 1 M NaCl showed a ~50 
fold reduction of subvisible particles along with a substantially increased number of submicron  
particles (~108 particles/ml) as shown in right panel of Figure 2.8.  Finally, mAb samples were 
shaken at pH 4 and displayed a third dominant aggregation mechanism (See Supplemental 
Figure 2.3): no soluble aggregates were detected by SEC, while submicron particle formation 
leveled off after 10 min as measured by Archimedes. The subvisible sized particle populations 
continued increasing over time as measured by MFI.  Under these conditions, the addition of 1 M 
NaCl caused increased formation of subvisible particles in the 25-70 µm size range. 
2.4. Discussion 
2.4.1. Utility of Radar Chart Arrays to Summarize and Analyze Protein 
Aggregate and Particle Formation Data Sets from Different Instruments 
 The ability of radar charts to better visualize protein aggregation and particle formation 
results for an IgG1 mAb in different formulations, as measured by multiple analytical 
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instruments, was investigated in this report.  We first used radar charts to examine the effect of 
pH, NaCl concentration, stress type, and length of stress exposure on the size and concentration 
of the sub-visible particles that were formed as measured by MFI.  A broader application of radar 
charts incorporating data from multiple analytical instruments was also investigated.  Radar chart 
array analysis was shown to be an effective tool for characterizing the effect of individual 
formulation composition and environmental stress variables on protein growth kinetics and 
particle size distribution.  For example, the pH dependent behavior of particle formation (number 
and size distribution) as a function of NaCl and stress (i.e., shaking and stirring) was established 
for an IgG1 mAb.  It is important to emphasize the utility of radar charts to plot large data sets of 
MFI data and compare trends across formulation conditions.  For example, the MFI data in 
Figure 2.3 represents 36 different experimental conditions (e.g., time, stress type, formulation 
composition) performed in triplicate resulting in a total of 108 experiments.  If histograms were 
to be used as shown in Figure 2.2A, many plots would be needed to summarize the results and 
compare the effects of time, stress type, and formulation composition on mAb particle formation 
(including particle concentration and size distribution) in solution.  This makes analysis of trends 
in particle size, concentration and morphology more challenging.  Using radar chart array 
analysis, however, all of these results are displayed, and trends across the 36 conditions are 
summarized in a single figure (Figure 2.3).  The radar chart arrays in this paper were modified to 
display statistical variability, in the form of standard deviation, of the various data sets. The 
ability to display the error makes these modified radar-chart arrays a more powerful tool to study 
protein aggregation than other data visualization methods such as the empirical phase diagrams. 
Another application of radar chart analysis is to analyze the effect of formulation 
composition and environmental stresses on the average morphology of any subvisible particle 
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size range.  MFI is capable of measuring multiple particle morphological parameters such as 
intensity, feret diameter, aspect ratio, circularity, etc.  Unfortunately, these data remain largely 
underutilized, especially in comparison to particle concentration and size range measurements.  
This is largely due to unfamiliarity with the parameters and the difficulty in presenting such large 
data sets in an organized fashion.  Several reports have recently presented MFI morphological 
data using scatter plots and line graphs (107, 134).  These graphical methods are effective at 
presenting a few morphological data sets, however, scatter plots and line graphs become 
cumbersome to interpret as the quantity of particles and/or the number of data sets (e.g., 
formulation conditions and time points) increase.  Other data visualization methods used for 
displaying biophysical stability data, such as the EPD, would also be inefficient at visualizing 
particle morphological trends because principle components analysis would complicate data 
interpretation since all of morphological parameters correlate to varying degrees.  Radar chart 
analysis was successful in elucidating the effect of buffer composition (pH and NaCl 
concentration) and stress conditions (shaking and stirring) on the morphology of sub-visible 
particles (aspect ratio and intensity) formed from IgG1 mAb solutions (Figure 2.6).  Radar-chart-
array analysis could be applied in the future to elucidate the effect of similar formulation 
variables on other particle parameters including particle mass, reversibility (defined as a decrease 
in particle size when diluted to stable pH conditions) (66), density, and surface irregularity 
(fractal dimension); such work is currently underway in our laboratory.    
Radar chart arrays were also used to visualize results from multiple analytical instruments 
that monitor protein aggregate and particle formation across size ranges from mAb soluble 
aggregates (SEC), to submicron particles (RMM), and to subvisible particles (MFI).  To our 
knowledge, there are no other data visualization methods available which provide such a 
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comprehensive picture of protein aggregation data across a wide size range.  Although radar 
chart array analysis provided qualitative comparisons of the effect of formulation variables on 
mAb aggregation, one limitation of this approach is that SEC, RMM and MFI use different 
measurement methods and provide information on different numerical scales.  For example, 
RMM measures a frequency shift caused by a particle passing through a resonator and calculates 
the buoyant mass based on the shift and the sensitivity of the resonator.  An equivalent spherical 
diameter is calculated using  the appropriate density value and the buoyant mass (refer to Burg et 
al. for further explanation) (112).  MFI measures the 2-dimensional area of particles and, through 
image analysis, calculates the equivalent circular diameter (ECD) of the particle (135).  ECD is 
not directly related to spherical diameter, and assuming such may result in an overestimation of 
particle volume.  Another current analytical limitation is the presence of a detection gap because 
of the inability to accurately measure very small particles from ~50 nm to 275 nm. The 
application of nanoparticle tracking analysis (NTA) or dynamic light scattering would be of 
interest in future studies to address a more complete size range. NTA requires, however, a high 
minimum concentration of submicron particles (>106/ml) and would likely be applied to select 
samples.   Nonetheless, radar chart analysis was an effective tool for probing complex protein 
growth mechanisms monitored by multiple analytical techniques (Figures 2.7 and 2.8) and, in 
general, offered the ability to more easily follow trends in the data, thus providing some 
additional insights as described below.  
2.4.2. Effects of pH, NaCl and Stress on IgG1 mAb Aggregate and Particle 
Formation and Morphology 
 The focus of this work was on the development of radar chart data visualization 
techniques for MFI data on subvisible particle formation (concentration, size range, and 
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morphology) due to different stresses (shaking, stirring, heating).  Once developed, however, 
interesting trends in the physical instability of this model IgG1 mAb were readily apparent.  For 
example, the pH and stress-type dependence of the NaCl effect on the aggregation profile of this 
IgG1 mAb was striking.  During stirring and heating, but not shaking, the presence of 1 M NaCl 
promoted particle growth at pH 4, but inhibited particle growth at pH 6 and 8 (refer to Figure 2.8 
and Figure 2.9).  In contrast, during shaking stress, the presence of NaCl increased the size and 
concentration of particles present at pH 4, 6, and 8 (refer to Figure 2.11).  This pH-dependent 
effect of NaCl on the physical instability of this IgG1 mAb was also observed by separate 
turbidity measurements (data not shown).  
 Studies have previously shown that anion binding promotes aggregation of an IgG mAb 
through charge shielding and by affecting conformational stability (118).  In this work, the 
presence of NaCl (> 0.15 M) destabilized the conformational of the mAb at pH 4 as measured by 
DSC in terms of Tonset and three Tm values (See Table 2.1).  NaCl had a much less pronounced 
effect on Tonset and Tm values for this IgG1 mAb at pH 6 and 8 (See Table 2.1).  The observed 
decrease in conformational stability provides some insight into why the presence of NaCl 
destabilizes this mAb at pH 4 during stress.  It does not, however, necessarily address the 
observed effects of NaCl on slowing particle formation during heating or stirring at pH 6 or 8.  
Kroetsch et al. showed that soluble aggregates of alpha-chymotrypsinogen A rapidly coalesce to 
form insoluble aggregates once a critical salt concentration was reached (116).  Our results 
suggest that addition of 1 M NaCl at pH 6 actually increases the colloidal stability of this mAb 
since the particles formed during heating and stirring are on average much smaller in size 
compared to samples with or without 0.15 M NaCl.  Accurate particle mass (or density) 
measurements/calculations, however, are needed in addition to particle size, to more 
47 
 
conclusively understand the effect of NaCl on the colloidal stability of this mAb.  Such 
measurements and calculations, combined with radar chart array analysis of the results, are 
currently underway.  
 Another interesting observation is that the average morphology of subvisible particles 
formed varies with solution pH and NaCl for shaking, but not stirring stress.  The particles 
created through stirring appear to form by a similar mechanism since they have similar size and 
morphology across the pH values and NaCl concentrations as measured by MFI.   In contrast, 
subvisible particles created through shaking have a diverse morphology (i.e., aspect ratio, 
intensity) that is sensitive to both the pH and NaCl concentration.   This result suggests that in 
addition to changing the conformational and colloidal stability of a mAb, the formulation 
composition can also influence the mechanism of aggregation under certain stresses, potentially 
by influencing the nature of the interactions between the associating molecules.   
 Since formation of aggregates and particulates during long-term and accelerated stability 
studies affect formulation composition choices and decisions about storage conditions and shelf 
life, radar chart analysis could assist in these important comparisons during formulation 
development.  Stability data are also a key part of comparability assessments, since changes in 
mAb drug product formulations or primary containers may affect the protein’s physical stability 
(136, 137).  Radar charts could potentially assist in these types of comparisons as well.   For 
example, the effect of formulation impurities from prefilled syringes such as silicon oil (64, 138) 
and tungsten (139) on protein particle formation could be evaluated by radar chart analysis using 





When conducting high throughput screening studies of protein instability under various 
formulation conditions, data visualization methods are crucial to quickly and effectively interpret 
large quantities of physical stability data (140, 141).   Radar chart analysis offers an exciting 
opportunity to improve the throughput and effectiveness of analyzing protein aggregation and 
particle formation studies.  Additionally, there is potential to combine particle size/concentration 
data sets with more accurate measurements/approximations of protein particle volume, partial 
specific volume, and mass (in development).  Radar chart analysis should also provide an 
improved understanding of the effect of formulation composition and environmental stresses on 
















2.6. Figures and Tables 
2.6.1 Tables 









4.0 0.00 48.1 0.9 56.1 0.1 70.7 0.2 72.6 0.1 
  0.15 46.6 0.4 53.0 0.1 68.3 0.1 70.8 0.1 
  1.00 44.7 0.2 50.9 0.1 67.3 0.1 68.5 0.1 
6.0 0.00 66.1 0.1 ND ND 73.0 <0.1 83.4 0.3 
  0.15 65.4 0.2 ND ND 72.7 <0.1 83.3 <0.1 
  1.00 62.6 0.5 69.9 0.1 74.3 <0.1 84.1 <0.1 
8.0 0.00 66.0 0.2 ND ND 72.3 <0.1 82.7 <0.1 
  0.15 66.0 0.3 ND ND 71.9 <0.1 82.7 <0.1 
  1.00 64.5 0.1 71.0 <0.1 73.6 <0.1 83.6 <0.1 
 
Table 2.1. Effect of Solution pH and NaCl Concentration on Thermal Onset (Tonset) and 
Thermal Melting (Tm1, Tm2, Tm3) Temperatures of an IgG1 mAb as Determined by DSC. 
See methods section for experimental details.  SD is standard deviation from triplicate (n=3) 







Figure 2.1.  Representative DSC Thermogram of the IgG1 mAb.  DSC thermogram of the 
IgG1 mAb (1 mg/mL) in a 20 mM citrate phosphate buffer, pH 4.0, no NaCl.  Tm1, Tm2, and Tm 





Figure 2.2.  Application of Radar Chart array Analysis to Evaluate Subvisible Particle 
Concentration and Size Distribution Data Measured by MFI. (a) Histogram (n=3) of 
representative MFI data plotting particle concentration versus particle size (ECD) for an IgG1 
mAb solution containing 20 mM citrate-phosphate buffer at pH 8.0 and 1 M NaCl subjected to 4 
hours of shaking. (b) Radar chart presentation of the same data set; each axis is labeled with a 
number and is the same size range as the corresponding numbered bin size in the histogram.  The 
values along the each axis of the radar chart are connected linearly to visualize the data set as a 
polygon.  The perimeter of the outermost polygon represents the mean particle concentration, the 
polygon labeled ‘mean - SD’ represents the mean minus one standard deviation, and the distance 
between the perimeters of the two polygons (along an axis) is equivalent to the lower error bar in 
the equivalent bin of the histogram (one standard deviation). (c)  Illustration of the particle 
concentration (log scale) used in the radar charts in this work to display experimentally measured 




Figure 2.3. Radar Chart Array Analysis of Subvisible Particle Concentration and Size Data 
for IgG1 mAb Solutions as Measured by MFI.  IgG1 mAb solutions of varying pH values and 
NaCl concentrations were exposed to different stress types over time as indicated in the figure 
(n=3), and resulting formation of subvisible particles was measured by MFI. The Y-axis 
represents the amount of time the formulations were stressed (in minutes), the X-axis represents 
NaCl concentrations, and each radar chart panel (left, middle, right) signifies a change in stress 
or pH.  See methods for experimental details of MFI measurements from each of these 
accelerated stress studies.  Refer to Figure 2.2 for an explanation of MFI particle concentration 





Figure 2.4. Representative Morphological Parameters for Protein Particles from MFI 
Analysis.  Examples of three different aspect ratios and intensity values (low, moderate, and 
high) are presented along with corresponding IgG1 mAb particle images from MFI.  Model 
ellipses of equivalent aspect ratios are presented to help visualize changes in particle shape.  For 




Figure 2.5.  Application of Radar Chart Array Analysis to Evaluate Subvisible Protein 
Particle Morphological Parameters Measured by MFI. (a) Scatter plots of a subset of particle 
data displaying aspect ratio (top) and intensity (bottom) versus ECD (first 3,000 from n=1 
experiments) counted within an IgG1 mAb solution containing 20 mM citrate buffer at pH 8.0 
and 0.15 M NaCl subjected to 4 h of shaking.   Light red shading represents size bins with 
insufficient data as defined by x < 25 particles counted.  (b) Radar chart presentations of the 
same experiment showing average aspect ratio (top) or intensity/1000 (bottom) per size range 
except with the complete data set (~200,000 particles, n=3);  each numerical axis in the radar 
chart is an equivalent size range to the corresponding numbered region in the scatter plots.  The 
perimeter of the outermost polygon displays the mean morphology parameter, the perimeter of 
the polygon labeled ‘mean + SD’ displays the mean plus one standard deviation, and the distance 
between the perimeters of the two polygons (along an axis) is one standard deviation. (c)  
Illustration of the scale/units used in the radar charts to display experimentally measured (MFI) 




Figure 2.6. Radar Chart Array Analysis of Protein Particle Morphological Parameters 
Versus Particle Size for IgG1 mAb Solutions as Measured by MFI.  IgG1 mAb solutions (at 
indicated pH and salt concentration) were stressed to generate protein particles (n=3), and 
solutions were analyzed by MFI.  See methods section for experimental details of each 
accelerated stress study.  The Y-axis is labeled with the morphological parameter, the X-axis 
represents the NaCl concentration, and each panel (left, middle, right) represents a change in 
stress or pH as indicated.  The numerical value/units of each concentric circle in this radar chart 
is shown in Figure 2.5C.  Light red shading represents a region where an insufficient number of 
particles (x < 25) were counted.  Refer to Figure 2.5 for an explanation of particle morphological 





Figure 2.7. Application of Radar Chart Array Analysis to Protein Aggregate and Particle 
Formation Data from Multiple Analytical Techniques.  An IgG1 mAb solution containing 20 
mM citrate phosphate buffer (pH 6.0) and 0.15 M NaCl was heated at 65˚C for 120 min and the 
levels of soluble aggregates, submicron and subvisible particles were measured using SEC, 
RMM and MFI, respectively. (a, b, c) Bar graph (n=3) of SEC, RMM particle concentrations 
(0.275-1.85 µm) and MFI particle concentrations (2-70 µm).  (d) Radar chart presentation of the 
same data sets shown bar graphs (a,b,c).  The SEC, RMM and MFI data denoted 1-3, 4-6 and 7-9 
in the bar charts (a, b, c, respectively) corresponds to axes 1-3, 4-6 and 7-9 in the corresponding 
radar chart (d). The perimeter of the outermost polygon in the radar chart displays the mean 
value (particle concentration or area gain/loss), the perimeter of the polygon labeled ‘mean - SD’ 
represents the mean value minus one standard deviation, and the distance between perimeters of 
the two polygons (along an axis) is one standard deviation. (e) Illustration of the numerical scales 
and units for the radar chart axes with different scales being highlighted with distinct background 




Figure 2.8. Radar Chart Analysis of Protein Aggregate and Particle Formation Data from 
Multiple Analytical Techniques to Visualize the Extent of IgG1 Physical Instability. IgG1 
mAb solutions containing 20 mM citrate phosphate buffer (pH 6.0) and varying NaCl 
concentrations were stressed by either heat at 65˚C or stirring over time (n=3).  Samples were 
evaluated by a combination of SEC, RMM and MFI.  See methods section for experimental 
details of each accelerated stress study.  The Y-axis represents the amount of time the samples 
was stressed (in minutes), the X-axis represents NaCl concentration, and each radar chart panel 
(left and right) denotes heating and stirring, respectively. Refer to Figure 2.7 for an explanation 
of units and scales used in the individual radar charts for each analytical method (SEC, RMM 




Figure 2.9. Multiple Instruments Radar Chart Array Analysis for Accelerated Stress Study 
with IgG1 mAb.  IgG1 mAb solutions containing 20 mM citrate phosphate buffer (pH 4.0) and 
varying NaCl concentrations were stressed by shaking side-to-side at 300 RPM over time (n=3).  
Samples were evaluated by a combination of SEC, RMM and MFI.  The Y-axis represents the 
amount of time the samples was stressed (in minutes), the X-axis represents NaCl concentration.  
Refer to Figure 2.7 for an explanation of units and scales for the individual radar charts for each 




Figure 2.10. Radar Chart Array Analysis of Subvisible Particle Concentration and Size for 
Particles Created by Stirring.  IgG1 mAb solutions of varying pH values and NaCl 
concentrations were exposed to stirring with a Teflon bar for up to 4 h (n=3). The Y-axis 
represents the amount of time the formulations were stressed (in minutes), the X-axis represents 
NaCl concentrations, and each radar chart panel (left, middle, right) signifies a change in pH.  
Refer to Figure 2.2 for an explanation of particle concentration and size scales shown in 









Figure 2.11. Radar chart array analysis of subvisible particle concentration and size for 
particles created by shaking.  IgG1 mAb solutions of varying pH values and NaCl 
concentrations were exposed to side-to-side shaking at 300RPM for up to 4 h (n=3). The Y-axis 
represents the amount of time the formulations were stressed (in minutes), the X-axis represents 
NaCl concentrations, and each radar chart panel (left, middle, right) signifies a change in pH.  
Refer to Figure 2.2 for an explanation of particle concentration and size scales shown in 








Chapter 3: Calculating the Mass of Subvisible Protein Particles with 























The formation of subvisible particles (1-100 µm in diameter) in therapeutic protein 
products has the potential to impact the clinical utility of these parenteral administered therapies.  
One major concern with monoclonal antibody (mAb) drugs is that subvisible particles could 
induce an immune response that results in the formation of neutralizing anti-drug antibodies that 
limit efficacy (1).  This presents as a unique formulation challenge because protein degradants 
can form not only during manufacturing, storage and shipping, but potentially during 
administration as a result of improper handling or dilution into an IV bag (120, 142, 143).   There 
have been numerous studies and reviews devoted to characterizing and classifying protein-based 
subvisible particles (66, 70, 95, 97, 100, 106, 108, 113).     Recently, the potential risks of 
different types of protein subvisible particles in inducing immune responses have been evaluated 
in various preclinical models including cell culture and animal studies (12, 13, 144, 145).   
Subvisible particles tend to be fragile associations of native-like or non-native protein 
molecules that typically represent only a small fraction of the entire protein mass in solution 
(e.g., ~0.01%) (122, 123, 134).  Consequently, isolating or enriching specific particle 
subpopulations by size or morphology is technically challenging.  The extent of protein particle 
formation can be modulated by changing the conformational and/or colloidal stability of a given 
protein in solution (4).  Controlling the size or morphology of the particles, however, is 
challenging since protein aggregation can occur by a number of different mechanisms that may 
vary based upon the protein, the formulation, exposure to nucleation sites, and the external stress 
applied (44, 54, 68, 81, 87, 134). Joubert et al.(66) and Luo et al.(113) have shown that different 
stress conditions create particles that vary in size, concentration, degree of structural 
perturbation, and extent of chemical modifications.   The effect of stress on the size, 
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morphology, and concentration of subvisible particles is also sensitive to formulation (e.g. pH, 
NaCl concentration) (54, 70).  Additionally, the initial presence of soluble aggregates(116) 
and/or submicron(146) particles can facilitate subvisible particle formation.    Finally, solution 
formulation conditions and sample handling encountered during experimental measurements can 
affect the size and number of subvisible particles observed.  For example, both flow microscopy 
and light obscuration decrease in accuracy when the refractive index (RI) of solution approaches 
the RI of particles (110, 147). Analytical methods should minimize sample handling to preserve 
the integrity of the resulting particles (101), while dilution and/or de-gassing procedures may be 
necessary to accommodate instrument capabilities. 
The number and size range of subvisible particles in parenteral products have 
traditionally been measured by light obscuration, but when applied to monitoring protein 
particles, accuracy may be limited since protein particles act as phase objects and primarily 
scatter visible light in the forward direction which can result in poor contrast (95, 108, 148, 149). 
Flow microscopy has emerged as a more effective method to count and characterize large, 
proteinaceous subvisible particles because contrast is enhanced by interference that results from 
the recombination of diffracted light waves that differ in phase (149, 150).  Particles can then be 
more accurately sized by combining positive and negative contrast thresholds with a 
neighborhood analysis algorithm (150). Microflow imaging (MFI) is often selected for flow 
microscopy measurements (107, 121, 123). Through automated image analysis, MFI provides 
various size, morphology and transparency parameters which can be applied to discriminate 
between proteinaceous particles and other contaminants such as silicone oil droplets (124).  
Wuchner et al reported a calculation of protein particle weight based on MFI data using 
simple assumptions of spherical shape and a reported value of protein partial specific volume 
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(123).  These calculations were comparable to experimentally determined levels in a high 
concentration IgG1-mAb solution after long-term storage at 2-8°C.  Barnard et al.,(122) used a 
similar approach to calculate the mass of individual protein particles in solution based on data 
from MFI measurements.  In their calculations, it was assumed that protein particles are spherical 
in shape, composed of 75% protein, and have a density of 1.43 g/ml (determined by Quillin et al) 
(151).  In this work, we sought to build on these reports by combining a new approach to 
calculate particle volume from MFI data with updated assumptions of protein particle 
composition and density.  The applications, shortcomings, and advantages of this new 
calculation method, as well as comparisons to the Barnard et al.(122) method, are also discussed. 
3.2. Experimental Procedures 
3.2.1. Materials and Sample Preparation 
An IgG1 mAb (pI ~ 9) was provided by Janssen Biotech Inc. (Horsham, Pennsylvania) at 
a concentration of ~40 mg/ml.  The stock mAb solution was diluted to a final concentration of 1 
mg/ml using 20 mM citrate-phosphate buffer (C-P buffer) prepared at pH 4.0, 6.0, or 8.0 with 0, 
0.15 or 1.0 M NaCl.  The samples were filled into glass vials (Schott, Lebanon, Pennsylvania), 
stoppered and  then subjected to 2 h of shaking or stirring stress as described previously (54).  
All buffers were sterile filtered (0.2 µm) prior to use.  Polystyrene spheres (3, 5, 10, 25, 50 and 
70 µm in diameter) obtained from Thermo-Fisher Scientific (Waltham, Massachusetts) were 
used for method development.  Extensively aggregated control samples were prepared by 
shaking samples containing 1 mg/ml IgG in pH 5.0, 20 mM acetate buffer with 150 mM NaCl 
for 115 h.   
65 
 
 Elongated PS particles were produced from polystyrene (PS) spheres (Microparticles, 
Berlin, Germany) and polyvinyl alcohol (PVA) from (Sigma-Aldrich, Steinheim, Germany) by 
using a film-stretching method in hot oil (152).  Briefly, PVA (10% w/v) and glycerol (2.5% 
w/v) were dissolved in water at 85°C. Spherical PS particles were added to this solution at a 
concentration of 0.1% (w/v). 15 ml of the mixture was poured into a 75 cm² film-casting mold 
and dried for 72h at 25°C. PS particle films were cut into 5 x 4 cm sections and stretched using a 
manual film-stretching device build in-house. The device consists of 2 metal clamps in an oil 
bath (120°C) and a screw, which separates the two clamps during the stretching process. 
Particles were recovered by dissolving the film in water, followed by several washing steps with 
water / 0.01% SDS cleaning solution. 
3.2.2. Microflow Digital Imaging (MFI) 
A DPA-4200 MFI flow microscope (Protein Simple, Santa Clara, California) was used to 
image and count subvisible IgG particles with an equivalent circular diameter (ECD) from 2-70 
µm.  Prior to measurement, particles were de-gassed in a vacuum chamber for 10 min.  Particle 
counting and sizing statistics were obtained using MFI View Analysis Suite MVAS 1.3 (Protein 
Simple, Santa Clara, California) and assigned to five size bins based on particle ECD values as 
described previously (54).  Particle data across each of the five size bins, which covered the 
entire IgG1 particle distribution were used to calculate the particle mass (as described below).  
Prior to measurement, the extensively aggregated control mAb sample was diluted 1:10 to reduce 
particle levels to within the instrument detection limit (< 900,000/ml).   
MFI measurements were also performed on spherical and non-spherical polystyrene 
standards.  These samples were not degassed, and the data was exported into a spreadsheet for 
analysis.  For the non-spherical polystyrene samples, MVAS software was used to implement 
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morphology filters to remove impurities (e.g., small air bubbles, fragmented and dimeric 
standards) from the datasets to ensure accurate and representative particle statistics 
corresponding to the non-spherical standards.  The Gaussian shaped peak corresponding to the 
non-spherical standard was saved while the Gaussian shaped peaks corresponding to dimers and 
small fragments were removed.  The results were visually confirmed to ensure that no standard 
images were removed and that no digital images corresponding to polystyrene dimers remained.    
3.2.3. Radar Chart Construction 
Radar chart arrays visualizing subvisible particle data from MFI (particle concentration 
vs. size and particle morphology vs. size) were generated as described previously using in-house 
software (Middaugh Suite) (54).  In addition, a radar chart array displaying the calculated 
particle mass vs. measured particle size was prepared using particle mass data calculated using 
the ellipsoid-volume and Barnard et al., analysis methods described later.  This was pre-
processed by calculating the mean, standard deviation, and mean minus standard deviation 
(mean-Sdev) for the particles within the following ECD bins: 2 ≤ x < 5, 5 ≤ x < 10, 10 ≤ x < 25, 
25 ≤ x < 50, and 50 ≤ x < 70 µm (later referred to as bins 1, 2, 3, 4 and 5, respectively).  The 
mean and m-SD values were uploaded to Middaugh Suite and the radar charts were set to a log 
scale.  Each axis was set to display minimum and maximum masses of 10-1.5 µg/ml (~0.032) and 
10 µg/ml, respectively.  
3.2.4. Experimental Determination of IgG1 mAb Mass Loss Due to 
Mechanical Stress     
Prior to mechanical stress, the protein concentration of the IgG1 mAb samples was 
determined by measuring the absorbance at 280 nm (ε0.1%= 1.37) using an 8453 UV-Vis 
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Spectrophotometer (Agilent, Santa Clara, California).  Baseline correction was applied by 
subtracting the average value over the range of 320 to 400 nm (Light scattering correction as 
suggested by Mach et al. was attempted, but not implemented because it resulted in reduced 
spectra quality due to the extremely low optical density at 350 nm after centrifugation) (153).  
After the samples were stressed (and particles were measured by MFI from an aliquot of the 
sample), the remaining sample fractions were subjected to centrifugation at 17,000 x g for 15 
min.  The supernatant fractions of the samples were collected and the centrifugation step 
repeated. This centrifugation procedure removed >99.5% of subvisible particles and essentially 
100% of subvisible particles larger than 10 µm from the stress condition that produced the most 
particles (data not shown).  The difference in concentration between the unstressed and stressed 
IgG1 samples was then calculated.  The UV-Visible spectrophotometer accurately measured the 
loss of IgG at >15 µg/ml. 
3.2.5. Calculation of Particle Mass from MFI Data by Assuming Spherical 
Volume   
The mass of a protein particle was calculated using the equation developed by Barnard et 
al (122). The assumptions being that protein particles possess a spherical volume, and are 
composed of 75% protein and 25% solvent.  The mass of a single particle can be described by 
equation 3.1:  
M = 0.75 ∗ 4
3
π(d/2)3 ∗ 1.43 g
ml
                                                                                                (3.1) 
where M represents the calculated mass of a particle and d represents the equivalent circular 
diameter.  The total mass of particles was calculated by summing the calculated particle masses 
and correcting for the analyzed volume.   
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3.2.6. Calculation of Particle Mass from MFI Data Using the Ellipsoid-Volume 
Method 
The ellipsoid-volume method uses individual subvisible particle values of size and 
morphology (determined from two dimensional images captured by MFI) to calculate the mass 
of the three dimensional particle.  To this end, each subvisible particle is modeled as a 2-
dimensional ellipse with equivalent area and circularity, which is then rotated about its minor 
axis, to calculate the volume of a prolate ellipsoid of revolution.  This calculated volume of the 
particle is then used to calculate particle mass.   This requires values of the particle density and 
composition (see below).   Because of the novel nature of this method, we provide both a 
theoretical derivation in the methods section and a case study using an MFI data set in the results 
section to illustrate the utility of the method. 
3.2.6.1. Theoretical Derivation 
In this section of the derivation, we determine the relationship between circularity and 
aspect ratio for an ellipse.  This relationship can be applied to calculate the aspect ratio (AR) of 
an ellipse with an equivalent circular diameter (d) and circularity (C) equal to the particle.   
Using an approximation, the perimeter of an ellipse can be written: 
Perimeter =  π [3 ∗ � a + b� − �(a + 3b)(3a + b)]                       
 
This equation has ~0.41% error for ellipses with very high eccentricities.  “a” denotes the major 
axis and “b” denotes the minor axis.  The aspect ratio of an ellipse can be expressed as AR =  b
a
  
and b can be expressed in terms of a as b = a ∗ AR. 
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The radius of a circle with equivalent area to an ellipse can be written as r = a√AR.  Thus, a can 
be expressed in terms of equivalent circular diameter as a = d
2×√AR
.   
Therefore, 
Perimeter =  π ∗ d
2√AR
∗  [� 3 + 3 ∗ AR� − � (3 + 10 ∗ AR + 3 ∗ AR2)]                               
(3.2) 




Substituting circularity into (2) yields, 
 C =  1
1
2∗√AR
∗ [� 3+3∗AR�−� (3+10∗AR+3∗AR2)] 
.           (3.3) 
The values generated by this mathematical relationship were plotted as aspect ratio as a function 
of circularity and fit using Mathematica 8.0 (Wolfram, Champaign, Illinois) to obtain a function 
that describes aspect ratio (AR) of a model ellipse as a function of particle circularity.  The 
mathematical fit describing aspect ratio in terms of circularity is described by equation 3.4: 
AR =  1.70763 − 1.70864 × (1 − C)0.45 − 0.70638 C                                                        
(3.4) 
In the following part of the derivation, we model the ellipse defined by equation 3.4 as a prolate 
ellipsoid of revolution to approximately calculate particle volume. 
The volume of a prolate ellipsoid of revolution can be written as follows: 
V = 4
3








The minor axis, b, can be expressed in terms of d as b = d∗√AR
2
  by equating the area of an ellipse 
to the area of a circle.  Using this relationship we can calculate the volume of a prolate ellipsoid 
of revolution with d and AR: 
 V = π
6
× d3√AR                (3.5) 
Combining the volume equation with our fitted function yields: 
V =  π
6
× d3 × �1.70763 − 1.70864 × (1 − C)0.45 − 0.70638 C                  (3.6)                                            
Using this equation (above), the volume of a distribution of particles ranging from fiber-like to 
spherical can be more accurately calculated by removing the assumption of spherical volume and 
considering particle morphology.   
To calculate particle mass from the modeled volume for protein particles, a value of 1.41 
g/ml was used as the density of IgG as recommended by Fischer et al. (98), and we assume the 
proteinaceous particles contain 20% protein and 80% solvent.  The rationales for these 
assumptions are presented in the discussion section.  Based on the ellipsoid volume calculations 
combined with these assumptions of protein density and particle composition, the mass of an 
individual subvisible particle can be calculated using equation 3.7: 
Mass of particle k (Mk) =   
π
6
× d3 × �1.70763 − 1.70864 × (1 − C)0.45 − 0.70638 C ∗  1.41 g
ml
∗ f             (3.7) 
Where f represents the fraction of protein bound within a prolate ellipsoid of equal equivalent 
circular diameter and circularity (i.e., a value of 0.2 for f as described above).  The total mass of 
subvisible particles in solution was then calculated by summing the masses of the individual 
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particles and then dividing the sum by the sample volume that was analyzed (Va, in mL) as 
shown in equation 3.8: 




                                                                                       (3.8) 
It is important to note that experimentally measured aspect ratio could also be used to calculate 
particle mass by substituting equation 3.4 into equation 3.7.  The application of the ellipsoid-
volume method to determine particle mass only requires the use of equations 3.7 and 3.8 and is 
simple to implement in standard spread sheet software.  This is illustrated in the results section 
using representative MFI data from shake stressed IgG1 mAb solutions. 
3.3. Results 
3.3.1. Ellipsoid-Volume Method Applied to a Representative Subvisible 
Particle MFI Dataset  
We selected an IgG1 mAb sample (1.0 mg/mL) in a pH 4 citrate-phosphate buffer 
containing 1 M NaCl that was shaken for 2 h, as a representative MFI data set to illustrate the 
ellipsoid volume method of calculating particle mass.  This condition produced a heterogeneous 
mix of subvisible particles with various morphologies that ranged from fiber-like to spherical as 
well as other irregular shapes.  A graphical representation of equation 3.4 (red curve) is provided 
to visualize the relationship between aspect ratio and circularity for an ellipse of varying 
circularity (Figure 3.1A).  Corresponding model ellipses are depicted along the curve in addition 
to values for actual digital images of IgG subvisible particles (shown as green dots).   Some of 
the particles show a small deviation from the red curve, and these particles tended to have slight 
surface irregularities.   The particles that displayed larger deviations from the ellipse curve tend 
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to have tangled, bent, or branched fiber-like morphology, which result in measured aspect ratio 
(from MFI) to be inaccurate (Figure 3.1A).  These findings resulted in the selection of particle 
circularity, rather than its aspect ratio, to fit the measured subvisible particle digital images into 
an ellipse model to calculate their volume.  As outlined in the methods section, circularity 
obtained from an MFI digital image of a subvisible particle was used to model the particle as an 
ellipse along the red curve (i.e., Equation 3.4).   Figure 3.1B provides a step-by-step illustration 
of the ellipsoid-volume method to calculate particle mass as described by equations 3.7 and 3.8.  
Figure 3.1C is a representative scatter plot of an MFI dataset acquired (blue diamonds) from the 
shake stressed mAb solution described above.  
To calculate the total mass of subvisible particles in this solution, the calculation 
methodology would be applied to each particle and then summed up across the entire data set 
(Figure 3.1B).  It is important to note that the ellipsoid-volume method functions by modelling 
the particles as ellipsoids along the power function curve (red diamonds) based upon their 
circularity. By comparison, if it is assumed that the subvisible particles are perfectly shaped 
spherical particles (i.e., Barnard et al, 2011), then all the subvisible particles will be modeled at 
the coordinates (1.0, 1.0). 
3.3.2. Experimental and Calculated Mass of Subvisible Particles Formed from 
Stressing IgG1 mAb Solutions 
A comparison of the calculated values for subvisible particle mass using a combination of 
the Barnard et al.(122) method and the ellipsoid-volume method described above, were used 
along with an approach to experimentally measure the mass of protein particles present in 
solution.  For the experimental approach, the concentration of protein in solution was monitored 
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before and after stress (and extensive centrifugation) by UV-visible absorption spectroscopy.  
Three different conditions were selected that resulted in the formation of different levels of 
particles.  First, mAb samples (pH 4 in a citrate-phosphate buffer) were stirred for 4 h resulting 
in ~one microgram of particles per ml (Figure 3.2A).  Second, mAb samples (pH 4 in a citrate-
phosphate buffer with 1M NaCl) were shaken for 4 h resulting in tens of microgram of particles 
(Figure 3.2B).  Finally, mAb samples (pH 5 in a sodium acetate buffer with 0.15M NaCl) were 
shaken for 115 hours resulting in hundreds of microgram of particles (Figure 3.2C).   
For the pH 4.0 mAb samples stirred for 2h (Figure 3.2A), the average calculated particle 
mass per ml for the Barnard et al. equation and the ellipsoid-volume equation were ~3.0 and ~0.4 
µg/mL.  This value was below the limit of quantitation (LOQ) of the experimental method of 
<15 µg/ml.  This result highlights the potential utility of such methods to estimate particle mass 
using experimentally measured particle number results at relatively low levels.   
For other two mAb sample conditions, which resulted in higher concentrations of 
subvisible particles, especially >25 µm, the total mass calculated by the Barnard et al.(122) 
equation greatly exceeded the experimentally determined mass loss.  For example, for the mAb 
samples at pH 4.0 containing 1M NaCl and shaken for 2h, the calculated average particle mass 
per ml for the Barnard et al. equation and the ellipsoid-volume equation were approximately 370 
and 26 µg/mL, respectively (Figure 3.2B).  It can be seen the latter result is much more closely 
aligned with the experimentally determined value of ~34 µg/mL.  Similarly, for the mAb 
samples at pH 5.0 containing 0.15M NaCl and shaken for 115h, the average calculated particle 
mass per ml for the Barnard et al. equation and the ellipsoid-volume equation were 
approximately 2400 and 280 µg/mL, respectively (Figure 3.2C).  Again, the latter result is much 
more closely aligned with the experimentally determined value of ~290 µg/mL.   
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  For some of these conditions, low numbers of visible particles with > 70 µm ECD were 
observed by MFI, but not included in the particle mass calculations because these values were 
below the limit of quantitation for this flow imaging instrument.  For example, including visible 
particles > 70 microns in the calculations for the mAb samples at pH 4, 1M NaCl shaken for 2 h 
increased the total calculated mass by ~240% for the Barnard et al. method and ~80% for 
ellipsoid-volume method (data not shown). 
3.3.3. Additional Verification of Particle Mass Calculations Using Polystyrene 
Bead Standards 
We used spherical and non-spherical polystyrene bead standards to more extensively 
evaluate the performance of the ellipsoid-volume equation versus simply assuming a spherical 
volume.  The ellipsoid volume equation and an assumption of spherical volume were used to 
predict the equivalent spherical diameters (ESD) of the polystyrene bead standards analyzed by 
MFI as shown in Table 3.1.  The ellipsoid-volume method calculated a more accurate ESD for 
the non-spherical standards.  The most inaccurate results of the standards tested resulted in a 
~64, and 200% estimation of the true volume for the ellipsoid-volume method (10 µm spheres) 
and assumption of spherical volume (10 µm, 3x stretched particles) , respectively.  The reason 
that the ellipsoid-volume method calculated slightly less accurate ESD values for the spherical 
standards than the assumption of spherical volume is presented in the discussion section. 
3.3.4. Application of Calculation Methods to Estimate Particle Mass Formed 
in a Variety of IgG1 mAb Formulations Based on MFI Data 
The concentration, size range, morphological parameters (aspect ratio and intensity) of 
subvisible particles were measured by MFI as formed after shaking or stirring IgG1 mAb 
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solutions with different pH values (pH 4.0, 6.0, 8.0) and salt concentrations (0, 0.15, and 1.0 M) 
over a 2 h time period.  The data were then used to calculate the total mass of the particles.  The 
subvisible particle concentration and size distribution at t = 0 and the morphology for this IgG1 
mAb have been reported previously at t = 4 h, and these experiments showed qualitatively 
similar results (54).  A radar chart array was used for data visualization of these large data sets to 
display the effect of pH, NaCl, and stress type on subvisible particle formation in terms of 
particle concentration and size (Figure 3.3).  A total of 9 mAb solution conditions and two 
different stresses were investigated in triplicate resulting in 54 separate experiments containing a 
total of ~1.28 million digital images.  It can be seen in Figure 3.3 that shaking stress produced 
larger but fewer subvisible particles compared to stirring the same mAb formulations under most 
conditions.  Formulations containing increasing amounts of NaCl at both pH 6 and 8 had a fewer 
number of particles form.   
A second radar chart array was generated to visualize the same MFI data set to evaluate 
how formulation composition and stress type affected the morphology of subvisible particles in 
relation to particle size (Figure 3.4).  The aspect ratio of the particles decreases as a function of 
increasing particle size for all of the formulation and stress conditions (i.e., the particles become 
more elongated as size increases).  The shaking of mAb formulations at pH 4 decreased the 
aspect ratio for most size ranges relative to pH 6 or 8, while 1M NaCl also decreased the aspect 
ratio for most size ranges compared to samples containing no or 0.15 M NaCl.  Thus, the 
combination of shaking stress on a sample at pH 4, 1 M NaCl reproducibly produced particles 
with the lowest average aspect ratio.  For the stirred samples, across all of the formulation 
conditions, the majority of subvisible particles produced were more circular in nature (high 
aspect ratio) with only a few of the larger particles having a moderately smaller aspect ratio 
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(~0.5).  In terms of the morphology parameter of particle intensity, no obvious trends were 
discernible for either stress or formulation composition. In general, however, a decrease in 
particle intensity (decreased transparency) was noted as particle size increased.   
The distribution of total mass as a function of particle size as calculated from MFI data 
by the two mass determination methods is presented in radar chart array format for mAb samples 
subjected to stirring stress (Figure 3.5).   For the same mAb samples exposed to shaking stress, 
both particle number and particle weight (ellipsoid volume method) from MFI data are shown.   
The radar chart arrays display the calculated mass distribution of the particles as a function of 
particle size: the particles are placed into five different particle size bins (i.e., 2-5, 5-10, 10-25, 
25-50 and 50-70 microns), and the average particle characteristics are calculated for each size 
bin to estimate the total mass.  In addition, the total calculated masses of the particles generated 
under each condition are provided in Table 3.2.  In this case, the total mass is calculated by 
summing the results of calculated particle mass from the measured particle numbers in the 
individual size bins in Figures 3.5 and 3.6. 
As shown in Figure 3.5 and Table 3.2, the ellipsoid volume method and the Barnard et al. 
equation generate notably different particle mass distributions as a function of particle size.  The 
Barnard et al. method shows greater bias towards more mass in the larger sized particles.  For 
example, using the pH 4, 1 M NaCl sample subjected to 2 h of stirring (Figure 3.6), the 
calculated mass of subvisible particles within bin 5 (50-70 micron sized particles) is ~1 µg/ml for 
the Barnard et al.(122) method, while the mass is calculated to be ~0.09 µg/ml by the ellipsoid-
volume method.  In general, when using the ellipsoid-volume method, the largest mass fraction 
of the subvisible particles generated from 2 h of stirring is the smaller sized particles (i.e., 2 to 10 
µm) for the mAb formulation conditions examined (Figure 3.6).   
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As a final example, the distribution of subvisible particles formed by shaking (2 h) 
different mAb solutions (pH 4, 6, 8 with varying NaCl levels) is displayed in Figure 3.6:  the 
experimentally measured particle concentration and the calculated mass particle mass (ellipsoid-
volume method) are displayed as function of particle size using a radar chart array.  Across the 
solution conditions, particle concentrations were highest in the smallest size ranges of 2-5 and 5-
10 microns (see size bins 1 or 2 in Figure 3.6). One exception was samples shaken at pH 4 with 1 
M NaCl, which produced similar concentrations of particles across the wider size range of 2-50 
microns (size bins 1-4 in Figure 3.6).  Interestingly, the particle size range with the highest 
calculated particle mass across the samples was 10-25 microns (located in bin 3 in Figure 3.6).  
In addition, the larger size range of 25-50 and 50 to 70 microns (Bins 4 and 5 in Figure 3.6), also 
contained a relatively large fraction of mass.  These results demonstrate the utility of radar chart 
arrays to summarize the size distribution of subvisible particles formed in terms of both particle 
concentration and their corresponding estimated particle mass. 
3.4. Discussion 
The morphology of proteinaceous subvisible particles can be highly heterogeneous within 
a given stressed mAb sample (54).  Proteinaceous subvisible particles are often non-spherical 
and have a wide range of forms that include globular, fiber-like, branched, and ribbon-like 
structures (154).  The assumption that protein particles in solution are spherical (i.e., ECD values 
from MFI is equivalent to particle ESD), as assumed in the method proposed by Barnard et 
al.,(122)  can lead to calculations of mass and volume with limited accuracy and precision.  As 
demonstrated in this study, improvements in particle mass calculations are possible by 
accounting for the non-spherical nature of these particles.  In addition, the mean and the variance 
of the morphological parameters may vary depending upon the individual mAb being evaluated, 
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the formulation and the type of stress exposure.  Thus, particle morphology measurements from 
MFI can be further used to develop mathematical models to improve calculated estimates of 
particle volume, surface area, and mass.    
 In the Barnard et al. method (122), it was not only assumed that protein particles were 
spherical in nature, but to determine the mass it was assumed the protein particles had a density 
of  1.43 g/ml (determined by Quillin et al) (151), and that they were composed of 75% protein 
and 25% water.  For our methods, we not only used MFI data to account for the non-spherical 
nature of the particles, we also implemented some updated assumptions about the composition of 
protein particles.  First, we used a mAb density value of 1.41 g/ml.  This value was obtained 
using an equation developed by Fischer et al that accounts for the empirical dependency of 
protein density on its molecular weight (98).  Second, we estimated the volume fraction of 
protein in a protein particle to be 0.2 based on several considerations:  (1) protein crystals have 
large interstitial volumes that are around 50% of the total volume (155),  (2) using a RI of 
1.41(110) and dn/dc of 0.19 ml/g(156) at 589 nm for protein particles, we can estimate the 
volume fraction of protein in a particle suspended in water as ~28% because the relationship 
should still be linear at this concentration (103, 157), and (3) the density of IgG layers adsorbed 
to different surfaces were measured to be 1.05-1.10 g/ml(158) which corresponds to volume 
fractions of ~10-24% in pure water.  By assuming 0.2 to be the fraction of protein in a particle, 
the protein mass values calculated by Barnard et al. method(122) is reduced by ~3.75 fold.  It 
would be beneficial in the future to develop an analytical method to determine the average 
fraction of protein contained within particles generated from different stresses to further improve 
the accuracy of these particle mass calculation methods.     
79 
 
The particle mass calculation used in this work is referred to as the ellipsoid-volume 
method.  Based on the observation that subvisible particles tend to range from fiber-like to 
roughly spherical, we tested the hypothesis that subvisible particles can be adequately modeled 
using calculated ellipses of different sizes and aspect ratios (Figure 3.1).  Although a number of 
particles were found to substantially deviate from the calculated ellipse curve, the majority of 
these particles were observed to be tangled or bent fibers or ribbon-like structures (data not 
shown).  The two dimensional ellipse shapes, calculated using particle circularity and ECD 
values from MFI, were used to model particles as different prolate ellipsoids of revolution.   
Therefore, the ellipsoid-volume method improved the particle volume calculation of subvisible 
protein particles to more accurately determine their mass compared to a spherical model.  Using 
the ellipsoid-volume method on spherical and non-spherical polystyrene particles resulted in 
calculated ESD values that deviated from 0.8 to 14% of the true value (Table 3.1).  The relatively 
higher values of error for the spherical standards were probably because MFI often measures the 
circularity of spherical standards to be less than 0.95 when they should theoretically be 1.0.  In 
the case of these inflexible polystyrene bead standards, using measured aspect ratio would have 
greatly improved the accuracy of the ellipsoid-volume calculations (data not shown). 
To compare the accuracy and precision of the two particle mass calculations (Barnard et 
al. (122), and the ellipsoid volume methods), we compared the calculated results (from MFI 
data) to an experimental procedure that was optimized to measure protein mass loss as a result of 
particle formation.  The experimental procedure with stressed samples of IgG1 mAb was shown 
to have a limit of quantitation of 15 µg/ml, and therefore was not sensitive enough to detect 
particle mass loss under most experimental conditions (Figure 3.2A).  At these low 
concentrations, experimental results could be complicated by adsorption of the protein particles 
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to the cuvette and/or centrifuge tube in some circumstances (data not shown).  Therefore, we 
generated more extensively aggregated samples to compare the accuracy and precision of the 
relevant particle mass equations (Figure 3.2B and 3.2C).  We found that the Barnard et al.(122) 
method had lower accuracy, and under certain conditions, could even approximate the mass of 
particles to be equal to or greater than the total mass of protein in solution.  The variability in the 
total mass calculations displayed in Figure 3.2 is primarily due to the variability of the MFI 
measurements for the number of particles > 25 µm ECD in each sample.  Since the Barnard et al. 
equation uses the assumption of spherical volume, it had the largest relative standard deviation.  
Although variability is commonly observed in particle counting experiments, the experimental 
approach to determine mass loss showed better precision than the calculation methods for the 
extensively aggregated sample (Figure 3.2C).  Another possible explanation could be that the 
average protein particle density may not be constant from vial to vial (similar to variability in 
particle number from vial to vial).  
The applicability and assumptions of the calculation methods to estimate the mass 
subvisible particles in a protein formulation are summarized in Table 3.3.  The ellipsoid volume 
method would be the method of choice from the practical point of view that it is simple to 
implement and provides better estimates of protein particle mass compared to the Barnard et al. 
equation.  In samples that have a large concentration of highly irregular particles due to extensive 
protein structural perturbation (e.g., heat stress), the ellipsoid volume method could also be 
inaccurate.  In such circumstances, a different shape model such as a cylinder could be evaluated.  
The primary advantage of implementing a calculation approach to estimate protein 
particle mass utilizing flow microscopy is that determination of subvisible particle concentration, 
size and particle mass come from the same experiment making direct comparisons 
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straightforward.  Otherwise, the fact that different instruments can have entirely different 
measurement principles and can vary in sensitivity, direct comparison between particle 
concentrations and mass can be extremely challenging.  Using this approach, protein particle 
mass can be calculated regardless of the concentration and size range of subvisible particles 
present in a given formulation, offering an ability to estimate particle mass when levels are 
below the experimental limits of quantification using UV absorbance detection.  In addition, 
individual particle masses can be assigned to specific particles populations within different size 
ranges.  Figure 3.6 illustrates that radar chart arrays can be used to compare the distribution of 
particles (size, number and weight) formed in different IgG1 mAb formulations during shaking.  
In addition, Figure 3.6 also displays the contribution of different particle sizes to the total particle 
mass.  For example, although subvisible particles produced by shaking generally showed the 
highest particle number in the 2-5 micron size bin, this size range contains a small fraction of the 
total calculated particle mass.  It would be of interest to generate a data base of such radar charts 
for different mAbs, different proteins, different formulations, and/or during accelerated and real-
time stability studies.  Such studies would facilitate better comparisons of the number, size and 






















70 µm spheres 
 
 
72.1 ± 0.7 63.9 ± 0.7 
50 µm spheres 
 
 
49.9 ± 0.6 44.4 ± 1.9 
25 µm spheres 
  
24.5 ± 0.5 21.5 ± 0.5 
10 µm spheres 
 
 9.9 ± 0.4 8.7 ± 0.4 
5 µm spheres 
 
 5.1 ± 0.2 4.4 ± 0.2 
3 µm spheres 
 
 3.2 ± 0.2 2.7 ± 0.1 
25 µm non-spherical 
4x stretched particles 
  
31.3 ± 3.2 25.2 ± 1.6 
25 µm non-spherical 
3x stretched particles 
 
 
29.1 ± 1.9 24.6 ± 1.3 
10 µm non-spherical 
3x stretched particles 
 
 12.6 ± 2.2 10.4 ± 1.7 
10 µm non-spherical 
2x stretched particles 
 
 11.8 ± 1.5 10.8 ± 1.3 
 
Table 3.1.  Calculated and Known Equivalent Spherical Diameters (ESD) for Spherical and 
Non-Spherical Polystyrene Standards.  The spherical ESD values represent the average and 
standard deviation of 3 replicates of MFI measurements using the assumption that ECD values 
are equivalent to ESD.  The E-V (ellipsoid volume) calculated ESD values are the average 
volume and standard deviation of 3 measurements calculated using the volume term of ellipsoid-




































2.9 ± 2.1 0.4 ± 0.3 10.2 ± 3.5 1.1 ± 0.5 
pH 4  
w/0.15 M NaCl 
 
13.9 ± 3.3 1.9 ± 0.5 19.7 ± 18.8 1.1 ± 1.0 
pH 4  
w/ 1 M NaCl 
 
21.3 ± 2.5 2.7 ± 0.2 365.8 ± 
257.0 
26.2 ± 16.1 
pH 6 
 
20.0 ± 5.6 2.8 ± 0.8 6.3 ± 1.3 0.7 ± 0.1 
pH 6  
w/0.15 M NaCl 
 
4.5 ± 0.7 0.5 ± 0.1 2.0 ± 1.1 0.2 ± 0.1 
pH 6  
w/ 1 M NaCl 
 
2.8 ± 0.1 0.3 ± 0.1 8.9 ± 2.2 0.5 ± 0.1 
pH 8 
 
5.9 ± 1.6 0.8 ± 0.2 10.5 ± 1.1 0.7 ± 0.2 
pH 8  
w/0.15 M NaCl 
 
5.8 ± 2.2 0.7 ± 0.3 12.2 ± 6.0 0.7 ± 0.3 
pH 8  
w/ 1 M NaCl 
 
7.0 ± 3.8 0.7 ± 0.4 19.9 ± 0.5 1.3 ± 0.1 
 
Table 3.2.  Calculated Total Mass of Subvisible Particles Formed in Various IgG1 mAb 
Formulations Subjected to 2 h of Shaking or Stirring Stress.  The total calculated mass of 
protein particles is determined by summing the calculated mass of particles of different sizes (the 
five size bins in Figures 3.5 and 3.6) measured by MFI.  The mass of the size bins was 
determined using the Barnard and ellipsoid-volume methods (see text).  The IgG1 mAb 
formulations contain 1 mg/mL protein in 20 mM citrate phosphate buffer at the indicated 





Table 3.3.  Summary of the Applicability and Assumptions of Particle Mass Calculation 
Methods.  S, F, B and R refer to spherical, fiber-like, branched, and ribbon, respectively.  See 
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+    Very Easy 
(Requires collection of size 
data) 
• Spherical morphology 
• Static density (1.43 g/ml) 




+ + +  Easy 
(Requires collection of size and 
circularity data) 
• Prolate ellipsoid of revolution morphology 
• Static density (1.41 g/ml) 





Figure 3.1. The Principle of the Ellipsoid-Volume Mass Calculation Method.  (A)  The 
mathematical relationship between aspect ratio and circularity for an ellipse (red curve).  Ellipse 
shapes are illustrated along the curve along with representative IgG1 particle images from MFI 
analysis to translate this information to particle morphology.  The green points represent the 
location of these IgG particles in relation to the curve.  (B) Flow chart to visualize the principles 
of the ellipsoid-volume method.  The entire multi-step process is directly calculated by equation 
5.  (C)  Scatter plot of IgG1 particles created after 2 h of shaking a pH 4.0, 1 M NaCl IgG1 
formulation.  The ellipse relationship from (A) is traced by the red points.  Total mass of 
subvisible particles in the mAb solution is determined by performing the calculation in (B) for 




Figure 3.2.  Comparison of the Particle Mass Calculation Methods (from MFI Data for 
Subvisible Particles from 2-70 µm) to Experimentally Determined Values in mAb 
Formulations with Low, Moderate and Extensive Particle Formation.  (A) Values calculated 
for particles formed by stirring at pH 4.0, 20 mM Citrate-phosphate buffered mAb samples (n=3) 
for 4 h.  (B) Values calculated and experimentally determined for particles formed by shaking 
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pH 4.0, 1.0 M NaCl, 20 mM Citrate-phosphate buffered mAb samples (n=3) for 4 h.  The insert 
is a zoomed in version of the corresponding bar graph.  (C) Values calculated and experimentally 
determined for particles formed by shaking pH 5, 0.15 M NaCl, 20 mM acetate buffered mAb 


















Figure 3.3. The Concentration and Size Range of Subvisible Particles Formed in Different 
IgG1 mAb Formulations Subjected to Shaking or Stirring. (A) Radar chart array analysis to 
evaluate the concentration of subvisible particles as measured by MFI.  The Y-axis denotes the 
stress (shaking or stirring), the X-axis denotes the NaCl concentration used, and the brackets 
(top) group the formulations by pH.  (B) A guide for the quantitative interpretation of the radar 
chart array in (A).  (B, left panel) Each numbered axis represents a size bin grouped using 
particle ECD.  The light blue polygon represents the mean concentration (n=3) of subvisible 
particles within each bin.  The pale-fuchsia polygon is the mean – standard deviation to provide 
an indication of variability. (B, right panel)  The concentration of a particular size range can be 
determined by the size of the polygon along that axis.  If the polygon is invisible along the axis 
there is less than 10 particles/ml in that size range and if the polygon extends to the outer 
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perimeter of the radar chart there is more than 1,000,000 particles/ml in that size range.  Each 
concentric ring from the center of the radar chart represents a 10-fold increase in concentration.  
The axes are linearly connected to clearly visualize a shift in concentration as a change in shape 























Figure 3.4. The Morphology of Subvisible Particles Formed in Different IgG1 mAb 
Formulations Subjected to Shaking or Stirring. (A) Radar chart array analysis to evaluate the 
aspect ratio and intensity of subvisible particles as measured by MFI.  The Y-axis denotes the 
parameter (intensity or aspect ratio) and the stress used (shaking or stirring), the X-axis denotes 
the NaCl concentration used, the brackets (top) group the formulations by pH. (B) A guide for 
the quantitative interpretation of the radar chart array in (A).  (B, left panel) Each numbered axis 
represents a size bin grouped using particle ECD.  The light blue polygon represents the mean 
morphology parameter (n=3) for the subvisible particles within each bin.  The pale-fuchsia 
polygon is the mean – standard deviation to provide an indication of variability.  An axis shaded 
91 
 
in light red denotes that there were insufficient particles (empirically defined as <25 counted) as 
compared to t=0. (B, right panel)  The intensity/1000 or aspect ratio of a particular size range can 
be determined by the size of the polygon along that axis.  If the polygon is invisible along the 
axis there the parameter is larger than 0.85 in that size range (AR = circular; int = opaque).  If the 
polygon extends to the outer perimeter of the radar chart the parameter is less than 0.35 in that 
size range (AR = elongated; Int = transparent).  Each concentric ring from the center of the radar 
chart represents a 0.1 decrease in the parameter (increasing elongation or transparency.  The axes 



















Figure 3.5. Radar chart analysis of the particle mass distributions as a function of particle 
size as determined by the various calculation methods after stirring different mAb 
formulations.  The mass of particles formed in nine formulations of an IgG1 mAb, n=3, 
subjected to stirring stress for 2 h, as calculated from MFI data.  The Y-axis represents the 
parameter (i.e., mass calculation method), the X-axis represents the NaCl concentration, and 
each bracketed group (top) represents a change in pH. (B) Key used for the interpretation of the 
radar chart array.  Each axis in the radar charts corresponds to a particle size range (left panel).  
The pink polygon represents the mean minus the standard deviation of the parameter, and the 
blue polygon represents the mean value for the parameter.  The radar chart array in (A) uses a 






Figure 3.6.  Radar chart analysis of the concentration and calculated mass of particles after 
shaking different mAb formulations.  (A) Nine formulations of an IgG1, n=3, subjected to 
shaking stress for 2 h, were evaluated by MFI to determine the concentration and size range of 
subvisible particles.  The Y-axis represents the parameter (i.e. concentration/mass calculation 
method), the X-axis represents the NaCl concentration, and each bracketed group (top) 
represents a change in pH.  (B) Key used for the interpretation of the radar chart array.  Each axis 
in the radar charts corresponds to a particle size range (left panel).  The pink polygon represents 
the mean minus the standard deviation of the parameter, and the blue polygon represents the 
mean value for the parameter.  The radar chart array in (A) uses a defined concentration scale 





Chapter 4: Evaluating the Role of the Air-Solution Interface on the 
Mechanism of Subvisible Particle Formation Caused by Mechanical Agitation 
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Protein aggregation and particle formation is a commonly observed degradation pathway 
of therapeutic mAb drug products, and is a significant cause for concern due to potential adverse 
effects on product safety and efficacy, either through decreasing potency or by enhancing 
product immunogenicity (2, 46).  Larger protein aggregates, in the size range of >0.1 µm and 
<100 µm, often called submicron and subvisible protein particles, are widely considered to be 
important to monitor and control, since particle sizes within this range potentially possess the 
ability to enhance the efficiency of uptake by antigen presenting cells (1, 12, 13, 96, 159).  
Characterization of such particles formed by exposure of protein solutions to different stresses 
(e.g., mechanical, chemical, and thermal) has shown that particles can vary in size, number and 
shape, as well as the degree of structural perturbation/chemical degradation of protein within the 
particles, leading to highly heterogeneous samples (66, 70, 113).  Preliminary studies attempting 
to purify fractions of particles based upon size suggest that protein particle immunogenicity 
potential may be size and concentration dependent as determined by in vitro cell-based models 
(13, 14).  As a result, the risk vs. benefit that these protein degradation products pose to patients 
has emerged as a major consideration during mAb drug formulation design and development (12, 
114, 160, 161).   
Successful development of protein formulations requires a thorough understanding of 
protein physical degradation pathways during exposure to different environmental stresses.  
Numerous studies have resulted in an improved mechanistic understanding of protein 
aggregation and particle formation in bulk protein solution from a pharmaceutical perspective 
(44, 59, 162).  Models describing protein aggregation and subsequent particle formation in bulk 
solution typically include nucleation, growth and condensation phases (45, 84, 85) and involve 
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unfolding and/or association steps.  As a result, protein candidates are often formulated to 
optimize conformational and colloidal stability to reduce the rate of aggregation in bulk solution 
during manufacturing, storage, transport and administration (4, 71, 163).  However, formulation 
conditions that stabilize some mAbs against aggregation and protein particle formation during 
thermal stress have been observed to be destabilizing during mechanical agitation(54). 
Therefore, in addition to evaluating protein interaction mechanisms occurring in the bulk 
solution, it is also important to consider the air-solution interface as a source of instability for 
therapeutic protein products (164).   
Several recent studies have provided evidence that disruption of a high concentration 
protein layer at air-solution interface can be responsible for producing protein particles in the 
bulk solution (62, 91, 92).  One of the most common ways to minimize interface induced 
aggregation of protein molecules has been the addition of nonionic surfactants such as 
polysorbate 20 or 80 or related surface active compounds(165, 166).  Competitive adsorption 
between the smaller surfactant molecules and the larger protein molecules has been shown to 
minimize adsorption of the proteins to the air-water interface, thereby reducing protein particle 
formation at the interface (167).  However, polysorbate-based excipients are themselves prone to 
physicochemical degradation and in some cases may even accelerate the aggregation of certain 
proteins (168).  Other formulation variables such as pH, ionic strength, and poly valent ions have 
been shown to have a large effect on protein instability during agitation and can impact protein-
protein interactions at the air-water interface (118, 169).  Therefore, developing a better 
understanding of how mAb formulation conditions affect air-solution interface mediated particle 
formation is critical to ultimately reduce the reliance on nonionic surfactant alone to provide 
stability against agitation induced protein particle formation.    
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In this work, we seek to further elucidate the mechanism of particle formation initiated at 
the air-solution interface during mechanical agitation, and to better understand the effect of 
solution pH and buffer ion type on this aggregation pathway, for a model IgG1 mAb.  A 
Langmuir trough is used to model pharmaceutical instability resulting from mechanical agitation 
of different formulations of the IgG1 mAb, where controlled compression/dilation cycles ensure 
that mechanical stresses are applied only to a protein film formed at the air-water interface.  
Analysis of protein particles formed in the bulk solution after compression/dilation cycles are 
correlated with high resolution atomic microscopy images of protein films at the interface, to 
better understand how protein aggregates at the air-solution interface effect the amount of 
particles present in the bulk solution.  In addition, we evaluate the role of formulation conditions 
on extent of particle formation for this IgG1 mAb at the air-solution interface, with and without 
mechanical stress, and correlate our results with surface pressure measurements.  
4.2. Experimental Procedures 
4.2.1. Materials and Sample Preparation 
The IgG1 mAb (pI range around ~ 9) used in this study was provided by Janssen 
Research & Development, LLC (Horsham, Pennsylvania) at a concentration of ~40 mg/ml.  
Stock buffers of 50 mM citrate and 50 mM histidine were prepared at pH 4.5 and 6.5.  The L-
histidine was purchased from Sigma-Aldrich (St. Louis, Missouri) and the sodium citrate 
dihydrate and citric acid anhydrous were purchased from Fisher Scientific (Hampton, New 
Hampshire).  Additionally, 1x phosphate buffered saline (PBS) buffer (Fisher Scientific, 
Hampton, New Hampshire) was prepared at pH 7.4 according to the manufacturer’s recipe, and a 
second preparation of 1x PBS buffer was titrated using hydrochloric acid to a pH of ~4.5.  All 
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stock buffers were prepared using Milli-Q water (EMD Millipore, Billerica, Massachusetts) and 
sterile filtered using a 0.2 μm filter. 
4.2.2. Mechanical Agitation Studies    
The mAb solution was diluted 1:40x into each of the stock buffers to generate working 
mAb solutions of 1.0 mg/ml.  The working mAb solutions were gently inverted and allowed to 
sit for half an hour to ensure proper mixing.  Three ml aliquots of each working solution were 
pipetted into 37.7 × 16.75 mm glass vials (Schott, Lebanon, Pennsylvania) and capped with 
uncoated rubber stoppers (West Pharmaceutical Services, Exton, Pennsylvania).  The mAb 
solutions were agitated using a HS 260 shaker (IKA Works, Inc., Wilmington, North Carolina) at 
300 cycles/minute as described previously (70).  The aliquots for each formulation condition 
were agitated for 0, 1 or 3 days (N=3 for each time point). 
4.2.3. Interfacial Compression-Expansion Studies2 
Working IgG1 mAb solutions at 0.37mg/ml were prepared by adding 370 µl of mAb 
stock solution to 40 ml of buffer (PBS, histidine, or citrate). Working solutions were loaded into 
a Langmuir trough that was controlled at 23 ± 2°C (Biolin Scientific Inc., Stockholm, Sweden).  
A Wilhelmy plate was used to measure surface pressure during adsorption and compression-
expansion experiments. The compression-expansion cycles began after a 2hr period for 
adsorption to become saturated.  The available interfacial area changed from 87 to 12 cm2 during 
each compression-expansion cycle by moving the barriers of the Langmuir trough. The 
compression ratio, defined as the ratio of the maximum possible area and the minimum area of 
the trough (CR=Amax/Amin), was held constant at 7.25 for this study.  For mAb samples prepared 
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in 1x PBS, the “slow” compression-expansion rate was 50 cycles/6 hours and the “fast” 
compression-expansion rate was 750 cycles/6 hours.  For the mAb samples prepared in histidine 
or citrate buffers, the “slow” compression-expansion rate was 50 cycles/6 hours and the “fast” 
compression-expansion rate was 1000 cycles/6 hours.  
4.2.4. Size-Exclusion Chromatography 
A Prominence UFLC HPLC (Shimadzu, Kyoto, Japan) with a diode array detector was 
used with a TSKgel G3000SWx1 stainless steel column (Tosoh Biosciences, San Francisco, 
California) and TSKgel SWxI guard column for size exclusion chromatography.  The column 
was operated at 30ᵒC and separation was achieved at a flow rate of 0.7 ml/min.  The areas of the 
stressed sample chromatograms were normalized to the total area of the unstressed sample 
chromatograms to detect a loss of total area.  A pH 6.8, 0.2 M phosphate buffer was selected as 
the mobile phase because the buffer has been shown to minimize protein adsorption to the 
column (133). 
4.2.5. Flow Microscopy 
A VS Series FlowCam (Fluid Imaging Technologies, Scarborough, Maine) benchtop 
flow microscope was used to count and characterize particles ≥ 1 μm but ≤ 100 μm in area based 
diameter (ABD).  A 10x objective was used with a 100 μm x 2 mm flow cell.  The sample 
volume analyzed was 0.5 ml, the flow rate was 0.15 ml/min, and the capture speed was set at 21 
frames per second.  Prior to measurement, the instrument was focused using NIST traceable 25 




4.2.6. Atomic Force Microscopy (AFM) 3   
Freshly cleaved mica (Ted pella Inc., Redding, CA) was used as a support to obtain high 
resolution images of IgG1 mAb particles isolated from the air-solution interface and the bulk 
solution. Transferring the IgG1 mAb particles from interface was done by briefly contacting the 
mica to the air-solution interface.  Mica sheets containing mAb particles from the bulk solution 
were prepared by placing the freshly cleaved mica sheet at the bottom of the trough prior to 
compression-expansion cycles and collected afterwards.  Once collected, the mica sheet for the 
mAb samples in citrate/histidine were immediately washed with Milli-Q water and dried with 
compressed air at 23 ± 2 oC.  The mica sheets for the mAb samples in 1x PBS were also washed 
with pH 7.0 acetate buffer prior to drying. The AFM setup used was a Veeco MultiMode V 
(Veeco Instruments Inc., Plainview, NY). All AFM measurements were performed in a tapping 
mode using silicon probes (TAP150 Bruker) with a spring constant of 5 Nm-1 at 150 kHz. Height 
analysis of the AFM images was done using Research NanoScope v7.30 (Veeco Instruments 
Inc., Plainview, NY). Imaging was done in a temperature controlled room maintained at 20oC.  
To evaluate the height of mAb particles analyzed by AFM, 3 images were collected from each 
mica sheet prepared during Langmuir trough experiments (N=3 for each sample condition).  The 
combined data points for each condition were plotted as box plots.  
4.2.7. Fourier Transform Infrared Microscopy (FTIR) 
A Vertex 70 FTIR and Hyperion microscope equipped with a 15x objective (Bruker, 
Billerica, Massachusetts) were used to image particles isolated from solution and measure their 
FTIR spectra. Particles were isolated using gold filters with a pore size of 5 µm (Pall 
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Corporation, Port Washington, New York). Heat-denatured controls were prepared by heating 1 
mg/ml mAb in pH 7.4 1x PBS at 90oC for 15 min. Native mAb control FTIR spectra were 
obtained by performing solution measurements on 5 mg/ml mAb in pH 7.4 1x PBS using the 
BIO-ATR II attachment for the Vertex 70 FTIR. 
4.3. Results 
To better understand how protein particle formation is occurring at the air-solution 
interface during mechanical agitation, a Langmuir trough experimental setup was used where an 
IgG1 mAb solution is exposed to controlled compression/dilation cycles resulting in mechanical 
stresses applied only at the air-water interface, and not in the bulk protein solution.  These results 
are then compared to agitation of the same mAb solution filled into glass vials.  Figure 4.1 
provides an overview of the experimental setup and the Langmuir trough instrument.  In both 
cases, changes in interfacial area available are hypothesized to disrupt the adsorbed mAb layer at 
the air-solution interface and potentially result in the release of particles into the bulk solution as 
shown schematically in Figure 4.1.   
4.3.1. Particle Formation in the Bulk Solution During Mechanical Agitation in 
PBS Buffer 
First, unstressed mAb samples (0 day), formulated in pH 4.5 or pH 7.4 PBS buffer, were 
analyzed for levels of protein subvisible particles by flow microscopy and were found to contain 
>300 subvisible particles/mL with most particles in the 2-5 μm and 5-10 μm particle size range 
(Figure 4.2, bottom panel).  After 3 days of side-to-side shaking in glass vials, however, both 
mAb samples showed a large, significant increase in particles in the bulk solution, with the 
mAbs samples at pH 4.5 containing more particles compared to the mAb samples at pH 7.4 
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(Figure 4.2, top panel). Moreover, particles formed in the agitated mAb sample at pH 4.5 were 
distributed across the size ranges analyzed.  The particle size distribution is shown on a 
logarithmic scale in Figure 4.2 and can be visualized from the shape of the polygon signal of the 
radar chart.  The average number of particles per ml in the pH 4.5 mAb samples was greater than 
100,000 for particles 2-5 μm, ~100,000 for particles 5-10 μm, and ~10,000 for particles ranging 
in size from 10-15, 15-25, 25-40, 40-50, and 50-100 μm.  The mAb sample at pH 7.4, on the 
other hand, did not have significant particle formation for sizes greater than 25 μm as compared 
to the unstressed sample (Figure 4.2, top right panel).  The average number of particles per ml in 
the pH 7.4 mAb samples was less than 10,000 for particles ranging from 2-5 μm and 5-10 μm, 
and less than 1,000 for particles ranging from 10-15 μm and 15-25 μm.    
The unstressed and mechanically agitated (at 1 and 3 days) mAb samples in PBS buffer 
were also analyzed using size exclusion chromatography (SEC).  The mAb sample at pH 4.5 had 
~1.0 ± 0.3 % monomer loss (N=3) whereas the mAb sample at pH 7.4 did not have significant 
monomer loss over the 3 days of agitation.  Additionally, no high molecular weight species 
(HMWS) or mAb fragments were observed by SEC (see Figures 4.3 and 4.4 for representative 
chromatograms and SEC stability data).  
4.3.2. Surface Properties of mAb Samples in PBS Buffer 4 
As a next step, we then established techniques to correlate these observed differences in 
particle formation with differences in the interfacial properties of these mAb samples, in the 
absence and presence of applied stress to the interface. As shown in Figure 4.5A, the surface 
pressure-area (П-A) isotherm of mAb solutions in PBS buffer at pH 7.4 was subjected to slow 
compression-expansion cycles.  Theoretically, the measured surface pressure corresponds to 
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possible adsorption and rearrangement of mAb molecules at the interface(92, 170).   Upon 
decreasing the interfacial area, the surface pressure increases (or the surface tension) decreases 
non-linearly.  Interfacial area expansion after a compression cycle resulted in an abrupt decrease 
in the surface pressure causing a visible hysteresis pattern.  The surface pressure at the beginning 
of first cycle corresponds to the equilibrium saturation value that was reached after the proteins 
were allowed to adsorb to the interface and equilibrate for two hours. This saturation value was 
not reached during compression-expansion cycles, because the proteins did not have enough time 
to reach their equilibrium value during continuous compression-expansion cycles.  The 
maximum surface pressure at minimum interfacial area was also found to be the maximum for 
the first cycle and decreased steadily over the 50 cycles reported here. Figure 4.6 shows 
negligible increase of surface pressure with time for protein-free polysorbate samples at 0.00012 
wt% (corresponds to the concentration of polysorbate in the mAb solutions being studied) during 
adsorption studies. Similarly, П-A isotherm studies show that the polysorbate solution itself is 
compressible further establishing that the increase in measured surface pressure may be 
attributed to the presence of mAb proteins at the air-solution interface.  
Figure 4.5B presents the first and last cycle for compression-expansion isotherms plotted 
for mAb solutions in PBS buffer at both pH 4.5 and pH 7.4. The hysteresis was found to be 
greater in the first cycle compared to the last cycle for both sample conditions. The first (blue 
and red) and last (black and pink) cycles in the surface pressure vs. area isotherms overlapped 
with no statistically significant difference for the two conditions (Figure 4.5B). Additionally, the 
initial and final surface pressures were higher for the first cycle compared to the last cycle for 
both sample conditions. Figure 4.5C presents the average area under the isotherm curves for the 
first and last cycle of mAb samples in PBS buffer at pH 4.5 and 7.4, used as a measure of the 
104 
 
total hysteresis in these protein films. The average value (N=3) of the total area under the curve 
for the first cycle was higher than that for the last cycle but the difference was not statistically 
significant. To investigate the effect of time of exposure of mAb samples to the air-solution 
interface during compression-expansion cycles, we compared 50 cycles of slow (6 hours) and 
fast (25 min) rate (Figure 4.6 panel C and D). To further investigate how the rate of the 
compression influenced the compression-expansion isotherms, we compared the surface pressure 
vs area isotherms for the 1st and 50th cycles corresponding to compression for 6 hours or 25 
minutes (fast). While no difference seen for the first cycles, the 50th cycle shows more hysteresis.  
4.3.3. The Effect of Compression Rate on Particle Formation at the Air-
Protein Solution Interface and in Bulk Solution 
 The number and size distribution of subvisible sized protein particles in the bulk solution, 
as measured by flow digital imaging, for mAb samples at pH 4.5 and pH 7.4 after being 
subjected to slow (A) or fast (B) compression-expansion cycles during 6 hours in the Langmuir 
trough, are shown in Figures 4.7A and 4.7B, respectively. The same mAb solutions that were not 
subjected to the compression/dilatational stresses, but for which all other environment conditions 
were kept identical (temperature, time of incubation, formulation pH) were used as control 
samples (Figure 4.7, Panel A/B, red signal).  Results show no statistically significant differences 
between the number and size distribution of particles in the bulk mAb samples subjected to the 
slow compression-expansion rate when compared to the corresponding control samples. 
Moreover, the control mAb samples at both pH conditions had similar numbers of particles 
detected in the bulk solution.  In contrast, mAb protein solutions that were subjected to fast 
interfacial compressive stresses for 6 hours, demonstrated more than an order of magnitude 
increase in the number of protein subvisible particles detected in the bulk solution.  Further, the 
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stressed mAb samples at pH 4.5 were found to contain a broader size range of particles (up to 50 
μm), when compared with mAb samples at pH 7.4.  
4.3.3.1 Atomic Force Microscopy Results 5 
Representative atomic force microscopy (AFM) images of mAb particle formation at the 
interface and in the bulk mAb solution, for both stressed mAb samples in PBS buffer at the two 
pHs, are presented in Figure 4.7, panel C and D.  For the slow compression-expansion rate 
(Panel C), the protein films transferred from the air-water interface contained greater number of 
protein aggregates compared with mica surfaces placed in the bulk mAb solution, irrespective of 
the solution pH.  In contrast,  mica sheets placed in bulk mAb solutions that were subjected to 
fast compression expansion cycles (Panel D), contained greater number of micron and sub-
micron protein aggregates when compared with films transferred from the air-solution interface.  
Additionally, the mAb pH 4.5 solutions, after being subjected to fast compression-expansion 
cycles, contained more particles at the interface and in the bulk solution, when compared to the 
pH 7.4 mAb solutions. Figure 4.8 also shows that the total time of compression, or number of 
total compression-expansion cycles, plays an important role. Keeping the total number of cycles 
constant, but applying stress at different rates (slow vs fast), we find that the total number and 
size distribution of mAb particles is not different both at bulk solution (Figure 4.8 panel A,B) 
and at the interface (Figure 4.8 panel C, D).  
In panels E and F of Figure 4.7, box plots displaying the height (median and range) of 
mAb particles as measured by AFM are presented to quantitatively compare the AFM images 
(N=9 for each condition).  For the slow compression-expansion rate (Panel E), the box plot of the 
height of protein particles at the interface of the pH 4.5 mAb sample had a higher median value 
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than the box plot of the interface for the mAb sample at pH 7.4.  For the bulk mAb solutions, the 
range of protein particle height data is much smaller compared to the range of particle height 
results at the interface.  It should be pointed out that areas that did not contain any particles or a 
lesser number of particles were included in the analysis thereby exacerbating the apparent 
standard deviations shown in Figure 4.7E and 4.7F.  For the mAb samples exposed to fast 
compression-expansion rate (Figure 4.7, Panel F), AFM results had similar median values for the 
height of mAb particles at the interface compared to the mAb samples exposed to low 
compression-expansion at both pH 4.5 and 7.4 conditions. Furthermore, the median value and 
the range of the particle height data from AFM for particles in bulk solution were similar 
between the fast and slow compression rates for the pH 7.4 mAb samples. However, the median 
and range of height data from AFM analysis of particles in bulk solution increased significantly 
for mAb pH 4.5 samples that were subjected to fast compression.  
4.3.4. Qualitative Comparison of the Morphology of mAb Particles Formed 
During Mechanical Agitation vs. Interfacial Compression-Expansion 
To further compare and characterize the protein particles formed during compression-
expansion cycles in the Langmuir trough vs. particles formed during agitation in vials, particle 
morphology data from flow microscopy digital images were analyzed.  Circularity (Hu), a 
measure of particle perimeter relative to a circle of equivalent area, and aspect ratio, a measure of 
elongation, were evaluated for particles formed by the two stresses and compared to theoretical 
values for prolate ellipsoids with varying aspect ratios (Figure 4.9)(104).  The solid blue curve is 
a calculation, described previously from Kalonia et al. 2015, that determines the circularity of 
theoretical prolate ellipses based on the aspect ratio and is meant to be used as a reference point 
for characterizing particle morphology as described previously (54).  For example, at the 
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coordinate (1, 1) in Figure 4.9, the blue curve represents a perfectly circular particle.  As the 
aspect ratio decreases, particle elongation increases and positive deviations from the curve 
represent the particle having a larger perimeter than an ellipse of equal aspect ratio (typically 
indicating an increase in surface roughness/fractal dimension).  The subvisible sized protein 
particles detected in the mAb sample subjected to fast compression-expansion were ellipse-like 
(circularity and aspect ratios close to the theoretical ellipse curve) and ranged from 1x elongation 
to 3x elongation relative to a circular particle of equal area (Figure 4.9, Panel A).   Protein 
particles generated by side-to-side agitation of the same mAb solution, on the other hand, were 
more elongated on average (up to 20x relative to a circular particle of equal area) and were not as 
ellipse-like as they showed positive deviations from the theoretical ellipse curve (Figure 4.9, 
Panel B) as compared to the same mAb sample exposed to compression in the Langmuir trough 
(see Figure 4.10).   
Several representative protein particle images from flow microscopy analysis are 
presented in Figure 4.9C for a mAb sample subjected to fast compression-expansion in the 
Langmuir trough.  The protein particles appear to be compact and circular/ellipse-like, consistent 
with results as seen in the corresponding morphology scatter plot (Figure 4.9A).  On the other 
hand, the representative images of protein particles detected in the side-to-side agitated mAb 
samples (Figure 4.9, Panel D) appear to be loose, tenuous structures with rough perimeters.  The 
images of the protein particles caused by agitation of the mAb solution in vials are also 
consistent with scatter plot data which showed positive deviations from the theoretical ellipse 
curve (Figure 4.9B).  Additionally we compared overall secondary structure of the mAb 
particles, formed during fast compression, using solution FTIR and FTIR microscopy (Figure 
4.11). Comparing interfacial stress-induced mAb particles with control and denatured (by heat) 
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mAb samples, a slight shift in second-derivative FTIR spectra is monitored in two peaks for 
intramolecular beta-sheet content (occurring between 1620-1640 and 1690-1700 cm-1) (N=3) 
(Figure 4.11). 
4.3.5. Analysis of the Surface Activity and Surface Pressure vs. Area 
Isotherms for mAb Samples in Histidine or Citrate Buffer 6 
The previous section presented data for an IgG1 mAb in PBS buffer at two different pH 
values.  As a next step, the effect of histidine and citrate buffers on the aggregation propensity of 
the same IgG1 mAb was examined.  The surface pressure-area (П-A) isotherm of mAb solutions 
in citrate buffer at pH 6.5 subjected to dilation cycles at a slow compression-expansion rate as 
shown in Figure 4.10A.  Similar to mAb formulated in PBS buffer, the initial surface pressure 
value corresponds to the value of the saturated surface pressure after 2 hours of adsorption. The 
initial and final surface pressures at the minimum and maximum interfacial area during 
compression-expansion cycles decreased over the 50 cycles.  
Figure 4.10, Panel B shows the surface pressure change with change in interfacial area 
during the first and last (50th) cycles for pH 4.5 and 6.5 mAb samples formulated in citrate 
buffer. Obvious changes in the shape of the curves as well as the values of the surface pressure 
were recorded in these samples. The mAb solution in citrate buffer at pH 4.5 demonstrated the 
maximum protein film compressibility (maximum change in surface pressure with changes in the 
trough area), while the mAb formulated citrate buffer at pH 6.5 showed protein films at the air-
water interface were the least compressible films. Further, for each of the excipient solutions, the 
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lower pH solutions demonstrated increased protein film compressibility at the air-solution 
interface.   
Figure 4.10, Panel C presents a quantitative comparison of the average area (N=3) within 
the surface pressure vs. area curves during the first and last compression-expansion cycles for 
mAb samples at pH 4.5 and 6.5 in histidine or citrate buffers. Such measurements represent 
differences in the hysteresis present in the mAb protein films. The difference between the 
hysteresis of the first and last compression-expansion cycle was significant for all conditions 
assessed (p<0.005). In addition, the area under the curve for the first compression-expansion 
cycle for mAb samples was larger when formulated in buffers at pH 4.5 than at pH 6.5, 
regardless of the buffer ion type (citrate vs. histidine). Most notably, the area under the isotherms 
for mAb samples in citrate buffer at pH 4.5 is significantly higher than all the other conditions 
studied (p<0.05). A summary of the statistical analysis of the differences in these areas is 
presented in Figure 4.10, Panel D. 
4.3.6. The Effect of pH and Buffer Composition of mAb Solution on Particle 
Formation at the Air-Solution Interface for the Slow Compression Rate 7 
To further explore the interfacial mAb particle formation process, topographical AFM 
images of protein films transferred from the air-solution interface were recorded. Representative 
images are presented in Figure 4.12 (top panel). Control mAb samples were incubated at room 
temperature without the application of interfacial stress. Irrespective of the buffer composition 
and pH of the mAb samples, the extent of protein aggregates formed at the air-solution interface 
(represented with lighter colors) was greater after being subjected to compression–expansion 
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cycles, compared to their corresponding control samples. Additionally, several raised/aggregated 
features in the AFM images were recorded for proteins at the air-solution interface of 
compressed mAb samples in citrate buffer compared to histidine, irrespective of the solution pH. 
 Figure 4.12 (bottom panel) presents a box plot analysis of the height (median and range) 
of AFM images of mAb particles formed in histidine and citrate buffers at pH 4.5 and 6.5. 
Comparing the protein particles of control mAb samples there was no significant increase in 
particle height within the formulation by changing the pH (comparing AFM images A with C as 
well as E with G). However, when comparing the AFM images of the protein particle formed at 
the interface of compressed mAb samples, by decreasing the solution pH, the median value of 
protein particle height from the AFM images increases for mAb samples in both histidine and 
citrate (comparing AFM images B with D as well as F with H). Compressed mAb samples in 
citrate buffer at air-solution interface had higher median value and range of particle height 
compared to mAb solution in histidine buffer (AFM images F and H compared to B and D).  
4.3.7. The Effect of pH and Buffer Composition of mAb Solution on Particle 
Number/Size Distribution in Bulk Solution After Compression-Expansion or 
Agitation 
An analysis of particle formation in the bulk mAb solutions filled in glass vials, before 
and after 3 days of side-to-side agitation, showed that all four of the mAb samples had 
substantial particle formation in the bulk, when compared to the unstressed (0 day) control 
(Figure 4.13, top panel). The mAb solution in citrate buffer at pH 4.5 formed the most subvisible 
particles as compared to the other three mAb samples (pH 4.5 and 6.5 in histidine buffer and pH 
6.5 in citrate buffer).  After agitation, the mAb sample in citrate buffer at pH 4.5 had over 
100,000 particles per ml from 2-5 μm, ~100,000 particles in each size range from 5-10 μm and 
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10-15 μm, and ~10,000 particles in each size range from 15-25, 25-40, 40-50, and 50-100 μm.  
On the other hand, the amount and size distribution of particles in the agitated mAb samples in 
histidine buffer at pH 4.5 and 6.5, as well as the agitated mAb samples in citrate buffer pH 6.5, 
were comparable and contained ~10,000 particles per ml from 2-5 μm, ~1,000 particles/ml in 
each range from 5-10, 10-15, and 15-25 μm, and less than 1,000 particles/ml in each of the larger 
size ranges. Additionally, the unstressed and mechanically agitated (at 1 and 3 days) mAb 
samples in citrate and histidine buffer were also analyzed using size exclusion chromatography 
(SEC) (Figure 4.11).  The mAb sample in citrate buffer at pH 4.5 had ~2.0 ± 0.7 % monomer 
loss (N=3) whereas the mAb samples at pH 6.5 in citrate buffer and histidine buffer (both pH 
values) did not have significant monomer loss over the 3 days of agitation.   
In addition to agitation in vials, mAb samples formulated in the same buffer conditions 
were subjected to controlled fast or slow compression-expansion rates in the Langmuir trough 
(see Experimental Procedures).  Particle numbers were evaluated for the above conditions 
(Figure 4.13, bottom panel, black signals) and for a control where the same sample mAb 
formulations were incubated at room temperature for the same amount of time.  Similar to results 
described above with the mAb samples in the PBS buffer, slow compression of the same mAb in 
the histidine and citrate buffers did not result in a statistically significant difference in the 
number of particles in bulk solution as compared to the control samples.  On the other hand, the 
fast compression-expansion caused significant increases in levels of particle observed versus the 
control samples for all four mAb samples.  Interestingly, the mAb samples in histidine buffer at 
pH 4.5 and 6.5, as well as mAb in citrate buffer at pH 6.5, had similar levels of particles after 
fast compression.  The mAb sample in citrate buffer at pH 4.5 generated the greatest number of 
subvisible particles as well as larger sized particles compared to the other mAb sample 
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conditions subjected to fast compression.  After the fast compression-expansion cycles, the mAb 
sample in citrate buffer at pH 4.5 had over 10,000 particles per ml from 2-5 μm, ~10,000 
particles in each size range from 5-10 μm and 10-15 μm, and 15-25 μm, and ~1,000 particles in 
each range from 25-40, 40-50, and 50-100 μm (Figure 4.13, bottom panel, black signal). 
4.4. Discussion      
The primary focus of this work was to elucidate the correlation between interfacial stress 
induced protein clustering at air-water interfaces and mechanical agitation induced protein 
particle formation in bulk mAb solutions.  Specifically, a Langmuir trough was used to induce 
controlled dilatational stress to protein films at the air-water interface, while high resolution 
imaging techniques were used to characterize, in more detail, protein particles formed at the 
interface (by AFM), and in the bulk solution (by flow digital imaging). Using Langmuir troughs 
to apply a compression/dilatation stress to mAb protein films at the air-water interface was 
recently described by Bee et al., to mimic changes in available surface area during agitation(62).  
The Langmuir trough ensures that only protein molecules at the interface, and not the bulk 
solution, are subjected to controlled stresses. This isolation of the bulk and interfacial stresses 
allowed for correlations to be developed between formation of protein particles in these two 
different environments with our model IgG1 mAb (see Figure 4.1 for a schematic of proposed 
correlation).  In this work, we also explored how changes in the bulk mAb solution conditions 
and formulation composition contributed to differences in the formation and morphology of 
protein aggregates at the air-solution interface.  Based on our results, we conclude that while 
interfacial stress initiates protein aggregation at the air-solution interface, the presence of protein 
particles in the bulk mAb solution formed as a result of mechanical agitation is only correlated 
with mAb solutions subjected to “fast” compression/dilatation cycles over an equal length of 
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time.  Further, both the solution pH and buffer composition control the morphology and size 
distribution of protein particles formed at the interface and in the bulk solution for this IgG1 
mAb.  These conclusions are discussed in more detail below.   
Based on a combination of light scattering and calorimetry characterization studies (data 
not shown), the four selected solution conditions (citrate and histidine buffer at pH 4.5 and 6.5) 
result in a range of conformational and colloidal stability values for this IgG1 mAb. The lack of 
correlation between the mAb’s biophysical parameters under these conditions (such as 
normalized second virial coefficient data from static light scattering and the apparent thermal 
onset and melting temperature obtained from DSC) and protein particle formation during thermal 
incubation will be described in an companion manuscript (Chapter 5).  Since mAb samples in 
histidine and citrate buffer at pH 4.5 and 6.5 are representative of a range of physical stability 
properties in the bulk solution,  differences in protein-protein interactions at the air-water 
interface, and not conformational and colloidal stability, better predict the physical stability of 
mAb samples subjected to the mechanical stresses.  In this paper we describe methodologies to 
thoroughly characterize the protein films formed at the air-water interface (e.g., Langmuir trough 
data and atomic force microscopy analysis) with this IgG1 mAb in PBS buffer (pH 4.5 and 7.4), 
in the absence and presence of interfacial stress, to better correlate the observed changes in 
particle formation in bulk mAb solutions to differences in interfacial protein film properties.  We 
then not only examine the effect of solution pH and buffer ion types (histidine and citrate buffers 
at pH 4.5 and 6.5) on the propensity of this IgG1 mAb to form aggregates and particles at the 
interface and in bulk solution, but also evaluate their effects on the resulting protein particle 
number, size and morphology.  
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4.4.1. Analysis of Surface Pressure Changes During Compression-Expansion 
Cycles 8 
As a first step towards analyzing interfacial phenomenon in various solutions of this gG1 
mAb, we measured the surface activity of the protein films in a Langmuir trough experimental 
setup (Figure 4.1). The equilibrium surface pressure measurements show that even at a 
concentration of 0.37 mg/ml, the IgG1 mAb samples were surface active when formulated in 
different buffers and pH values.  These results suggest that surface pressure measurements alone 
do not correlate with protein particle formation.  Shieh et al. have recently shown, in fact, that 
equilibrium surface pressure values were not an adequate predictor of a different mAb sample’s 
susceptibility to aggregate (92).  Instead, the kinetics of antibody rearrangement after adsorbing 
to the interface was shown to be better correlated with the extent of observed aggregation(92).  
In this work, we present a comparison of how differences in the application of surface stresses, 
as well as protein solution composition, influence protein particle formation in the bulk solution. 
Particularly, surface pressure vs. area isotherms during the compression-expansion cycles were 
recorded and analyzed in detail to determine evidence of strong attractive antibody-antibody 
interactions that may result from mechanical agitation or stresses. Specifically, we compared the 
difference between the hysteresis of the first and last cycle of surface pressure vs. area isotherms 
that could potentially indicate the extent of particle loss from the interface. The isotherms 
indicate the formation of an incompressible film at the interface while the hysteresis indicates the 
likely possibility of formation of irreversible protein associations during a compression-
expansion cycle. Further, mAb samples in citrate buffer at pH 4.5 were found to possess the 
largest difference in hysteresis between first and last cycles, suggesting the most associations 
                                                 
8 The work described in this section was performed by Saba Ghazvini from the Bioengineering Department at the 
University of Kansas.  The work is included in this thesis to support the conclusions drawn in this chapter. 
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between the proteins at the air-water interface in this solution. Figure 4.6 also conclusively 
established that the observed phenomena are due to protein-protein interactions, and not due to 
the presence of surfactant (polysorbate).  
4.4.2. Analysis of Protein Particles Formed at the Air-Water Interface or in 
Bulk Solution 
The analysis of the interfacial properties of the protein films were complemented with 
high resolution AFM imaging of protein aggregates. Our AFM images confirmed the formation 
of protein aggregates at the air-water interface in mAb samples that were mechanically stressed 
in the Langmuir trough.  The lack of any notable raised features in the AFM images of mAb 
samples not subjected to mechanical stresses confirmed that application of interfacial stresses 
was the key to protein aggregate formation at the air-protein solution interface.  It was also 
interesting to note that protein films transferred from mAb solutions in citrate buffer at pH 4.5 
produced the maximum number of protein aggregates, particularly fold-like fibrils, that resemble 
collapsed protein, polymer or lipid films at air-water interfaces, when they are subjected to very 
high compression(171, 172) . Therefore, both the presence of compressive stresses, as well as 
different bulk mAb solution composition (pH and buffer ion type) contributes to the protein 
aggregate formation at the air-solution interface. 9  
Differences in the formation of protein particles in bulk solution, as measured by radar 
chart analysis of digital flow imaging data,  for the slow and fast compressions, together with the 
AFM images of the protein aggregates at the interface and bulk solution for slow and fast 
compressions, establish that in addition to being subjected to interfacial stresses, the protein 
                                                 
9 The work described in this paragraph was performed by Saba Ghazvini from the Bioengineering Department at the 
University of Kansas.  The work is included in this thesis to support the conclusions drawn in this chapter. 
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particles can be lost from the interface into the bulk and serve as nucleation points only if the 
interface is sufficiently perturbed.  When the number of cycles was kept constant at 50, but the 
stress was applied for different amounts of time, no difference is observed in the formation of 
mAb particles, at the interface or in the bulk, further establishing the need for extensive 
perturbation of the interface. Additionally, hysteresis in the protein films corresponds well with 
presence of protein particles in bulk protein samples. For example, not only did the mAb sample 
in citrate buffer at pH 4.5 have the largest difference in hysteresis, suggesting the highest 
protein-protein associations, the bulk mAb solution for this formulation also had the highest 
particle formation among mechanically agitated samples (see Figure 4.13).  These observations, 
along with the direct visual evidence of protein aggregates at mechanically stressed air-protein 
solution interfaces, further establish that while mechanical agitation to the interfacial protein film 
alone is sufficient to cause protein particle formation, even in relatively dilute solutions of this 
IgG1 mAb, continuous and aggressive disruption of the interfacial film is also necessary for 
more extensive protein particle formation in the bulk mAb solution.      
Further analysis of the high resolution AFM images of the protein films transferred from 
the air-water interface suggest that protein particles present at air-water interface of mAb 
samples formulated in citrate buffer were more fibril-like compared to protein particles present 
in mAb samples in PBS buffer and larger compared to fibrils formed in mAb samples in histidine 
buffer (see Fig. 4.7 and 4.12).  Interestingly, similar fibril/filament morphology of protein 
particles with a different mAb in citrate buffer has been reported using other techniques such as 
electron scanning imaging (88, 173). Interestingly, subvisible particle images of our model IgG1 
mAb particles in bulk solution, using flow digital imaging measurements, showed similar fibril 
morphology for mAb samples in citrate buffer, which further suggests the possibility of 
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detachment of mAb particles from the interface to the bulk solution. Additionally, the compact 
morphology of mAb particles formed as a result of interfacial stresses compared to those formed 
by agitation of the same mAb samples in glass vials (Figure 4.9) suggests that the larger 
compression ratio of the Langmuir trough compared to vials possibly influences the morphology 
of the observed protein particles in these mAb samples.  Differences in the rate and nature of 
interfacial perturbation between shaking and interfacial compression-expansion cycles could also 
be responsible for the different particle morphologies observed.  Protein molecules that associate 
rapidly tend to form loose, tenuous aggregate structures whereas molecules that associate slowly 
have more time to reorient and tend to form more compact aggregates (174). 
4.4.3. Impact of Buffer Ion and pH Conditions of mAb Samples on Protein 
Particle Formation 
To better explain the observed differences in the morphology and number of protein 
particles formed at the air-solution interface, we turn our attention to protein-protein interactions 
observed in highly concentrated bulk protein solutions. Although one might argue that the bulk 
protein solution in our studies is very dilute, the two-dimensional air-water interface is in fact 
highly concentrated, because of the saturation of this interface with protein molecules.  Literature 
survey of highly concentrated mAb protein solution suggests that increased protein-protein 
interactions in highly concentrated mAb solutions can in fact be correlated with bulk viscosity 
measurements at high protein concentrations (88, 173, 175-177). For example, Esue et al. 
reported on the appearance of large bulk elasticity for a mAb solution in citrate buffer at a mAb 
concentration higher than 25 mg/ml at pH 6.0.  The elastic modulus of the protein solution was 
not affected by ionic strength of the formulation but concentration of carboxylate ions (88).  On 
the other hand, decreases in bulk viscosity of mAb samples in histidine buffer have been reported 
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at pH 6.0 (175-177).  Esue et al. further reported that while the highest elastic modulus or gel-
like behavior was found in the mAb protein solution in the pH range 4-6, deprotonation of 
histidine residue decreased the ability of mAb to interact with citrate ion (with a net negative 
charge) (173).  As a result, the mAb samples in histidine buffer had lower protein-ion interaction, 
resulting in lower gel-like properties. These observations, although with a different IgG1 mAb, 
are consistent with particle formation at the air-solution interface observed in this work.  Surface 
pressures vs. area isotherms demonstrate the highest hysteresis for mAb solution in citrate buffer, 
suggesting the formation of the elastic gel-like film at the interface.  Further, mAb samples in 
citrate buffer at pH 4.5 displayed gel-like fibril formation, rather than clusters at the interface.  
Moreover, compared to citrate, mAb samples in histidine buffer showed less hysteresis at each of 
the solution pH values studied. In addition, AFM images of mAb proteins in solutions containing 
histidine ions formed more loose thread-like structures at the interface.  
4.5. Conclusions  
In this work, we have examined protein particle formation in bulk solution and in 
interfacial protein films for a model IgG1 mAb in different formulations, as a means to correlate 
how stresses and protein interactions at the air-water interface may be attributed to differences in 
protein particle levels in mechanically agitated mAb solutions.  Our results demonstrate that the 
buffer type and the solution pH of mAb samples affect the extent and morphology of mAb 
particle formation at the air-solution interface, which in turn affects the levels and shape of 
protein particles detected in the bulk mAb solution.  Comparison of particle formation between 
mechanical agitated and interfacial stressed mAb protein samples in this work confirmed 
previous findings with other mAbs on the significant role of interfacial stress in protein particle 
formation in bulk mAb solutions (62, 91).  One common approach to stabilize mAb formulations 
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from agitation stress is to avoid/reduce the surface activity of mAb samples, by adding more 
thermodynamically favorable compounds, such as non-ionic surfactants such as polysorbates, 
that compete with mAb molecules for the air-water interface (178, 179).  However, these 
additives are difficult to remove, may accelerate other protein degradation/aggregation pathways, 
and are labile and prone to self-degrade (168, 178).  Although this study focused on mAb particle 
formation in response to changes in buffer type and pH, future work will include addition of 
different concentrations of polysorbates and other surface active molecules.  Finally, we suggest 
that the experimental methodology, as summarized Figure 4.1, could be an effective screening 
tool of various excipient classes and types to identify combinations of additives to minimize 


















Figure 4.1. Schematic illustration of interfacial stress and subsequent protein particle formation 
during mechanical agitation of mAb samples in glass vials vs. controlled compression-expansion 
in a Langmuir trough.  (A) System used to shake sample vials in a side-to-side motion.  (B) 
Image of the Langmuir trough connected to a pressure sensor used to apply interfacial 
mechanical stress and monitor the surface pressure with changes in interfacial area.  Panel C and 
D are schematic illustrations of the potential correlation between mechanisms of protein particle 
formation in mAb samples subjected to (C) mechanical agitation in vials, and (D) interfacial 




Figure 4.2.  Radar chart analysis of flow digital images of subvisible particles formed in mAb 
solutions in PBS buffer at pH 4.5 or 7.4 at time 0 or after 3 days of side-to-side shaking in glass 
vials.  Each axis of the radar charts represent a particular particle size range (labelled on figure).  
The black signal represents the average number of protein particles (n=3) and the grey signal 
represents average plus the standard deviation.  The radar charts in this figure use a logarithmic 
scale with the center of chart representing 10 particles/ml and each concentric polygon of the 
chart marking a 10x increase in the particle number.  The outermost polygon comprising each 







Figure 4.3.  Representative SEC chromatogram overlay for mAb  samples in pH 7.4 PBS buffer 
that were shaken in vials side-to side for 3 days (blue) and the corresponding unstressed control 
(red).  The insert is a zoomed in view of the chromatograms. Aggregates are also referred to as 








Figure 4.4.  The fraction of monomer, high molecular weight species (HMWS), and fragments 
for the shake stressed mAb samples in PBS buffer as measured by size exclusion 
chromatography (SEC).  Values obtained from integrated SEC chromatograms normalized to t=0 
values. The SEC was performed in triplicate (n=3) and error bars are plotted as standard 












Figure 4.5. (A) Surface pressure vs. area isotherms of 0.37 mg/ml mAb samples in PBS buffer at 
pH 7.4 subjected to 50 cycles of compressions-expansion during 6 hours (slow rate) in Langmuir 
trough. Results are presented as mean and SD (n=3). (B) The first and last cycle of compression-
expansion isotherms for mAb sample in PBS buffer at pH 7.4 and 4.5. Results are presented as 
mean and SD, (n=3).  (C) Comparing the area under the compression-expansion isotherm 
(hysteresis) of the first and last cycle for mAb sample in PBS buffer at pH 7.4 and at 4.5. Results 







                                                 
10 Figure 4.5 represents experimental work contributed by Saba Ghazvini from the Bioengineering Department at the 





Figure 4.6.  (A) Adsorption of polysorbate 80 at 0.00012 wt.% as surface pressure vs time. (B) 
Surface pressure-area isotherm of polysorbate 80 at 0.00012 wt.% through slow compression-
expansion cycles. The samples contain the same concentration of polysorbate 80 in water that is 
present in the mAb samples throughout the study. The low surface pressure of polysorbate 80 at 
this concentration indicates the surface pressure that was measured through the study is due to 
presence of mAb itself. (C) the first and 50th cycle of slow (6hours) and fast rate (25min) of 
compression-expansion isotherms for mAb sample in 1x PBS buffer at pH7.4 and at 4.5. Results 
are presented as mean and SD, (n=3). (D) Comparing the area under the compression-expansion 
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isotherm (hysteresis) of the first and 50th cycle for mAb sample in 1x PBS buffer at pH 7.4 and 
at 4.5 for both slow and fast compression. Results are presented as mean and SD (n=3). 11 
 
 
                                                 
11 Figure 4.6 represents experimental work contributed by Saba Ghazvini from the Bioengineering Department at the 





Figure 4.7.  (A, B) Radar chart analysis of flow digital images of subvisible particles formed in 
Langmuir trough for mAb samples in PBS buffer at pH 4.5 and 7.4 after 6 hours of slow 
compression (panel A), fast compression (Panel B), or room temperature incubation (red trace in 
panel A and B).  Each axis of the radar charts represent a particular particle size range (labelled 
on figure).  The black signal represents the average number of particles (n=3) formed during 
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stressed conditions and the grey signal represents average plus the standard deviation.  The red 
signal represents the average number of particles (n=3) formed during a ‘no-stress’ condition 
with the dark red signal representing the average plus standard deviation.  The radar charts in this 
figure use a logarithmic scale with the center of chart representing 10 particles/ml and each 
concentric polygon of the chart marking a 10x increase in the particle number.  The outermost 
polygon comprising each radar chart marks a particle concentration of 1,000,000 particles/ml for 
each corresponding size range. (C, D) AFM images of protein particles formed at air-solution 
interface and bulk mAb solution subjected to the slow (Panel C) or fast (Panel D) compression. 
The mAb particles at interface or in the bulk solution were transferred on a freshly cleaved mica 
sheet by a brief horizontal contact with the interface or being allowed to sit in trough, 
respectively. (E, F) the height analysis of AFM images of the mAb particles formed at air-
solution interface or bulk solution of compressed samples in 1x PBS buffer at pH 4.5 or 7.4 







                                                 
12 Panel C–F of Figure 4.7 represents experimental work contributed by Saba Ghazvini from the Bioengineering 





Figure 4.8.  (A,B) Radar chart array of mAb particles suspended in bulk solution of pH 4.5 or 
7.4 1x PBS buffer after 50 cycles (6 hours) of slow compression (panel A), 50 cycles (25 min) of 
fast compression (Panel B), or room temperature incubation (red trace in panel A and B).  Each 
axis of the radar charts represent a particular particle size range (labelled on figure).  The black 
signal represents the average number of particles (n=3) formed during stressed conditions and 
the grey signal represents average plus the standard deviation.  The red signal represents the 
average number of particles (n=3) formed during a ‘non-stressed condition’ with the dark red 
signal representing the average plus standard deviation.  The radar charts in this figure use a 
logarithmic scale with the center of chart representing 10 particles/ml.  The outermost polygon 
comprising each radar chart marks a particle concentration of 1,000,000 particles/ml for each 
corresponding size range. (C,D) representative AFM images of IgG1 mAb particles formed at 
air-solution interface subjected to 50 cycles (6 hours) of slow compression (Panel C) or 50 cycles 
(25 min) of fast compression (Panel D) compression. MAb particles at interface or bulk solution 
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were transferred on a freshly cleaved mica sheet by a brief horizontal contact with the interface 





















                                                 
13 Figure 4.8 represents experimental work contributed by Saba Ghazvini from the Bioengineering Department at the 




Figure 4.9. Morphology of protein particles detected in bulk solution after stress conditions as 
measured by flow digital imaging.  (A) Scatter plot of the first 500 particles detected in a mAb 
sample in PBS buffer at pH 4.5 subjected to 8 hours of fast compression.  The blue line 
represents the morphology of an ellipse calculated using the Ellipsoid-Volume method(104) to 
characterize the morphology of the particles (see text).  (B) Scatter plot of the first 500 particles 
detected in a mAb sample in PBS buffer at pH 4.5 subjected to 3 days of side-to-side shaking in 
a glass vial at 300 RPM.  (C) Representative protein particle images for the fast compression 
sample.  (D) Representative protein particle images of the stressed mAb samples from flow 







Figure 4.10. (A) Surface pressure vs. area isotherms of 0.37 mg/ml IgG1 mAb in citrate buffer at 
pH 6.5 subjected to slow compressions-expansions rate in Langmuir trough.  Results are 
presented as mean and SD, (n=3).  (B) Comparison of the first and last cycle of compression-
expansion isotherms for mAb samples in citrate buffer at pH 4.5 and 6.5.  Results are presented 
as mean and SD, (n=3).  (C) Comparison of the area under the compression isotherms of the first 
and last cycles for mAb samples in histidine or citrate buffer at pH 4.5 and 6.5.  Results are 
presented as mean SD, (n=3).  (D) One-way ANOVA analysis of the area under the compression 
isotherms (hysteresis) of the first and last cycles of mAb samples presented in panel C. 14 
                                                 
14 Figure 4.10 represents experimental work contributed by Saba Ghazvini from the Bioengineering Department at 




Figure 4.11.  Secondary structure analysis of imaged protein particles (formed in pH 7.4 PBS 
mAb samples subjected to fast compression for 6 hours) as measured by FTIR and FTIR 
microscopy.  A) Representative FTIR spectra of the native mAb control solution.  B) 
Representative second derivative spectra of the amide I region for the native mAb control.  Peaks 
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are given as the average of 3 replicates.  C)  Representative particle image captured using FTIR 
microscopy to analyze particles formed during fast compression.  D) Representative second 
derivative FTIR spectra of the amide I region for a particle formed during fast compression. Peak 
values (mean and SD) are given as the average of 9 particles.  E)  Representative particle image 
captured using FTIR microscopy to analyze particles formed after extensive heat denaturation at 
90 ᵒC.  D) Representative second derivative FTIR spectra of the amide I region for a particle 
formed during extensive heat denaturation at 90 ᵒC. Peak values (mean and SD) are given as the 








Figure 4.12. (Top Panel) High resolution topographical AFM images of mAb protein films show 
IgG1 mAb particles formed at air-solution interface of samples formulated in histidine or citrate 
buffer at pH 4.5 and 6.5 and subjected to slow compression-expansion in Langmuir trough.  
(Bottom Panel) Height analysis of the AFM images of the mAb particles in slow compression-
expansion and control for the same conditions as the top panel (n=9).  The control samples 
correspond to protein films transferred from the air-protein solution interface of mAb samples 
that were not subjected to any interfacial mechanical stresses. 15 
                                                 
15 Figure 4.12 represents experimental work contributed by Saba Ghazvini from the Bioengineering Department at 




Figure 4.13.  Radar chart analysis of flow digital images of subvisible particles formed in bulk 
mAb samples in histidine or citrate buffers at pH 4.5 or 6.5.  (Top) samples subjected to 0 or 3 
days of side-to-side shaking in glass vials at 300 RPM.  The black signal represents the average 
number of particles (n=3) and the grey signal represents average plus the standard deviation.  
(Bottom) samples subjected to 6 hours of fast compression, slow compression, or room 
temperature incubation in Langmuir trough.  The black signal represents the average number of 
particles (n=3) formed during compression and the grey signal represents average plus the 
standard deviation.  The red signal represents the average number of particles (n=3) formed 
during room temperature incubation with the dark red signal representing the average plus 
standard deviation.  The radar charts in this figure use a logarithmic scale with the center of chart 
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representing 10 particles/ml and each concentric polygon of the chart marking a 10x increase in 
the particle number.  The outermost polygon comprising each radar chart marks a particle 

















Figure 4.14.  The fraction of monomer, high molecular weight species (HMWS), and fragments 
for the shake stressed mAb samples in different formulations.  Values obtained from integrated 
SEC chromatograms normalized to t=0 values. The SEC is performed in triplicate (n=3), error 
bars were plotted as standard deviation. MAb solution at (A) pH 4.5 in 50mM citrate buffer, (B) 
pH 6.5 in 50mM citrate buffer, (C) pH 4.5 in 50mM histidine buffer, and (D) pH 6.5 in 50mM 






Chapter 5: Effects of Protein Conformation, Apparent Solubility, and 
Protein-Protein Interactions on the Rates and Mechanisms of Aggregation for 

















Non-native protein aggregation, or the assembly of proteins into conformationally altered 
agglomerates, is multistep process that can occur by different mechanisms through various 
molecular and colloidal steps (10, 44, 45).  In the biopharmaceutical industry, non-native 
aggregation of therapeutic proteins is a highly undesirable phenomenon because the presence of 
protein aggregates can compromise drug efficacy by decreasing potency and/or by increasing 
product immunogenicity potential (i.e., formation of anti-drug antibodies) (1, 2, 12-14, 46, 47).  
The process of non-native, irreversible protein aggregation (hereafter referred to as aggregation) 
results in aggregates of varying size ranging from soluble dimers to insoluble macroscopic 
particles (66).  The extent of protein aggregation is largely determined by the sequence and 
structure of the protein itself (67, 68), solution environment (e.g., pH, ionic strength, cosolutes) 
(51, 54, 69),  and stress condition applied to induce aggregation (e.g., temperature, mechanical 
agitation, light, etc.) (70).  Recent studies, for example, suggest that mechanical agitation induces 
aggregation of protein molecules at the air-solution interface (62) whereas incubation at elevated 
temperatures promotes aggregation of proteins in bulk solution (71).  Cosolutes may affect 
protein aggregation mechanisms and/or rates by modifying protein conformation, protein 
structural stability, apparent solubility, and/or protein-protein interactions in solution (11). 
Traditionally, protein aggregation has been mechanistically interpreted using the Lumry-
Eyring model, in which a reversible conformational change of the protein is followed by an 
irreversible association step (4).  If aggregation follows the Lumry-Eyring model, the kinetics 
should be highly temperature sensitive (to a greater extent than predicted by the Arrhenius 
equation) because of the second order dependence on the concentration of partially unfolded 
species.  For this reason, evaluating protein conformational stability is an important 
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consideration for understanding protein aggregation mechanisms.  For example, differential 
scanning calorimetry is commonly employed to measure endothermic transitions attributed to 
protein unfolding as a function of temperature under different solution conditions.    
Contrary to the Lumry-Eyring model, there are examples of native proteins associating 
prior to undergoing a conformational change to form an aggregate (4, 59).  Quantifying the 
concentration of such transient encounter complexes by direct experimental methods is 
technically challenging because of the reversible, and thermodynamically unstable, nature of 
these intermediates, which may cause them to exist for only a short time in extremely small 
quantities.  In several studies, one approach to address this challenge involved the observation 
that protein aggregation propensity in different solutions correlated to apparent solubility values 
in the presence of an inert crowding agent (59, 180).  Middaugh and coworkers used an 
extrapolation method to determine the apparent thermodynamic activity of saturated protein 
solutions from protein precipitation data in solutions with different polyethylene glycol (PEG) 
concentrations (181).  Other studies have used descriptive parameters derived from precipitation 
profiles (e.g., midpoint values) as a means of rapidly rank ordering different solutions conditions 
for pharmaceutical development (59, 180, 182).  Fundamentally, apparent solubility 
measurements reflect the free energy difference between amorphous solid and solution phases if 
the system is at equilibrium.  It is suggested that such experimentally determined apparent 
protein solubility (or extrapolated thermodynamic activity) values can be used as an 
experimental surrogate for the thermodynamic favorability of reversible encounter complex 
formation (intermediates) prior to irreversible aggregate formation, and thus correlate with 
observed propensity of a protein to aggregate under the same conditions (59).   
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Measures of non-specific, weak protein-protein interactions (referred to hereafter as PPI) 
under different solution conditions are commonly used to interpret protein aggregation data 
under those same conditions.  The rationale behind such approaches is that mechanistically 
protein aggregation must have one or more association steps.  Weak PPI are often characterized 
using experimental measures of protein charge and/or the second osmotic virial coefficient (B2) 
(5, 7, 71).  Using statistical mechanics, the second osmotic virial coefficient can be defined as 
B2 = −
NA
2M2 ∫{exp[−W22(r)/kBT] − 1} 4πr
2dr,                    
(5.01) 
where M is the molecular weight of the protein, NA is Avogadro’s number, kB is the Boltzmann 
constant, T is the absolute temperature and W22(r) is the protein-protein potential of mean force 
(averaged over all orientations) as a function of center-to center distance, r (6, 28, 30).  If a 
protein is globular, and if two protein molecules effectively stick together irreversibly upon 
association, the kinetics of protein aggregation should closely follow the theory of slow 







 ,          (5.02) 
where k is the rate of association, D1 and D2 are the diffusion coefficients of the aggregating 
species (1 and 2), and Rs1 and Rs2 are the spherical radii of the aggregating species.  Φ12(r) is 
the interaction potential between species 1 and 2 as a function of center-to-center distance r.  In 
the scenario described above, we can assume that protein aggregation should directly correlate to 
B2.  There are several prominent examples in the literature, however, where observed protein 
aggregation results do not necessarily show any apparent direct correlation to such PPI values 
(56, 57).         
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 In this work, we seek to examine the effects of protein conformational stability, apparent 
solubility, and PPI parameters on the mechanism and rate of aggregation for an IgG1 mAb stored 
at different incubation temperatures under different solution conditions.  In the following section, 
we develop several theoretical kinetic models to explain why protein aggregation may appear to 
correlate with weak PPI, apparent solubility, and conformational stability in some cases but not 
in others.  The models are then applied to interpret experimental protein aggregation data 
collected over a range of incubation temperatures for an IgG1 mAb prepared in different solution 
conditions possessing varying values of PPI, apparent solubility, and conformational stability. 
5.2. Theory 
5.2.1. Kinetic Model of Protein Aggregation    
This model uses the framework of the Lumry-Eyring Nucleated Polymerization model 
developed by Roberts and coworkers, to consider protein aggregation, in bulk solution, as a 
multi-step process that may involve several competing nucleation and growth pathways (84, 85).  
The formation of an irreversible dimer (nucleation event) may be described by one or more of 
the following potentially competing pathways: 
N∗ + N∗
Ka1,(N∗,N∗)
�⎯⎯⎯⎯⎯�  {N∗}2 
knuc,{N∗}2�⎯⎯⎯⎯⎯�A2,{N∗}2                                                 
(5.03a) 
N∗ + m 
Ka1,(N∗,m)
�⎯⎯⎯⎯⎯�  {N∗m} 
knuc,{N∗m}
�⎯⎯⎯⎯⎯⎯�A2,{N∗m}                      (5.03b) 
m + m 
Ka1,(m,m)
�⎯⎯⎯⎯�  {m}2 
knuc,{m}2�⎯⎯⎯⎯⎯�A2,{m}2                              (5.03c) 
Where N∗ is a conformationally altered monomer, m is a native monomer, and 
A2,{encounter complex} is an “irreversible” dimer (net thermodynamic irreversibility relative to the 
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current solution environment) that has formed through an encounter complex intermediate.  
{N∗}2, {N∗m}, and {m}2 are reversible encounter complexes whose initial structures should 
depend upon the structure of the associating species.  Ka1,(N∗,N∗), Ka1,(N∗,m), and Ka1,(m,m) are the 
equilibrium association constants for the reversible dimeric encounter complex formation.  The 
subscript of the equilibrium association constant in parenthesis is used to differentiate between 
the aggregating monomer species.  knuc is a rate constant describing conformational 
rearrangement of an encounter complex to an irreversible aggregate (referred to as nucleation in 
the LENP model).  The subscript of knuc specifies the type of encounter complex undergoing the 
nucleation event.  Figure 5.1 is a visual scheme depicting the nucleation mechanisms described 
by Equations 5.03a-c.    
After the nucleation event, the existing dimer may enter a growth phase where the 
oligomeric state of the aggregate grows through the addition of a native monomer, 
conformationally altered monomer, or an aggregate to the existing structure.  The nature and 
extent of any growth event probably depends upon the type of nucleus (e.g.{N∗}2,{N∗m}, 
or{m}2).  For practical purposes, however, we ignore these potential differences in this model.  
This association process is thus represented by the following equations: 
 Aj +  N∗
Kaj,(N∗)
�⎯⎯⎯�  {N∗Aj} 
kg,{N∗Aj}
�⎯⎯⎯⎯�Aj+1       (5.04a) 
Aj +  m
Kaj,(m)
�⎯⎯�  {Aj m} 
kg,{Aj m}
�⎯⎯⎯⎯�Aj+1                                                                    (5.04b) 
Aj + Ai
kagg(j,i)
�⎯⎯⎯�Aj+i …           (5.05) 
Where j and i represent the number of monomeric units contained within an aggregate, and 
2 ≤ (j or i) < ∞.  Kaj,(N∗) and Kaj,(m) represent the equilibrium association constants for growth 
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of an aggregate, composed of j monomers, by addition of a conformationally altered monomer 
(N∗) or native monomer (m), respectively.  Similar to aggregate nucleation, the brackets “{}” 
denote a reversible encounter complex composed of two species.  The rate constant, kg, 
describes the conformational rearrangement of an aggregate-monomer encounter complex to a 
larger, irreversible aggregate.  kagg(j,i) is a rate constant for the formation of an aggregate 
composed of j + i monomeric units from two aggregates of size j and i.  Figure 5.2 is a visual 
scheme depicting the growth mechanisms for different dimers described by Equations 5.04a, 
5.04b and 5.05.   
If we define the total monomer concentration as being equal to the concentration of 
native monomer plus the concentration of partially unfolded monomer (i.e., mtot = m + N∗), 
then Equations 5.03-5.05 can be used to express the rate of monomer loss as 
−d[m]
dt
= 2 ∗ knuc,obs[mtot]2 +  ∑ kg,obs,{Aj}
∞
j=2 �Aj�[mtot] ,                 (5.06) 
where knuc,obs and kg,obs are the observed rate constants for nucleation and growth events and 
will reflect some combination of the competing aggregation pathways.  The first term on the left 
hand side of Equation 5.06 describes monomer loss as a result of a nucleation event, and the 
second term describes monomer loss as a result of monomers adding to aggregates of all possible 
sizes.  The subscript {Aj} on kg,obs is used to differentiate between the observed rate constants of 
growth events for aggregates of different sizes. Additionally, the subscript {Aj} on kg,obs  
intentionally neglects to specify the monomer type (N∗ or m) involved in the growth event since 
the observed rate constant could be a convolution of both growth mechanisms.   
146 
 
The rate of aggregate formation for an aggregate consisting of j monomers can be 
described by the following equation: 
d�Aj�
dt
= kg,obs,�Aj−1�[mtot]�Aj−1� − kg,obs,�Aj�[mtot]�Aj� − kagg(j,j)�Aj�
2















.          (5.07) 
5.2.2. Role of Conformational Stability on Aggregation Rates 
Considering that knuc,obs is the observed rate constant for three potentially competing 
pathways, it can be expressed in terms of the observed rate constants for each mechanism and 
the fraction of conformationally distorted protein, f.  If we define N∗ = f ∗ mtot and m = (1 −
f) ∗ mtot, then   
 knuc,obs = knuc,obs,{N∗}2 ∗ f
2 + knuc,obs,{N∗m} ∗ f(1 − f)+ knuc,{m}2 ∗ (1 − f)
2 .                  (5.08) 
kg,obs for an aggregate of size j can be similarly defined as 
kg,obs,{Aj } = kg,obs,{N∗Aj} ∗ f+ kg,obs,{Aj m} ∗ (1 − f) .                     (5.09) 
  If a protein does not aggregate by a particular pathway, then the observed rate constant can 
simply be set to 0.   
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5.2.3. Role of Colloidal Stability and Apparent Solubility on Aggregation 
Rates 
The equilibrium constants describing encounter complex formation for aggregate 
nucleation (i.e., Ka1,(N∗,N∗), Ka1,(N∗,m), and Ka1,(m,m)) and aggregate growth (i.e., Kaj,(N∗) and 
Kaj,(m)) can be described as an association rate constant divided by a dissociation rate constant. 








= 0), the 
observed rate constant for a particular nucleation mechanism is given by knuc,obs,{} =
ka1,{}knuc,{}
k−a1,{}+ knuc,{}
, where {} represents the {N∗}2, {N∗m}, or {m}2 pathway.  If the same assumption is 
applied to aggregate growth, kg,obs,{} =
kaj,{}kg,{}
k−aj,{}+ kg,{}
.  When two protein monomer/aggregates 
species diffuse together to form an encounter complex, there are 2 limiting cases of particular 
interest: (1) the encounter complex rapidly forms a stable aggregate (knuc,{} >> k−a,{} and/or kg,{} 
>> k−aj,{}), and (2) the encounter complex tends to diffuse apart (k−a1,{} >> knuc,{} and/or k−aj,{} 
>> kg,{}).   
Considering limiting case (1) in further detail,  knuc,obs,{} ≈ ka1,{} and/or kg,obs,{} ≈ kaj,{}.  
Under such conditions, the observed rate constant for a particular mechanism will approximately 
equal the rate of protein association which is directly related to colloidal stability (see 
introduction).  This limiting case could occur if the activation energy barrier for association is 
sufficiently higher than the activation energy barrier for nucleation. When limiting case (2) is 
further examined, knuc,obs,{} ≈ knuc,{}Ka1,{} and/or kg,obs,{} ≈ kg,{}Kaj,{}.  Ka1,{} and Kaj,{} are 
equilibrium constants describing encounter complex formation for a particular nucleation and 
growth pathway, respectively.  knuc,{} and kg,{} are rate constants describing conformational 
148 
 
rearrangement of the encounter complex into a stable aggregate.  Under this limiting case, 
aggregation kinetics will not be related to colloidal stability in a kinetic sense, but will instead 
depend upon equilibrium encounter complex formation and subsequent structural rearrangement.  
If apparent solubility (or extrapolated thermodynamic activity) measurements in solutions with 
inert crowding agents reflect the thermodynamic favorability of protein in solution vs. an 
amorphous solid phase, it could be used as surrogate parameter to evaluate changes in Ka1,{} and 
Kaj,{} between solution conditions. 
5.3. Materials and Methods 
5.3.1. Sample Preparation 
The IgG1 mAb (pI ~ 9) was donated by Janssen Research & Development, LLC 
(Horsham, Pennsylvania) at an approximate concentration of ~40 mg/ml.  Citrate and histidine 
stock formulation buffers (50 mM) were prepared at pH 4.5 and 6.5 with and without 100 mM 
NaCl.  L-histidine was obtained from Sigma-Aldrich (St. Louis, Missouri).  Citric acid 
anhydrous and sodium citrate dihydrate were from Fisher Scientific (Hampton, New Hampshire). 
Buffers were prepared with Milli-Q water (EMD Millipore, Billerica, Massachusetts) and were 
sterile filtered using a 0.2 μm filter. Final mAb solutions for these studies were prepared at a 
concentration of 1.0 mg/ml by diluting the mAb stock solution (1/40) into each of the four 
formulation buffers.  The working mAb solutions of 3 mL each were aliquoted into 37.7 × 16.75 
mm Fiolax® glass vials (Schott, Lebanon, Pennsylvania) capped with elastomeric stoppers that 
were treated with a fluorocarbon film (West Pharmaceutical Services, Exton, Pennsylvania).  
The sample preparation procedures outlined above are described as well in a separate but 
complimentary study examining aggregation at the air-water interface in the presence of 
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mechanical agitation(183).  Vials intended for long term incubation were sealed with flip-off 
CCS seals (West Pharmaceutical Services).  The IgG1 mAb containing sample vials were 
subjected to shorter term incubation at 57°C for up to 5 days or longer term incubation for up to 
7 months at either 40 °C or 25 °C. 
5.3.2. Differential Scanning Calorimetry (DSC)   
A VP-Capillary DSC (Malvern Instruments, Worcestershire, United Kingdom) was used 
to obtain apparent melting thermograms for 1.0 mg/ml mAb in different solution conditions.  The 
differential heat capacity between the mAb solution (sample cell) and corresponding buffer 
(reference cell) was scanned over a temperature range of 10 to 90ºC at a rate of 1ºC/min.  The 
MicroCal LLC DSC plug-in for Origin 7.0 was used for data analysis by iteratively fitting 
processed thermograms to a non-two state model for protein unfolding. 
5.3.3. Size Exclusion Chromatography (SEC) 
SEC was performed using a prominence UFLC HPLC system (Shimadzu, Kyoto, Japan) 
equipped with a diode array detector.  A TSKgel G3000SWx1 stainless steel column (Tosoh 
Biosciences, San Francisco, California) with a TSKgel SWxI guard column were used at 30°C to 
separate and quantitate monomer, aggregate, and fragment populations.  A pH 6.8, 0.2 M sodium 
phosphate buffer was used as the mobile phase to reduce protein adsorption to the column (133).  
The flow rate was set to 0.7 ml/min and the column was allowed to equilibrate for 3 h prior to 
measurement. For each sample, 30 μl was injected onto the column and the absorbance at 214 
nm was collected for 30 min.  LC Solution software from Shimadzu was used to integrate 
monomer, aggregate, and fragment peaks.  Integrated peak areas were normalized by the total 
area at t=0 to monitor the loss in peak area between different time points. 
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5.3.4. Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) 
An Optima XL-I analytical ultracentrifuge (Beckman Coulter, Fullerton, CA) equipped 
with an interference optical system was used for sedimentation velocity measurements.  
Experiments were conducted at 20 °C, at a rotor speed of 40,000 RPM.  Samples and reference 
were loaded into Beckman charcoal-epon two sector cells with 12 mm sapphire windows.  The 
samples were incubated within the centrifuge for an additional hour after the chamber reached 
temperature. Analysis of the sedimentation data was performed using Sedfit software (184).  A 
continuous sedimentation coefficient distribution c(s) was used with 100 scans of the 
sedimentation data to determine monomer and aggregate content in pH 4.5, fifty mM Histidine 
mAb samples incubated at 57°C.  The partial specific volume, buffer density and viscosity 
values used to model the data were 0.73 ml/g, 1.00 g/ml, and 1.002 cP, respectively.  A range of 
0 to 30 s was used (after verifying that there was no signal outside of this range) with a 
resolution of 300 points per distribution and a confidence level of 0.95.  Baseline, radial 
independent noise, and time independent noise were fit by the software.  The meniscus and 
bottom positions were set manually.  Integrated peak areas were normalized by the total area at 
t=0 to monitor the loss in peak area between different time points. 
5.3.5. Static Light Scattering 
Composition gradient multi-angle light scattering (CG-MALS) was performed to 
determine the apparent second virial coefficient (A2) of the various mAb solutions.  The CG-
MALS configuration consisted of a Calypso-II equipped with 20 nm polyether sulfone (PES) 
membrane filters to mix, degas, filter and inject mAb concentration gradients into a Dawn 
Heleos II multi-angle light scattering (MALS) detector with a 658 nm laser for static light 
scattering (Wyatt Technology Corp, Santa Barbara, CA), and an in-line Optilab rEX differential 
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refractive index detector to measure protein concentration.  Protein solutions for light scattering 
were purified by performing four 15x dilution buffer exchanges using Amicon Ultra-15 10kDa 
molecular weight cutoff centrifugal filter devices (EMD Millipore, Billerica, MA).  After the 
final buffer exchange, the protein and the buffer fractions were collected and filtered using a 
Whatman 0.1 μm PVDF syringe driven membrane filter (GE Healthcare, Little Chalfont, United 
Kingdom) to remove large impurities.  Protein concentrations were measured with a NanoDrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA) using a 0.1% extinction coefficient 
of 1.4 at 280 nm.  The initial target protein concentration for static light scattering experiments 
was ~10 mg/ml.  If |2A2Mwc2| ≤ 0.05 then the protein concentration was increased to ~30 
mg/ml for subsequent experiments, where |2A2Mwc2| is a unit-less fraction that reflects the 
contribution of non-ideal interactions to the total light scattering signal. A2 is the apparent 
second virial coefficient, Mw is the weight averaged molecular weight, and c2 is the protein 
concentration.  The apparent second virial coefficient was determined by regressing SLS data at 





+ 2A2c2 ,           (5.10) 
where R(θ), the excess Rayleigh ratio, describes the intensity of scattered light.  K∗ is an optical 








,            (5.11) 
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where n0 is the refractive index of the buffer, λ0 is the wavelength of the laser in a vacuum, NA 
is Avogadro’s number, and dn
dc
 is the differential refractive index increment of the protein.  The 
value of dn
dc
 was set to 0.185 ml/g.   
 Using statistical mechanical arguments, the theoretical contributions of excluded volume 
to the second osmotic virial coefficient can be expressed as (3) 
B2 =  
NAu
2M2
 ,             (5.12) 
where is M the molecular weight of the protein, and u is the excluded volume.  The excluded 
volume for a spherical system can be expressed as 8V, where V is the volume of a single sphere.  
Therefore, the theoretical contribution of excluded volume on the apparent second virial 
coefficient can be calculated for spherical particles (9) by    
B2exc =  
16πNAr3
3M2
 .            (5.13) 
Experimental apparent second virial coefficients were then normalized by B2exc to provide a 
unitless parameter sensitive to protein-protein interactions: 
a2 =  
A2−B2exc
B2exc
 .            (5.14) 
Using M = 150,000 Da and a spherical diameter of 10 nm, B2exc =  0.556 ∗ 10−4 mol ml g−2.  
The normalized virial coefficient calculations described above are built into the Calypso V2.1.3 




5.3.6. Polyethylene Glycol (PEG) Precipitation 
Stock solutions of PEG-10,000 ranging from 0 to 40% w/v were prepared for each buffer 
condition.  244 µL of each solution (0 to 40% w/v) were added to a 96-well polystyrene filter 
plate (Corning Life Sciences, Corning, NY).  Six μL of an IgG1 mAb stock solution (~40 
mg/mL) was added to the wells to achieve final protein concentrations of 1 mg/mL.  The plates 
were incubated overnight at room temperature and centrifuged at 3,500g for 15 min.  The filtrate 
was collected in a clear 96 well collection plate (Greiner Bio-One North America Inc., Monroe, 
NC).  Afterwards, 200 µL of the filtrate was transferred into a 96 well UV Star microplate. The 
filtrate was measured using SpectraMax M5 UV-Visible plate reader (Molecular Devices LLC, 
Sunnyvale, CA) at 280 nm to determine the protein concentration.  Concentration of IgG1 mAb 
vs % PEG-10,000 data were fit using a standard four-parameter modified Hill-slope sigmoidal 
curve equation: 
y = b + � t−b
1+ e s(mid−x)
� ,                              (5.15)                
where t = top plateau, b = bottom plateau, mid = x-axis midpoint, and s =slope.  Midpoint values 
were determined from the resulting curve fit as described in detail elsewhere (182).   
5.3.7. Determination of Aggregation Kinetic Rate Constants 
Rate constants describing the aggregation process (knuc,obs and kg,obs) were determined 
by simulating fits to experimental SEC data using an in-house script in Python v2.7.10.  The 
script iteratively solves Equations 5.06 and 5.07 based on user entered values for the number of 
time steps, range of aggregate polymerization (j), and rate constants knuc,obs, kg,obs, and kagg.  
Simulated monomer loss as a function of time was compared to experimental monomer loss 
presumably due to aggregation (and with fragment peaks treated as monomer).  SV-AUC was 
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used to measure monomer loss (instead of SEC) for stressed mAb samples in certain 
formulations that were determined to adsorb to the SEC column (see text).  Aggregate-aggregate 
association was set to zero in mathematical simulations, and kg,obs was treated as constant for all 
aggregate sizes (kg,obs,{A2} ≈ kg,obs,{A∞}).  Additionally, the polymerization state j was set to 
∞ to reduce the amount of data points required to distinguish between simulations.  The effects 
and purpose of these modeling parameters and treatments are discussed in the Supplemental 
Materials section.  Simulations were performed for each sample until the residuals (experimental 
data point – simulated data point) were within the range of the experimental standard deviation 
and randomly distributed about zero.   
5.3.8. Empirical Modeling of Net Protein Charge 
The molecular modeling and visualization program PyMol v1.5 was used to construct the 
Fab, hinge, and Fc regions of an IgG1 antibody model (185). The Fab and hinge coordinates 
were obtained from the in silico KOL-Padlan structure of an IgG1 molecule (186). Homology 
models of the antibody sequence were mapped onto the template Fab regions with Modeller 
version 9.12 (187). The Fc region was retrieved from the x-ray structure, 3AVE, maintaining the 
linked G0F glycan residues (188).   
The homology model was analyzed using PROPKA v3.1, an empirical algorithm that 
calculates the pKa of titratable residues based on interactions with nearby functional groups and 
desolvation effects due to the structural position of the residue (189) (190). The net charge of the 
IgG1 mAb was then calculated using the Henderson–Hasselbalch relationship with user entered 





5.3.9. Calculation of the Second Osmotic Virial Coefficient 
The theoretical second osmotic virial coefficient for uniformly charged spheres was 
calculated using an equation developed Winzor and coworkers (9): 






� 1+2кrs(1+кrs)2 + ⋯�,       (5.16) 
where Bex is the excluded volume contribution to the second virial coefficient, Bz is the 
electrostatic contribution, Z is the net charge, I is the ionic strength (mol/L), rs is the solvated 
radius, and к is the Debye inverse screening length.  The value of Bex was 
0.556 ∗ 10−4 mol ml g−2 (see static light scattering section) and rs was approximated as 5 nm. 
The ionic strength was calculated using the relationship I = 1
2
∑ cizi2 where ci is the 
concentration of an electrolyte species and zi is its valence.  The charged state of the citrate 
buffer was determined by solving equations for triprotic acids with pKa values of 3.1, 4.7, and 
6.4 whereas histidine was treated as a weak base with a pKa value of 6.1.  To our knowledge, 
there is no straight forward approach to calculating the ionic strength of an ampholytes solution.  
Therefore, we decided to approximate the ionic strength of solutions containing histidine by 
treating histidine as having a total charge of 0 or +1.  The inverse Debye screening length was 
determined at 20 °C using the expression к = 3.27 ∗ 107√I (cm−1).  The theoretical normalized 
second osmotic virial coefficient (b2) was calculated using the equation:  





 .           (5.17) 
5.3.10. Flow Microscopy 
A FlowCam VS Series (Fluid Imaging Technologies, Scarborough, Maine) benchtop 
flow microscope was used to image particles with area based diameters (ABD) in the range of 1-
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100 μm.  The instrumental setup included a 100 μm x 2 mm flow cell and a 10x objective.  A 
total volume of 0.5 ml was analyzed per sample at a flow rate of 0.15 ml/min with an image 
capture speed of 21 frames per second.  Each day, the instrument was focused using NIST 
traceable 25 μm polystyrene spheres (Thermo Fisher Scientific, Waltham, Massachusetts).  The 
mass of each particle was calculated using 
Mass of particle k (Mk) =   
π
6
× d3 × �1.70763 − 1.70864 × (1 − C)0.45 − 0.70638 C ∗  1.41 g
ml
∗ f           (5.18) 
Where d is the equivalent circular diameter of the particle, C is the circularity of the particle, and 
f is the fraction of protein within the calculated volume.(104)  The total mass of all the imaged 
particles was calculated using 




         (5.19) 
Va is the volume analyzed, and E is a term to correct for the efficiency of imaging.  
Experimentally determined values of ABD and circularity (hu) were used for the calculations.  
The fraction of protein within a particle was taken to be 0.2 as described previously (104).  
5.3.11. Absorbance Spectroscopy 
The absorbance at 280 nm was measured for IgG1 mAb samples using an 8453 UV-Vis 
Spectrophotometer (Agilent, Santa Clara, California).  Baseline correction was applied by 
subtracting the average optical density over the range of 500 to 600 nm.   The concentration of 
mAb solutions was calculated using Beer’s Law (𝐸1 𝑜𝑜0.1%= 1.4).  After 1 day of incubation at 57 
°C, the samples were centrifuged at 13,500 g for 15 min to remove insoluble particulates and the 
absorbance of the supernatant fraction was measured.  In addition to baseline correction, light 
scattering correction as suggested by Mach and Middaugh was also applied to account for 
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increased light scattering by large aggregates (153). The loss of protein in solution due to the 
formation of large precipitates was approximated by subtracting the mAb concentration after one 
day of thermal stress from the initial mAb concentration. 
5.4. Results and Discussion 
5.4.1. Conformational Stability of mAb under Different Solution Conditions 
As a first step to better understand the relationship between temperature and observed 
aggregation rates, differential scanning calorimetry (DSC) was used to assess how changes in 
solution conditions (pH, ionic strength, buffer ion type) effect the apparent thermal onset (T0) 
and thermal melting temperature values (Tm) for an IgG1 mAb.  It has previously been shown 
that IgG1 mAbs undergo thermal unfolding steps which correspond to structural alterations of 
distinct domains/regions of the antibody (78, 79).  We apply the model proposed by Ionescu and 
coworkers to interpret deconvoluted thermal melting events for this IgG1 mAb in terms of its 
CH2 domain, Fab region, and CH3 domain unfolding events as previously shown for three other 
IgG1 mAbs (80).   
The IgG1 mAb used in this study displays two endothermic transitions at pH 4.5 and 6.5 
in histidine buffered solutions as measured by DSC (Figure 5.3A).  At pH 4.5, the first melting 
transition can be attributed to unfolding of the CH2 domain and the second larger transition is 
probably a convolution of Fab region and CH3 domain unfolding events (80).  The first apparent 
melting temperature (Tm1) was at 58.3 ± 0.1 ºC, and the second was at 71.7 ± 0.1 ºC.  Addition 
of 100 mM NaCl to the pH 4.5 histidine solution did not change the number or order of the 
observed transitions in the DSC thermogram, but the Tm1 value for the mAb decreased to 56.1 ± 
0.1 ºC and the second Tm decreased to 70.3 ± 0.1 ºC (Table 5.1).  The decrease in Tm values, 
compared to the NaCl absent solution, probably signifies a decrease in the conformational 
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stability of this mAb, but it could also potentially be an artifact caused by faster aggregation rate 
constants (48).  At pH 6.5, the mAb in the histidine solution also displayed two endothermic 
transitions (Figure 5.3A). In this case, however, the first transition is probably a convolution of 
CH2 domain and Fab region unfolding (80) with an observed Tm value at 72.9 ± 0.1 ºC while the 
second transition reflects unfolding of the CH3 domain with a Tm3 at 79.2 ± 0.1 ºC.  A summary 
of the apparent thermal onset and thermal melting temperatures are summarized in Table 5.1.   
DSC thermograms of the mAb in pH 4.5 and 6.5 citrate solutions had higher onset and 
melting temperatures compared to the mAb in histidine solution (Figure 5.3B).  At pH 4.5, there 
were 3 endothermic transitions with the first, second, and third corresponding to the CH2 domain, 
Fab region, and CH3 domain, respectively (80).  Apparent melting temperatures for the first, 
second and third transitions were 59.5 ± 0.1, 73.1 ± 0.1, and 79.2 ± 0.1 ºC, respectively.  
Addition of 100 mM NaCl, to the pH 4.5 citrate formulation decreased the apparent melting 
temperatures slightly with  Tm1, Tm2, and Tm3 values decreasing to 59.0 ± 0.1, 72.7 ± 0.1, and 
79.0 ± 0.1 ºC, respectively (Table 5.1).  Interestingly, mAb melting temperatures decreased more 
when NaCl was added to the histidine solution than when it was added to the citrate solution.  
This could be because the ionic strength of the histidine solution was substantially lower than the 
citrate solution (see calculated ionic strength values for each condition summarized in Table 5.2).  
At pH 6.5, the mAb in citrate solution displayed 2 endothermic transitions similar to the pH 6.5 
mAb histidine solution.  The first transition is presumably a convolution of CH2 domain and Fab 
region unfolding with an observed Tm occurring at 73.1 ± 0.1 ºC and the second transition 
reflecting unfolding of the CH3 domain with a Tm3 at 83.1 ± 0.1 ºC.  
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5.4.2. Apparent Solubility of mAb Under Different Solution Conditions 
Apparent protein solubility as a function of polyethylene glycol (PEG) concentration was 
measured to better understand the thermodynamics of mAb precipitation in different solution 
environments.  The apparent solubility values were extrapolated to determine the apparent 
thermodynamic activity of saturated mAb solutions without PEG (181).  Representative 
experimental data showing mAb concentration in different solutions as a function of PEG 
concentration are presented in Figure 5.3C.  Extrapolated apparent thermodynamic activity 
values (in the absence of PEG) and [PEG] midpoint values (i.e., 50% of the mAb in the 
amorphous phase) were determined.  In pH 4.5 histidine solution, the mAb had the highest 
[PEG] midpoint value of 24.6 % w/v (with an extrapolated apparent activity value of 1.86 ± 0.4 
g/ml).  Addition of 100 mM NaCl to the pH 4.5 histidine formulation caused the precipitation 
curve to shift to a midpoint value of 15.1 % w/v PEG (with an extrapolated apparent activity 
value of 1.10 ± 0.08 g/ml) corresponding to an increase in the ionic strength of the solution.  At 
pH 6.5, the midpoint value was 8.5 % w/v PEG (with an extrapolated apparent activity value of 
0.11 ± 0.01 g/ml).  The mAb in the citrate solutions had [PEG] midpoint values ranking as 
follows and the values are summarized in Table 5.2: pH 4.5 citrate + NaCl > pH 4.5 citrate > pH 
6.5 citrate.  The extrapolated activity values for the mAb were 0.04, 0.01, and 0.02 g/ml for the 
pH 4.5, pH 4.5 + NaCl, and pH 6.5 citrate solutions, respectively.   
Mahadevan and Hall developed a statistical mechanical model to predict trends in 
apparent solubility in polyethylene glycol solutions by considering excluded volume, osmotic 
and electrostatic interactions (191).  In general, our observed results are consistent with their 
model because apparent solubility values in mAb solutions with PEG decreased with decreasing 
calculated values of protein charge and/or increased ionic strength (see calculated charge and 
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ionic strength values for each condition summarized in Table 5.2).  As described previously in 
other studies (59, 180), and as described in our experiments below, these descriptive parameters 
derived from the PEG precipitation profile can be valuable for interpreting observed protein 
aggregation data under different solutions conditions.    
The PEG concentration (% w/v) vs. protein concentration (i.e., precipitation) profile of 
this mAb was fit to a sigmoidal function and the [PEG] midpoint values (Figure 5.3C) were used 
to compare the relative thermodynamic favorability of non-specific IgG1 mAb associations 
leading to amorphous precipitation.  We hypothesize that differences in the relative apparent 
solubility values of the mAb in different solutions could indicate the thermodynamic favorability 
of transient encounter complex formation in the same solutions.  At the [PEG] midpoint, the ∆G 
between protein in the solution and solid amorphous phases is zero if the solution is at 
equilibrium.  Additionally, the protein-protein potential of mean force (PMF), W22(r) can be 
expressed as (5, 6)    
W22(r) = WHS(r) + WZ(r) + Wdisp(r) + Wosmotic(r) + Wdipole(r)  + Wassoc(r).              (5.20) 
From left to right, the terms on the right hand side of Equation 5.20 represent contributions of 
excluded volume, electrical double layer, dispersion forces, osmotic forces, dipole interactions, 
and specific interaction sites to the protein-protein PMF (5, 6).  As the concentration of PEG is 
increased, the short range osmotic potential reflected by the Wosmotic(r) term becomes 
increasingly attractive.  These osmotic attractions have been previously modeled using a theory 
developed by Asakura and Oosawa (192, 193).  Based on these models, differences in [PEG] 
midpoint values should approximately reflect the extent to which osmotic forces are required to 
overcome other repulsive interactions and induce mAb precipitation.  On the other hand, this 
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approach has some limitations.  For example, Sarangapani et al. have demonstrated that such 
models can be inadequate for describing protein behavior with changes in pH or protein 
concentration because they neglect to account for changes in intrinsic flexibility and protein 
conformation (194).  Additionally, this approach assumes that the PEG molecules are inert and 
do not interact with the protein molecules which may not always be the case.  
5.4.3. Colloidal Stability of Native mAb under Different Solution Conditions 
To compare protein-protein interactions (PPI) in different solution conditions on a 
relative basis, static light scattering was used to obtain normalized apparent second virial 
coefficient (a2) values for the IgG1 mAb as a function of solution pH, ionic strength and buffer 
ion type (Figure 5.3D).  Traditionally, the second virial coefficient A2, obtained from classical 
analysis of static light scattering data (Equation 5.10), was equated to the second osmotic virial 
coefficient, B2  (3, 195).  More recently, however, the two virial coefficients have been shown to 
formally differ (30, 32, 33). Under sufficiently dilute conditions (e.g., |2A2Mwc2| ≤ 0.12), 
differences between  A2 and B2 may not be significant in terms of statistical uncertainty (33-35).  
Otherwise, the value of A2 was theoretically proposed to systematically over estimate repulsive 
interactions and underestimate attractive interactions compared to B2 (33).  In protein solutions 
with weak PPI, the second virial coefficient can be dominated by contributions from excluded 
volume (38).  Normalization of the second virial coefficient by correcting for the excluded 
volume contribution of spheres ( A2 → a2) can be used to help tease out weak protein-protein 
interactions (36, 37). 
In solutions containing histidine, the IgG1 mAb was found to have the most repulsive PPI 
with a2 values of 1.18 ± 0.29 and 0.58 ± 0.02 at pH 4.5 and 6.5, respectively (Figure 5.3C & 
Table 5.2).  The mAb in these histidine solutions were the only conditions where |2A2Mwc2| >
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0.12.  Addition of 100 mM NaCl to the pH 4.5 histidine solution changed the sign of a2 from 
positive to negative, to a value of -0.43 ± 0.03, suggesting that PPI changed from repulsive to 
slightly attractive for the mAb (Figure 5.3C).  In the pH 4.5 and 6.5 citrate containing solutions, 
the mAb had the lowest values of a2 which argues that the mAb under these conditions had the 
most attractive PPI.  This result was notable because the pH 4.5 histidine solution with NaCl has 
a greater calculated ionic strength than the pH 4.5 citrate solution (Table 5.2).  Addition of 100 
mM NaCl to the pH 4.5 citrate formulation did not significantly change the a2 value despite 
substantially increasing the ionic strength of the solution.  At pH 6.5, the mAb in the citrate 
solution had the most attractive PPI.  This result was expected because the solution had the 
highest ionic strength and the mAb had the lowest calculated net charge of all conditions tested 
(see Table 5.2 for summary of the calculated protein charge and solution ionic effect values; also 
see next section). 
5.4.4. Evaluation of Experimental Apparent Solubility and Colloidal Stability 
vs. Calculated Values of Various Solution and Protein Properties 
Theoretical values of solution ionic strength, protein charge as a function of pH, and the 
second virial coefficient were calculated to aid in the interpretation of the experimental a2 and 
PEG precipitation data sets for this mAb under the different solutions (Table 5.2).  The 
theoretical normalized second osmotic virial coefficient (b2) for spheres with a uniformly 
distributed net charge was also determined to better understand how mAb charge and ionic 
strength might affect colloidal interactions for an idealized case.  The value of b2 for the mAb in 
pH 4.5 histidine solution indicated that this condition should have the most repulsive protein-
protein interactions (Table 5.2), which was in agreement with the experimentally determined a2.  
The [PEG] midpoint value, one experimental measure of the relative apparent solubility of the 
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mAb in different solutions (see previous section), was also the highest in the pH 4.5 histidine 
solution indicating that the charged state of the mAb could also affect the favorability of forming 
transient associating species.  Neal et al. incorporated anisotropic charge distributions into their 
models of B2 and found that electrostatic effects are especially magnified in complementary 
configurations (196).  They also found that attractive molecular orientations can 
disproportionally affect the value of B2 compared to repulsive orientations.  This is one possible 
explanation for the large difference between the calculated b2 and experimental a2 values.   
At pH 6.5, the mAb in histidine solution had the second largest value of b2 which was 
also in agreement with the experimentally determined value of  a2 (Table 5.2).  The apparent 
solubility data, however, showed the precipitation profile shifting substantially to the left 
indicating lower amounts of PEG led to mAb precipitation (Figure 5.3D).  This discrepancy 
between PPI and apparent solubility (in PEG solutions) is not surprising because  b2 describes 
PPI in dilute solutions and may not accurately represent interactions in more crowded solution 
environments.  On the other hand, b2 values for the mAb under this solution condition could be 
related to specific charged amino acid residues within the mAb modulating potential self-
association configurations.  For example, Arora et al. demonstrated that protonation of histidine 
residues located within an association interface of a different IgG1 mAb greatly reduced the 
formation of self-associated mAb species (20).   
After increasing the solution ionic strength, the trend of the theoretical b2 did not agree 
with the experimental a2 of the mAb in the pH 4.5 histidine solution containing 100 mM NaCl.  
The theoretical value indicated that there should be slightly repulsive PPI while the experimental 
value indicated that slightly attractive interactions were present.   The PEG precipitation data 
showed that mAb in the pH 4.5 histidine solution with NaCl had higher apparent solubility 
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values than the mAb in the pH 6.5 histidine solution (see previous section and Table 5.2).  This 
result could suggest that the formation of transient complexes becomes less favorable as the 
molecular charge of this mAb increases. From the discrepancies noted above, we notice that 
increasing the solution ionic strength did not have as great of an effect on the apparent solubility 
values measured.  The differences between the calculated and experimentally determined virial 
coefficients could arise from the mAb having a few slightly attractive molecular orientations 
available while the model only considers a uniform repulsive interaction (197).  The 
discrepancies observed in the PEG precipitation data noted above also support such an argument 
because double layer repulsions are expected to be largely screened at an ionic strength of 0.124 
M (pH 4.5 histidine + NaCl) compared to 0.007 M (pH 6.5 histidine).  Thus, it is possible that 
the charged state of specific titratable residues on the mAb could potentially have a large effect 
on the thermodynamics of protein association causing the observed differences in PEG 
concentration required to induce precipitation. 
Interesting deviations between a2 and b2 were also observed for the mAb in the citrate 
solutions.  At pH 4.5, the calculated b2 indicated that there should be substantial repulsive 
colloidal interactions in citrate solution, but slightly attractive PPI were measured for the mAb as 
reflected by a2 values (Table 5.2).  Surprisingly, a2 did not decrease when 100 mM NaCl was 
added to the pH 4.5 citrate formulation despite the calculated ionic strength increasing from 
0.089 M (citrate) to 0.189 M (citrate + NaCl).  On the other hand, b2 predicted decreased 
protein-protein interactions based on the increased ionic strength.  It is likely that this 
discrepancy could be caused by citrate ions preferentially accumulating on the surface of the 
mAb when histidine residues are charged, as has been described previously for other mAbs (35, 
88, 89).  Furthermore, the Shultz-Hardy rule suggests that multivalent anions will be more 
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effective at screening the charge on the mAb than monovalent anions or multivalent cations (3).  
Interestingly, the apparent solubility values observed for the mAb in pH 4.5 citrate solution 
increased upon addition of 100 mM NaCl.  This could suggest that any negative charge imparted 
by the accumulation of citrate is screened by the addition of NaCl.  At pH 6.5, b2 and a2  showed 
good agreement because both values suggest that this condition has the most attractive (or least 
repulsive) PPI for the mAb.  This was an expected result because the mAb has the lowest net 
charge and the solution had the highest ionic strength out of all conditions examined.  It is 
important to note that the a2 results suggest that the charges on the mAb is effectively screened 
in 50 mM citrate solutions because a2 decreased from -0.84 ± 0.03 at pH 4.5 to only -1.14 ± 0.02 
at pH 6.5, despite the ionic strength increasing from 0.089 M to 0.243 M. 
In summary, we compared calculated parameters of charge, ionic strength, and b2 to 
experimentally measured parameters of a2, [PEG] precipitation midpoint, and extrapolated 
apparent thermodynamic activity.  These results showed that changes in solution pH affected the 
experimentally determined apparent solubility (and extrapolated thermodynamic activity) more 
than ionic strength (i.e., [PEG] midpoint for pH 4.5 histidine with 100 mM NaCl vs. pH 6.5 
histidine solution).  On the other hand, the calculated b2 and experimental a2 values showed that 
ionic strength substantially decreased the strength of protein-protein interactions under the same 
solution conditions.  It is possible that differences in protein conformation and/or the charged 
state of specific titratable residues could be responsible for the observed trends in the PEG 
precipitation data while long range colloidal interactions are responsible for the trends observed 
in the a2 data.  This is probable because protein-protein interactions measured by a2 seemed to 
follow the same trends as the theoretical calculation (b2) which used spherical geometry to 
calculate the contribution of excluded volume and Debye-Hückel theory (3) to account for 
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screening of electrostatic repulsions (except in the case of mAb in pH 4.5 citrate vs. pH 4.5 
citrate + NaCl as described earlier).    
5.4.5. Experimental and Modeled mAb Aggregation Results in Different 
Solutions 
Using experimental data from either SEC or SV-AUC, monomer loss as a function of 
time can be used to obtain an apparent reaction order and time scale for protein aggregation.  If 
the size of aggregates remains small, dimers are the smallest aggregate species, and aggregate-
aggregate association can be neglected.  Then, completely nucleation dominated aggregation 
should have an effective reaction order of 2.  In contrast, aggregation dominated by monomer 
addition growth mechanisms will have an effective reaction order that approaches 1 if reversible 
self-association is negligible as is the case for this mAb (data not shown).  Under this particular 
limiting case, monomer loss of this mAb can be modeled and used to obtain rate constants and/or 
characteristic time scales for both aggregate nucleation and growth by monomer addition (84). 
Prior to modelling the kinetics of experimental mAb aggregation data sets, simulations of 
Equations 5.06 and 5.07 were performed to better understand how nucleation and aggregate 
growth affect the overall observed rate of the aggregation process.  The effect of varying 
nucleation and growth rate constants on the simulation was investigated systematically over 4 
orders of magnitude for nucleation and 3 orders of magnitude for growth (Figure 5.4).  Although 
it was possible to simulate several conditions that resulted in a similar amount of aggregation 
over a certain time period, the profiles clearly displayed characteristic differences thereby 
supporting our modeling approach of fitting monomer loss vs time for this mAb.  For example, 
samples with slower nucleation rates and faster growth rates displayed an initial “lag” phase 
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compared to samples with a faster nucleation rate and slower growth rate.  Based on the results 
of these initial simulations, we collected a range of experimental mAb aggregation stability data 
in different solutions to capture the lag perceived by slower nucleation rates and acceleration 
produced by fast growth rates.  The timescale of the stability study for each mAb solution 
condition needed to be optimized to capture a full range of aggregation data to properly 
discriminate between different combinations of nucleation and growth rates.  
Simulated fits of experimental mAb aggregation data were then generated for the fraction 
of non-aggregated mAb species (monomer + fragment) for each solution and temperature 
condition to determine observed rate constants for aggregate nucleation and growth processes.  
The rationalization for modeling both monomer and fragments populations as aggregate prone 
species is discussed in detail the Supplemental Materials section (see Rationalization of 
Assumptions Present in Aggregation Model).  Briefly, substantial fragmentation did not appear 
to deplete reactive species populations by causing mAb aggregation rates to decelerate.  In a 
future study, we plan to investigate the effect of considering fragmentation as the initiation step 
in separate mAb aggregation pathways to more accurately model such cases.  Representative 
SEC chromatograms and SV-AUC data demonstrating separation profiles and peak integration 
of the different mAb species are presented in Figure 5.5 (panels A-B).  In addition, integrated 
SEC aggregation profiles for mAb samples under different histidine buffer solution conditions as 
a function of time and temperature are presented in Figure 5.5 (panels C-H).  Integrated SEC 
aggregation profiles for the mAb in different citrate buffer solution conditions at different 
temperatures are shown in Figure 5.6.  
Figure 5.7 shows the simulation results for the SEC aggregation data for the pH 4.5 mAb 
solutions, in both citrate and histidine buffers with/without NaCl, after being incubated at 57 ºC 
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for up to 5 days.  The red squares in the figure represent the average concentration (mg/ml) of 
non-aggregated species for mAb solutions in three different sample vials measured by SEC or 
SV-AUC.  In the pH 4.5 citrate solution, incubation resulted in rapid monomer loss with no 
monomer detected in solution after 1 day of incubation (Figure 5.7A, top panel).  Absorbance 
spectroscopy of the supernatant fraction after centrifugation confirmed that loss of monomer was 
because of non-native amorphous precipitation (Figure 5.8, panel A).  Additionally, the modeled 
observed growth rate constant dominated the overall aggregation kinetics compared to the 
nucleation process (Table 5.3).  The mAb in the pH 4.5 citrate solution with NaCl also had a 
similar rate of monomer loss (Figure 5.7A, bottom panel) and also underwent phase separation 
after one day.  The overall kinetics of aggregation was also growth dominated (Supplemental 
Table 5.3).  On the other hand, although monomer loss of the mAb in the pH 4.5 histidine 
solution was also rapid (Figure 5.7B, top panel), no significant increase (compared to t=0) in the 
calculated mass of larger aggregates (i.e., particles larger than 2 µm in diameter), based on 
FlowCam particle data, was detected after 3 days (Figure 5.6, panel B).  The shape of the 
simulated result also suggests that the mAb sample has a nucleation dominated aggregation 
mechanism similar to the light blue trace in Figure 5.4, panel A.  Increasing the ionic strength of 
the mAb in histidine buffer (with NaCl) causes the observed aggregation rate to increase, and 
resulted in significant non-native phase separation after 1 day of incubation (Figure 5.6, panel 
A).  In this sample condition, neither aggregate nucleation nor growth clearly dominated the 
aggregation mechanism (Table 5.3).   
The pH 4.5 mAb solutions, in both citrate and histidine buffers with/without NaCl were 
also incubated at 40 ºC for up to 7 months (Figure 5.9).  Integrated SEC results for mAb samples 
incubated at 40 ºC as a function of time are presented in Figure 5.6.   It is apparent that less mAb 
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aggregated over the course of 7 months when incubated at 40 ºC compared to 1 day at 57 ºC.  
The mAb in the pH 4.5 citrate solutions with and without NaCl had similar rates of aggregation 
at 40 ºC (Figure 5.7A).  In these sample conditions, a slower ‘lag phase’ in which aggregate 
nucleation primarily occurs was observed prior the rate accelerating due to aggregate growth.  
The simulated rate constant values support these observations because the observed rate 
constants of aggregate growth were ~3 orders of magnitude larger than those of nucleation 
(Table 5.3).  On the other hand, a lag phase was not readily observable in the pH 4.5 histidine 
mAb solutions with and without NaCl, but the profile displayed some early curvature indicative 
of both aggregate nucleation and growth processes occurring.  The simulated rate constants, 
however, suggest that the observed growth rate constant was ~3 orders of magnitude larger than 
the nucleation rate constant.  Although aggregate growth was non-trivial, no significant increases 
in the calculated mass of larger aggregates (i.e., particles greater than 2 µm in diameter), as 
calculated from the experimentally determined MFI data, was detected after 7 months (Figure 
5.6, panel C). 
The mAb samples at pH 6.5 were also incubated at 40 ºC for up to 7 months and fit to the 
kinetic models described by Equations 5.06 and 5.07 (Figure 5.10).  The rate and extent of 
aggregation at pH 6.5 was much less than at pH 4.5, despite reduced values of apparent solubility 
(and extrapolated thermodynamic activity, determined by PEG precipitation) and having more 
attractive PPI (A2 values by static light scattering), as presented in the previous section, and as 
discussed in the next section. Curvature of the simulated fit to the experimental SEC aggregation 
data was also observed for mAb in pH 6.5 citrate solution incubated at 40 ºC.  The aggregation 
profile for the mAb in the pH 6.5 histidine solution did not display major curvature since both 
the modeled nucleation and growth rates were very slow over this time period.   
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At 25 ºC, the aggregation profiles for the mAb in the pH 4.5 histidine and citrate 
solutions was even slower with less than 3% monomer loss occurring in both samples after 7 
months (Figure 5.11).  Although such degradation could be considered significant from a 
pharmaceutical storage stability perspective, the modeled nucleation and growth rate constants 
for both conditions were extremely slow and did not show any appreciable differences between 
the samples.  To be more rigorous for modeling aggregation of this mAb at this temperature 
condition, future work will need to include a longer-term stability study to mechanistically 
examine mAb aggregation at lower temperatures and to test the applicability of these models to 
predict protein storage life under lower temperature conditions.  Thus, although the results at 
25°C do not show any appreciable differences in their modeled rate constants, the data should 
not be over interpreted due to the lack of an apparent characteristic time scale observed in the 
monomer loss vs. time data.   
5.4.5. The Effect of the Physical Properties of the mAb in Different Solutions 
on Aggregate Nucleation and Growth 
When taken together, the two simulated aggregation rate constants modeled from the 
mAb stability data in various solution and temperature conditions provide several important 
results in terms of better understanding the aggregation mechanism of experimental data in 
relation to the physical properties of the mAb.  To this end, as shown in Figure 5.12A, the 
modeled values of knuc,obs (mAb aggregation nucleation rate constants) are presented as a 
function of apparent melting temperature (Tm values from DSC measurements; see Table 5.1) 
minus incubation storage temperature (T) for all of the examined storage and solution conditions.  
This temperature scale of (Tm − T) was used to better evaluate the effect of partially unfolded 
mAb on the observed aggregation nucleation rate constants.  The modeled nucleation rate 
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constants were normalized by the smallest value to observe differences between the solution and 
temperature conditions on a relative scale (also, it should be noted that for this analysis 
aggregation data for pH 6.5 mAb samples incubated at 57 ºC, and for mAb samples incubated at 
25 ºC, are not included because of the limitations outlined in the previous sections).     
 At 40 ºC incubation (Tm − T ranging from ~15 to 20 ºC in Figure 5.12A), the observed 
nucleation rate constants for the mAb in pH 4.5 histidine (dark red), pH 4.5 histidine + NaCl 
(light red), pH 4.5 citrate (dark blue), and pH 4.5 citrate + NaCl (light blue) solutions appear to 
be similar and randomly distributed.  Interestingly, differences in a2 or the apparent solubility 
profiles (e.g., midpoint or extrapolated activity values, Table 5.2) were not reflected in the 
modeled knuc,obs values for solution conditions with similar Tm − T values (Figure 5.12A).  At 
57 ºC incubation (Tm − T < 5 ºC), the modeled nucleation rates increased rapidly as Tm − T 
decreased.  This seems intuitive because the nucleation mechanism expected to be fastest at high 
temperatures has an observed rate constant which scales with the fraction of unfolded protein 
squared.  It was unexpected, however, that the colloidal environment in the different solution 
conditions did not appear to have any affect on the observed nucleation rate constants, since we 
had originally hypothesized that conformationally altered proteins were more likely to stick upon 
collisions and would therefore appear to follow the theory of slow coagulation (see introduction).  
In the context of this model, this result from Figure 5.12A implies that the process of 
aggregate nucleation for this mAb behaves similarly to limiting case 2 as presented in the 
Theoretical Role of Colloidal Stability on Aggregation Rates section.  In other words, structural 
alterations of associated mAb monomers to form a stable irreversible mAb dimer could be the 
rate limiting component of aggregate nucleation.  Additionally, we did not observe any apparent 
correlation of the experimental aggregation rate in different solutions to the apparent solubility 
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values of the mAb in the same solutions (as measured in PEG precipitation assay).  This is 
probably because partially unfolded intermediates of the mAb would be expected to have lower 
solubility values.  If the equilibrium association constant is high for the mAb in every solution, 
then we would expect only conformational rearrangement of an encounter complex to be the rate 
limiting step.  In this study, the nucleation mechanism involving encounter complex formation 
between native mAb molecules, described by Equation 5.03c, did not appear to be a major 
pathway for this mAb.  It would be interesting to see in future work if nucleation of other mAb 
molecules, which undergo that pathway to a greater extent, correlates with such apparent 
solubility measurements as seen previously by others with using different mAbs (59, 180). 
Using the same approach described above (Figure 5.12A) with the model nucleation rate 
constants, the modeled values of kg,obs (observed growth rate constants for mAb aggregation) 
are presented as a function Tm − T to better observe the role of conformational changes (i.e., 
CH2 domain unfolding as seen by DSC) on growth processes during aggregation of this mAb 
(Figure 5.12B).  In contrast to Figure 5.12A, it is readily apparent in Figure 5.12B that aggregate 
growth does not correlate as well to the relative concentration of partially unfolded mAb as 
approximately given by Tm − T.  One potential explanation is that the observed growth rate 
constants (Figure 5.12B) were more sensitive to the colloidal environment of the mAb as 
measured by a2 and PEG precipitation values (Table 5.2).  The deviations between kg,obs values 
for the mAb in different solution environments, but at similar Tm − T values, appear to best 
correlate with the rank ordering of the apparent solubility profiles for the native mAb in different 
solutions (Figure 5.3C).  Furthermore, it is difficult to physically justify how encounter complex 
formation could be rate limiting at the relatively low a2 values observed in this study.  Therefore, 
although we conclude that aggregate growth by monomer addition was sensitive to the colloidal 
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environment of the mAb under these conditions, we suspect that rates were affected by 
association thermodynamics rather than kinetics.  In other words, based on these considerations, 
it is reasonable to conclude that similar to aggregate nucleation, aggregate growth also follows 
limiting case 2 as presented in the Theory - Role of Colloidal Stability and Apparent Solubility on 
Aggregation Rates section.  Except that in this case, it was probably the equilibrium 
concentration of associated encounter complex that was rate limiting rather than the structural 
rearrangement of the encounter complex.  For example, although there was substantial monomer 
loss in the pH 4.5 mAb sample in histidine buffer incubated at 57°C for 3 days, there was limited 
aggregate growth.  Note that this solution condition had the highest solubility in PEG solutions 
compared to the other mAb solution conditions.  Barnett et al. previously rationalized this type of 
observation by arguing that when protein-protein interactions are strongly repulsive, a monomer 
diffusing towards an aggregate would be felt simultaneously by all of the monomeric 
components within the aggregate causing extensive growth to become highly unfavorable (35).   
5.4.6. Rationalization of Assumptions Present in Aggregation Model 
In our simulations, aggregate-aggregate association was set to zero because accurately 
quantifying aggregate populations was challenging due the limited size resolution of the SEC 
column and the potential of aggregates to either adsorb to or be filtered out by the guard column.  
In the context of this model, however, aggregate-aggregate association will deplete the total 
aggregate population which could decrease the observed rate of growth by monomer addition for 
this model (Equation 5.07).  Fortunately, the observed rates of aggregate-aggregate association 
should be very slow until aggregate populations become large enough to overcome the second 
order concentration dependence.  In this study, the last experimental time points for most of the 
solution and temperature conditions investigated showed no significant particle formation.  For 
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sample conditions that did have measurable precipitation at the end of the time scales examined, 
early time points without significant particle formation were used to simulate the fit of monomer 
loss.  Additionally, we ran simulations which included a large kagg term and found that it did not 
affect the fit residuals indicating that the modeled time points were sufficiently early to avoid 
large errors from neglecting aggregate-aggregate growth (data not shown).  Another assumption 
included in the simulation was that kg,obs,{A2} ≈ kg,obs,{A∞}.  This assumption was made 
necessary because it was not feasible to individually model each and every growth rate constant 
due to the challenges of resolving aggregate sizes.  Fortunately, this assumption does not affect 
the number of reactive aggregates within the context of this model and should therefore provide 
a relative rate constant that describes aggregate growth by monomer addition.   
  Interestingly, the fragmentation pathway did not appear to interfere with the aggregation 
pathway (i.e. the rate of area loss of the monomer + fragment peaks did not decelerate or 
decrease with substantial fragmentation).  If the fragmentation pathway prevented mAb species 
from aggregating, the rate should have decelerated reflecting the reduced population of reactive 
species.  As a result of the previous observation, aggregation rates were modeled without 
explicitly considering fragmentation pathways.  In terms of future work, it will be important to 
explore ways to explicitly consider fragmentation pathways and integrate them with the 
aggregation models developed here. 
Within the context of this model, the pH 6.5 mAb samples incubated at 57 ºC were not 
able to be accurately simulated without constraining the number of aggregate prone monomer 
species.  The early plateau in monomer loss after ~3 days (Figure 5.5 G & H) may reflect 
depletion in the amount of aggregate prone species.  This result further underscores the 
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challenges and inherent limitations of treating complex proteins as simple colloidal particles (i.e., 
pH only alters surface charge and fraction of reactive species). 
5.5. Conclusions 
In this study we evaluated the aggregation vs. storage time profile of an IgG1 mAb under 
different solution conditions across a range of temperatures by SEC and SV-AUC, and compared 
results to the physical properties of the mAb in different solutions including those that produced 
partially unfolded intermediates (conformational stability by DSC), apparent solubility (in PEG 
solutions), and protein-protein interactions (second virial coefficients by SLS).  A kinetic model 
for aggregation was developed and applied to interpret SEC and SV-AUC aggregation data 
during storage of the IgG1 mAb at different temperatures in terms of the roles of aggregate 
nucleation and growth.  Additional kinetic equations describing the effects of conformational 
stability, colloidal stability, and equilibrium encounter complex formation were also proposed.   
We found that the modeled nucleation rate constants for aggregation of this mAb in 
different solutions were most sensitive to the formation of partially unfolded intermediates (i.e., 
conformational stability of the mAb).  In other words, as the incubation temperature approached 
the thermal melting temperature (as measured by DSC), the observed aggregation nucleation 
increased as expected.  Interestingly, the observed aggregation nucleation rate constants did not 
appear to be affected by protein-protein interactions and/or apparent solubility values for this 
mAb under these various solution and temperature conditions.  As a result, we conclude that the 
association processes between protein monomers were not a rate limiting step of aggregate 
nucleation for this mAb under these solution and storage conditions. 
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  On the other hand, aggregate growth rate constants (by monomer addition) for this mAb 
in the same solutions were highly sensitive to protein-protein interactions and/or apparent 
solubility values (i.e., association thermodynamics) as well as to the conformational stability 
(i.e., concentration of partially unfolded intermediates) when the mAb was incubated at 57 and 
40 ºC.  Based on the relatively low values of a2 measured in this study, it is difficult to 
physically justify long range repulsive interactions causing the rate of protein associations to 
become the rate limiting step; thus, it is more likely that the thermodynamics of encounter 
complex formation of the mAb in the different solutions was the rate limiting component of 
aggregate growth in the same solutions during storage.  Thus, this work provides a method to 
model experimentally obtained protein aggregation stability data to enable a better mechanistic 
understanding of the relative contributions of nucleation and growth components of the 



































pH 4.5 histidine w/ 






pH 6.5 histidine 62.8 72.9 83.4 
pH 4.5 citrate 51.5 59.5 73.1 79.2 
pH 4.5 citrate w/ 




pH 6.5 citrate 62.0 73.1 83.1 
 
Table 5.1. Apparent thermal melting temperatures for mAb in solution conditions as 
measured by DSC.   Apparent thermal melting temperature values are reported as Tm1, Tm2, and 
Tm3 representing the CH2,Fab, and CH3 domains of the mAb, respectively  (see Figure 5.1 and 
text).  A thermal melting profile that fails to display melting temperatures for each 
domain/region is considered an observed  Tm to highlight that the melting event could be a 
convolution of two unfolding events.  Each reported value is the average of n=3 experiments, 





















Mean SD Mean 
50 mM Citrate 4.5 104.3 0.089 7.6 -0.84 0.03 6.8 
50 mM Citrate 6.5 41.3 0.243 0.3 -1.14 0.02 5.2 
50 mM Citrate w/ 
100 mM NaCl 
4.5 104.3 0.189 2.6 -0.82 0.01 7.9 
50 mM Histidine 4.5 104.3 0.024 43.1 1.18 0.29 24.6 
50 mM Histidine 6.5 41.3 0.007 31.9 0.58 0.02 8.5 
50 mM Histidine 
w/ 100 mM NaCl 
4.5 104.3 0.124 4.8 -0.43 0.03 15.1 
 
Table 5.2. Summary of experimental and calculated physical parameters of different mAb 
solutions. Values for approximate mAb Net Charge, approximate solution Ionic Strength, and 
Theoretical b2 values (theoretical surrogate parameter for protein-protein interactions ) were 
calculated as described in the methods section.  The experimental surrogate parameter for 
protein-protein interactions (  a2 ) and [PEG] midpoint values (midpoint of mAb vs PEG 
concentration curves; see text) are presented as the average and standard deviation of 3 
experiments.  Values of b2 and a2 are normalized and therefore have no units.  [PEG] midpoint 









Solution Condition knuc, obs kg,obs T 
pH 4.5 Histidine 1.67E-04 2.08E-03 57 
pH 4.5 Histidine 3.75E-08 1.35E-05 40 
pH 4.5 Histidine 2.29E-08 1.15E-05 25 
pH 4.5 Histidine NaCl 1.41E-03 1.63E-02 57 
pH 4.5 Histidine NaCl 8.13E-08 1.67E-05 40 
pH 6.5 Histidine 2.71E-08 1.77E-05 40 
pH 4.5 Citrate 1.00E-05 1.32E+00 57 
pH 4.5 Citrate 5.42E-08 7.71E-05 40 
pH 4.5 Citrate 2.29E-08 1.46E-05 25 
pH 4.5 Citrate NaCl 1.54E-05 1.53E+00 57 
pH 4.5 Citrate NaCl 6.88E-08 7.50E-05 40 
pH 6.5 Citrate 2.71E-08 2.08E-05 40 
 
Table 5.3.  Modeled values of observed rate constants for aggregate nucleation and growth.  
The simulated values of knuc, obs and kg,obs have units of min
−1ml ∗ mg−1.  The incubation 










Figure 5.1.  Visual scheme of potential mAb nucleation mechanisms.  The various mAb 
nucleation mechanisms of aggregation shown in the figure correspond to Equations 5.03a, 5.03b, 
and 5.03c.  The visual schematic is not intended to be structurally accurate at a molecular level, 
and therefore should not be over interpreted in terms of actual mAb aggregate structure.  Red 
color represents a disordered domain, grey color a native domain, and blue color an inter-domain 







Figure 5.2.  Visual scheme of growth mechanisms for different dimers produced through 
nucleation mechanism 3a or 3b.  The different mAb growth mechanisms of aggregation shown 
in the figure correspond to Equations 5.04a, 5.04b, and 5.05.  The visual schematic is not 
intended to reflect accurate structure at a molecular level, and therefore should not be directly 
interpreted in terms of aggregate structure.  Red color represents a disordered domain, a grey 
color a native domain, and blue color represents an inter-domain structure between two mAbs.  




Figure 5.3. Representative conformational stability, apparent solubility, and protein-
protein interactions data for IgG1 mAb in different pH and buffer conditions.  (A)  DSC 
thermogram of mAb in pH 4.5 (red trace) and pH 6.5 (black trace) histidine buffer.  (B) DSC 
thermogram of mAb in pH 4.5 (blue trace) and pH 6.5 (black trace) citrate buffer.  A thermal 
melting profile that fails to display a melting temperature for each domain is labelled with an 
observed  Tm to highlight that the melting event could be a convolution of two domain unfolding 
events. (C) Protein-PEG precipitation curves for 1 mg/ml mAb at pH 4.5 (denoted by circles) 
and pH 6.5 (squares) in histidine buffer (red), histidine buffer w/ 100 mM NaCl (purple), citrate 
buffer (blue), and citrate buffer w/ 100 mM NaCl (cyan).  (D) Normalized second virial 
coefficient values at pH 4.5 and 6.5 in citrate buffer (blue), citrate buffer w/ 100 mM NaCl 
(cyan), histidine buffer (red) and histidine buffer w/ 100 mM NaCl (purple) as measured by static 




Figure 5.4. Simulated mAb aggregation profiles generated using the LENP-based model (as 
described in the theory section of the main text) using various nucleation and growth rate 
constants.  Simulations were conducted using arbitrary time units (ATU) causing rate constants 
to have units of ml/(mg ATU). (A) Aggregation profiles for molecules with “faster” nucleation 
rates.  The red traces have a nucleation rate of 0.0002 and the blue traces have a nucleation rate 
10x faster than the red trace.  The lightest red color (topmost) trace has a growth rate of 0.05, the 
darkest red color (middle) trace has a growth rate of 0.5, and the red color (bottom) trace has a 
growth rate of 0.99.  The light blue (topmost) trace has a growth rate of 0.005, the dark blue 
(middle) trace has a growth rate of 0.05 and the teal (bottom) trace has a growth rate of 0.5.  (B) 
184 
 
Zoomed-in version of the early stage of the aggregation profiles displayed in Panel A. (C) 
Aggregation profiles for molecules with “slower” nucleation rates.  The red traces have a 
nucleation rate of 2 x 10^-6 and the blue traces have a nucleation rate 10x faster than the red 
trace.  The pastel blue and pastel red (topmost) traces have a growth rate of 0.005, the dark blue 
and dark red (middle) traces have growth rates of 0.05, and the red/teal (bottom) traces have a 
growth rate of 0.5.  (D)  Zoomed-in version of the early stages of aggregation profiles displayed 
















Figure 5.5. SEC and SV-AUC data for mAb incubated at 40 or 57 °C in histidine solutions 
at different pH/ionic strengths.  (A) Representative SEC chromatograms showing mAb 
aggregate, monomer and fragment peaks changing in area as a function of incubation time.  (B) 
Representative SV-AUC data showing mAb monomer and aggregate peaks changing in area as a 
function of incubation time.  (C-H)  Profiles showing loss of mAb monomer (red diamonds) and 
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increase in mAb aggregates (black open circles), and increase in mAb fragments (blue open 
triangles) as a function of incubation time. SEC and SV-AUC data normalized to total area at t=0 
to capture loss due to insoluble aggregate formation.  Data presented as the average of 3 
experiments.  Error bars reflect the standard deviation.  Buffer conditions and incubation 
temperatures are labelled above each graph.  Lines simply connect the data points for ease of 














Figure 5.6. SEC data for mAb incubated at 40 or 57 °C in citrate solutions with different 
pH/ionic strengths. (A-F)  Profiles showing loss of mAb monomer (red diamonds) and increase 
in mAb aggregates (black open circles), and increase in mAb fragments (blue open triangles) as a 
function of incubation time. SEC data were normalized to total area at t=0 to capture loss due to 
insoluble aggregate formation.  Data presented as the average of 3 experiments.  Error bars 
reflect the standard deviation.  Buffer conditions and incubation temperature are labelled above 
each graph.  Lines simply connect the data points for ease of viewing and are not meant to fit the 




Figure 5.7.  Simulated fit of experimental SEC and SV-AUC data of loss of non-aggregated 
(monomer + fragment) mAb over time at 57°C.  Experimental (solid red squares, n= 3) and 
simulated profiles (solid red line) of non-aggregated mAb concentration in different solution 
conditions as a function of incubation time.  The residuals of each fit are presented in the upper 
right corner of the corresponding graph.  Error bars reflect the experimental standard deviation.  
Buffer conditions are labelled above each graph. The top panel of (B) was acquired using SV-







Figure 5.8.  Precipitation and particle formation of the mAb after incubation at different 
temperatures/time scales.  (A)  Loss of protein mass in solution measured by absorbance 
spectroscopy after 1 day of incubation at 57 °C.  (B) Calculated mass of subvisible protein 
particles suspended in solution, using particle number and size data from flow imaging 
measurements using a method developed reported previously (104), after 1 day of incubation at 
57 °C.  No visible precipitate was observed in these samples.  (C)  Calculated mass of subvisible 
sized protein particles suspended in solution after 7 months of incubation at 40 °C.  No visible 




Figure 5.9.  Simulated fit of experimental SEC data of loss of non-aggregated (monomer + 
fragment) mAb over time at 40°C. Experimental (solid red squares, n= 3) and simulated 
profiles (solid red line) of non-aggregated mAb concentration in different solution conditions as 
a function of incubation time as measured by SEC.  The residuals of each fit are presented in the 
lower left corner of the corresponding graph. Error bars reflect the experimental standard 







Figure 5.10.  Simulated fit of experimental data of non-aggregated (monomer + fragment) 
mAb at pH 6.5 at 40°C during storage.  (A, B) Experimental (solid red squares, n= 3) and 
simulated profiles (solid red line) of non-aggregated mAb concentration in different solution 
conditions as a function of incubation time.  The residuals of each fit are presented in the lower 
left corner of the corresponding graph.  Error bars reflect the experimental standard deviation.  












Figure 5.11.  Simulated fit of experimental data of non-aggregated (monomer + fragment) 
mAb at pH 4.5 at 25°C during storage.  (A, B) Experimental (solid red squares, n= 3) and 
simulated profiles (solid red line) of non-aggregated mAb concentration in different solution 
conditions as a function of incubation time.  The residuals of each fit are presented in the lower 
left corner of the corresponding graph.  Error bars reflect the experimental standard deviation.  












Figure 5.12.  The effect of conformational stability (presence of partially unfolded mAb 
species) on the observed rate constants for mAb aggregate nucleation and growth.  
Observed nucleation and growth aggregation rate constants were obtained by fitting simulations 
of Equations 5.06 and 5.07 to experimental SEC and SV-AUC stability data for mAb stored in 
different solutions at different temperatures.  The values reported are dimensionless numbers 
which were normalized by the smallest observed rate constant for each process.  The colors dark 
blue, light blue, dark red, and light red correspond to the mAb prepared in the citrate, citrate + 
NaCl, histidine, and histidine + NaCl solution conditions where the diamond and circle shapes 
correspond to solution pH values of 4.5 and 6.5, respectively.  (A.) Modeled values for the 
observed nucleation rate constant as a function of the first apparent melting temperature 
(measured by DSC) minus incubation temperature.  (B.) Modeled values for the observed growth 
rate constant as a function of first apparent melting temperature (measured by DSC) minus 
































6.1. Summary and Discussion 
The presence of protein aggregates in therapeutic biopharmaceuticals is hypothesized to 
increase the risk of unwanted immunogenicity in patients leading to decreased efficacy or even 
potentially inducing anaphylaxis (1, 2).  Therefore, protein formulations are designed to 
minimize aggregation during manufacturing, storage and administration through empirical 
stability testing as well as by maximizing experimental surrogate parameters of protein 
conformational and colloidal stability.  This latter approach is theoretically valid when protein 
aggregation is understood in terms of the Lumry-Eyring model.  In actuality, however, protein 
aggregation describes a collection of multiple potentially competing pathways that can be 
initiated through chemical degradation, conformational changes, reversible associations, and/or 
adsorption to interfaces (44, 58, 61-65).  As such, the role of conformational and colloidal 
stability in preventing protein aggregation induced during long term storage and by various 
environmental stress conditions remains unclear. 
    Competing protein aggregation pathways can result in heterogeneous aggregate 
populations in a protein formulation that possess wide distributions for aggregate size and 
morphological properties.  One outstanding challenge in the preformulation characterization and 
formulation development of protein drug candidates is how to quantify and present such large 
protein aggregation/particle data sets without substantially decreasing the resolution of the data.  
Such methods are critical to interpret the effects of formulation variables on aggregation 
processes induced through various accelerated stress conditions.   
In chapter 2 of this thesis, we develop and propose a data visualization method using 
radar charts to simultaneously quantify, present and compare the effects of multiple formulation 
variables on the properties of protein aggregates as a function of their measured size.  The first 
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method presented in chapter 2 demonstrates how changes in solution pH, ionic strength, type of 
external stress condition, and duration of stress exposure can differentially affect the size and 
number of subvisible particles (~1-100 microns) detected in IgG1 monoclonal antibody 
solutions.  The second method presented considers how the morphology of particles (e.g., aspect 
ratio and particle intensity) is affected as the formulation variables outlined above are 
systematically varied.  In the third method presented, we demonstrate how data outputs from 
multiple analytical instruments can be combined to more comprehensively observe the effects of 
pharmaceutically relevant variables on aggregation pathways.  Through application of the radar 
chart analysis method, we clearly demonstrate that formulations with increased conformational 
and colloidal stability can be effective at reducing protein aggregation and particle formation 
induced through specific stress conditions.  At the same time, we also demonstrate that these 
same formulation conditions can also exacerbate aggregation/particle formation that is induced 
through other stress conditions which may promote aggregation through pathways that are poorly 
described by the Lumry-Eyring model.  
 Larger subvisible particles are typically counted and quantified experimentally using 
digital imaging techniques (e.g., 2-dimensional size).  There has been a general desire to quantify 
such data in terms of a 3-dimensional volume and/or protein particle mass.  In the 
pharmaceutical biotechnology literature, multiple research groups have assumed for simplicity 
that a 2-dimensional equivalent circular diameter can be equated to a 3-dimensional equivalent 
spherical diameter without significant error.  In chapter 3, we first demonstrate that such 
assumptions can be highly erroneous depending upon the morphology of protein particles (e.g., 
error increases as particles become more elongated).  As such, we propose using prolate ellipsoid 
of revolution geometry to more accurately model protein particle volume from 2-dimensional 
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size and morphology parameters.  This model was tested on elongated polystyrene standards 
obtained through collaborators and produced superior results than the common approach of 
equating 2-D and 3-D diameters.  Based on the boundary conditions described by a 3-
dimensional prolate ellipsoid of revolution, a protein density value reflecting a 20% protein and 
an 80% solvent was used to calculate protein particle mass in this work.  This assumed density 
value produced calculated mass values that agreed with experimental measures of protein mass 
loss in highly aggregated samples.   
 An observation reviewed in the introductory chapter of this thesis (chapter 1) is that the 
extent of aggregation induced by mechanical agitation (e.g., side-to-side shaking) of IgG1 mAb 
solutions does not appear to be reduced by changing the solution composition to increase mAb 
conformational stability and/or colloidal stability.  Recent studies have hypothesized that protein 
particles can be produced by disrupting a high concentration gel-like layer of protein at the air-
solution interface (62).  In chapter 4, we collaborate with Professor Prajnaparamita Dhar and 
Saba Ghazvini, a graduate student in her lab, in the Chemical Engineering Department of the 
University of Kansas to better characterize and determine the origin of subvisible sized protein 
particles detected in solution after mechanical agitation.   
In this chapter, the same IgG1 mAb was prepared in solutions containing different buffer 
ions and pH values and evaluated to determine if such changes affect the properties of the gel-
like protein layer at the air-solution interface and/or the resulting subvisible particles produced.  
Saba Ghazvini demonstrated that both slow and fast compression rates of these various mAb 
solutions in a Langmuir trough system resulted in significant protein particle formation at the air-
solution interface.  We found that subvisible particles were only detected in significant numbers 
(relative to t=0 control) in bulk mAb solution for the fast compression rate.  These results 
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suggest that mechanical stress can produce subvisible protein particles at the air water interface, 
but sufficient stress needs to be applied to release the particles from the interface into the bulk 
solution.  Furthermore, while we found that formulation composition had a large effect on the 
particle formation tendencies of this IgG1 at the air-solution interface, the results could not be 
entirely explained using conformational stability, colloidal stability, and/or surface pressure vs. 
area isotherms obtained from the Langmuir trough measurements. This will be a topic of 
ongoing and future research in the Dhar and Volkin laboratories. 
 In addition to aggregating at interfaces, proteins can aggregate in bulk solution by 
mechanisms which are initiated by partial unfolding or reversible association of proteins.  In 
chapter 5, we develop a theoretical model describing aggregation in terms of multiple nucleation 
(dimer formation) mechanisms and multiple aggregate growth mechanisms.  Furthermore, we 
describe the theoretical role of both conformational and colloidal stability on both aggregate 
nucleation and growth.  Experimentally, we measured conformational stability using DSC and 
colloidal stability using the second virial coefficient obtained from SLS.  Additionally, we used a 
PEG precipitation assay to determine relative apparent solubility (and extrapolate to obtain the 
apparent thermodynamic activity) of mAb in different solutions, and compared these values as a 
potential surrogate for the relative thermodynamic favorability of protein in solution vs. 
amorphous precipitate.  Aggregation data was collected for mAb using SEC and flow 
microscopy over the same range of formulation conditions incubated for up to 7 months.  We 
found that solutions that resulted in decreased conformational stability of the mAb increased the 
rate of both nucleation and growth aggregation mechanisms during storage at temperatures well 
below the thermal onset temperature (as measured by DSC).  On the other hand, we found that 
colloidal stability of the mAb in different solutions, as given by a2 values from SLS, did not 
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appear to affect the rate of aggregate nucleation.  The rate of aggregate growth however, could 
be controlled by increasing the net charge of the mAb molecule.  The extent of aggregate growth 
of the mAb in different solutions correlated with both a2 and apparent solubility data from the 
PEG precipitation experiments for the mAb in the same solutions. 
 Quantitative data visualization methods, mathematical models and kinetic models were 
developed in this thesis to better characterize and mechanistically study protein aggregation.  The 
methods developed here were then applied to comprehensively map and better understand the 
effects of formulation composition and environmental stress on the aggregation pathways of an 
IgG1 mAb.  A rigorous understanding of the different protein aggregation mechanisms is 
important to properly formulate proteins, especially because the classically used Lumry-Eyring 
type aggregation mechanisms, which may occur at elevated temperatures, may not be predictive 
of protein aggregation during long term storage or under mechanical agitation.  The various tools 
developed here in this thesis offer a broad range of approaches which could be applied to the 
topic of protein aggregation for both pharmaceutical development and basic research purposes.   
6.2. Future Directions 
 There are several exciting possibilities to build upon the research results, data 
visualization methods, and mathematical modeling tools presented here.  This section will briefly 
highlight some outstanding challenges in the field of protein aggregation with a focus on work 
that could build upon the methods presented in this thesis.  The projects suggested below could 
offer new insights into protein aggregation from a basic science perspective, and mechanistic 




One major limitation in the current understanding of protein subvisible particles is a lack 
of knowledge about their packing (i.e., density).  As presented in the introduction of this thesis, 
part of the problem is an unclear definition of the “boundary” of a subvisible sized (~1-100 
micron) protein particle.  Protein particle density is an extremely important value that is used in 
resonant mass measurements to calculate protein particle size and is also used in calculations of 
protein particle mass from flow microscopy data.  One potential way to define the boundaries of 
protein particle is to use inert molecules which are too large to diffuse into particle “channels.”  
Various sized polymer molecules could be used to change the size of the “probe.”  Subvisible 
particles of various proteins could be spiked into these solutions and particle density could be 
calculated using a standard densitometer by varying the inert polymer concentration.  A potential 
complication of this approach is that high polymer concentration could induce protein 
precipitation through unbalanced osmotic forces at high excluded volumes. 
Another potential avenue for future research would be to understand the link between 
protein solution properties (e.g., protein charge, ionic strength, conformational integrity) and 
aggregation at the air-solution by creating mathematical models to account for the relative 
concentration of adsorbed protein at the interface.  Currently, most industry and academic studies 
published to date are focused on finding parameters which correlate or can predict surface 
induced aggregation.  As demonstrated in this thesis, aggregation is a multi-step process any of 
which can become rate limiting at different solution conditions.  Development of such a model 
could help to clarify how and when parameters such as protein conformational stability and 
surface pressure correlate with surface induced aggregation.       
A third exciting possibility would be to further improve the kinetic models for protein 
aggregation developed in chapter 5.  Other degradation pathways can occur which remove 
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reactive monomer from solution.  One major pathway which can affect aggregation in such a 
manner is mAb fragmentation.  Additional terms could be developed to account for cases where 
fragments are either aggregate prone or unreactive.  Furthermore, the simulation scripts used to 
model protein aggregation data could be equipped with statistical analysis to report confidence 
intervals.  Such statistical analysis will become critical as the number of simulated parameters 
increases.  Unfortunately, the models developed here cannot be used for prediction of protein 
aggregation until protein-protein interactions can be better predicted.  
Performing these future studies would go a long way towards advancing the 
understanding of protein aggregation from a basic biophysics and colloid science perspective.  
One potential reason for why these studies have not been performed to date is because of their 
complicated nature requiring both theoretical and technical expertise in several different fields.  
This is one major reason why our collaboration with Professor Dhar at the University of Kansas 
and conversations Professor Christopher Roberts at the University of Delaware have been so 
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